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ABSTRACT 
Adverse drug events (ADEs) are a significant cause of patient morbidity and hospital admissions. 
There are many studies in this area in Western countries. However, little is known about the 
prevalence and patterns of such events in Malaysia. Health care professionals are in the best position 
to reduce and prevent adverse drug events. In order to devise preventive strategies based on the 
prevalence studies, it is important to understand the current practices of health care professionals in 
this area. This study aimed to determine the different occurrences of ADEs in a Malaysian public 
ŚŽƐƉŝƚĂůĂƐǁĞůůĂƐƚŚĞĞǆƉĞƌŝĞŶĐĞƐŽĨƐŽŵĞDĂůĂǇƐŝĂŶƉŚĂƌŵĂĐŝƐƚƐ ?of ADEs. 
A study of an observational chart review determined the prevalence of adverse drug event-related 
admissions in a tertiary public hospital and drugs implicated in such. This was achieved through a 
prospective review of the patients ? medical notes and charts in two medical wards. All cases were 
assessed using a classification tool which was developed after a pilot study. Following this, a postal 
survey of some Malaysian pharmacists explored their experiences about ADEs: the types of ADEs 
they have observed, actions taken in response to these incidents and their awareness of and 
involvement in adverse drug reaction reporting, and their attitudes towards this task. 
Both studies revealed that the occurrence of adverse drug events was high in Malaysia  W the chart 
review study found that 39% of admissions to two medical wards were related to ADEs whilst more 
than half of the sample pharmacists revealed having observed them in their daily work activities.  
Moreover, cardiovascular drugs, anti-diabetics, anti-asthmatics, and analgesics were responsible for 
more than 80% of the admissions related to an ADE. Similar drug classes were also associated with 
ADEs as recounted by the pharmacists. Moreover they claimed to have communicated with patients 
about ADEs: on the ADE experienced by a patient, proper use of medicine, importance of adherence, 
alternate medicines and other appropriate measurements. Although more than 80% hospital and 
clinic pharmacists claimed to have reported adverse drug reactions, less than 20% of community 
pharmacists have claimed sending a report. This may have resulted from their lack of awareness of 
the procedures and processes of reporting an adverse drug reaction. 
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Compared to other countries, the prevalence of ADEs is higher in Malaysia. It remains to be an 
important cause of patient injury and hospital admissions. Some useful strategies such as educational 
intervention on main causes of adverse drug events, monitoring of patients, and appropriate 
prescribing should be targeted at all health care professionals to prevent its likely future occurrences. 
Pharmacists play an important role in preventing ADEs by providing education and counselling to 
patients. Furthermore, as they were able to identify ADEs in their daily work activities, they should be 
included in any prevention programs. Documenting ADEs and interventions taken in relation to those 
ADEs should be encouraged, as this will be useful in monitoring the occurrence of ADEs and sharing 
the documented information with others could improve awareness and therefore improve 
prevention.  
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GLOSSARY 
 
ADVERSE DRUG EVENT Any untoward medical occurrence that may appear during treatment 
with a pharmaceutical product, but which does not necessarily have a 
causal relationship with the treatment 
 
ADVERSE DRUG 
REACTION 
A response to a drug that is noxious and unintended, and occurs at doses 
normally used in humans for prophylaxis, diagnosis or therapy of 
disease, or for modification of physiological function 
 
ADVERSE DRUG 
WITHDRAWAL 
SYNDROME 
 
A clinical set of symptoms or signs that are related to the removal of a 
drug 
DRUG OVERDOSE The exposure of an individual (by ingestion or inhalation) to an amount 
of substance associated with the significant potential to cause harm 
 
DRUG-RELATED 
PROBLEM 
An event or circumstance involving drug treatment that actually or 
ƉŽƚĞŶƚŝĂůůǇŝŶƚĞƌĨĞƌĞƐǁŝƚŚƚŚĞƉĂƚŝĞŶƚ ?ƐĞǆƉĞƌŝĞŶĐŝŶŐĂŶŽƉƚimum 
outcome of medical care 
 
DRUG-RELATED 
MORBIDITY 
The failure of a therapeutic agent to produce the intended therapeutic 
outcome, or the clinical biosocial manifestation of unresolved drug-
related problems 
 
 
 
 
Glossary 
 
 
xix 
 
MEDICATION ERROR Any preventable event that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of 
the health care professional, patient, or consumer. Such events may be 
related to professional practice, health care products, procedures, and 
systems, including the following: prescribing; order communications; 
product labelling, packaging, and nomenclature; compounding; 
dispensing; distribution; administration; education; monitoring; and use 
 
THERAPEUTIC FAILURE An inadequate therapeutic response to a drug as evidenced by the 
presence of symptoms of a diagnosed disease state or condition 
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CHAPTER 1 
 
INTRODUCTION 
 
This chapter describes the background to this thesis. It starts with the problem statement followed 
by a brief introduction to Malaysia and its health care system. Literature were reviewed to further 
understand the work that has been done in the area of adverse drug event-related admissions, the 
terminology and classification of adverse drug events, the types of methods that can be used to 
identify them, the prevalence of adverse drug events and the role of health care professionals in 
recognising, resolving, monitoring and preventing them. 
 
1.1 The problem statement 
Patient safety and initiatives to develop safety cultures to protect patients from harm are 
increasingly becoming a major concern in health care quality improvement.  Studies of adverse drug 
reactions and drug-related admissions have been published as early as the 1960s [1, 2] and lately, 
there is a growing interest in identifying strategies to prevent or reduce adverse drug events (ADEs) 
[3-6]. 
In 1999, a report entitled, To Err is Human by Institute of Medicine (a United States-based 
independent and non-profit organization), astonished the medical world by claiming that between 
44,000 and 98,000 patients in the US die every year from preventable adverse events [7]. Since then 
several studies conducted among hospitalised patients reported ADE rates from 2.5% to 30.4% [8-
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11], and a meta-analysis revealed that fatal adverse drug reactions (ADR) occurred in 0.32% of 
patients [12]. There is potential for these percentages to rise with the changes in patterns of diseases 
and growth in the availability and consumption of medication. ADEs not only cause patient morbidity 
and mortality, but also contributes substantially to health care costs as a result of prolonged hospital 
stays and additional interventions [13-16].  
The biggest indicator of the DĂůĂǇƐŝĂŶDŝŶŝƐƚƌǇŽĨ,ĞĂůƚŚ ?ƐĐŽŵŵŝƚŵĞnt to patient safety is the 
creation of the Patient Safety Council in 2003 to ensure that its citizens receive safe health care [17]. 
This council follows closely the recommendation made by tŽƌůĚ,ĞĂůƚŚKƌŐĂŶŝƐĂƚŝŽŶ ?Ɛ ?t,K ?
ůůŝĂŶĐĞĨŽƌWĂƚŝĞŶƚ ?Ɛ^ĂĨĞƚǇƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐŽŶƉĂƚŝĞŶƚƐĂĨĞƚǇƐƚƌĂƚĞŐŝĞƐĂŶĚƉƌŽŐƌĂŵƐ [17]. The 
council aims to develop a national, electronic database system for reporting and documenting 
medical errors in hospitals, promote an open and fair system for confidential reporting of incidents, 
analyse these incidents and learn how to avoid them in the future, devise strategies to improve 
safety and quality, and publish reports on adverse incidents and patient safety [17]. In line with 
t,K ?ƐƉĂƚŝĞŶƚƐĂĨĞƚǇƉƌŽŐƌĂŵ ?ƚŚĞĐŽƵŶĐŝůŚĂƐŝŵƉůĞŵĞŶƚĞĚǀĂrious strategies such as improving 
hand hygiene standards, safety of surgical care, tackling antimicrobial resistance, promoting research 
for patient safety, and establishing a medical incident reporting system. 
Established for more than a decade under the Drug Control Authority (DCA), Malaysian ADR 
Committee (MADRAC) receives and reviews ADR reports from health care professionals and patients 
and submits them to the WHO International Centre of Drug Monitoring in Uppsala, Sweden [18].  The 
reporting rate for ADRs in Malaysia was found to be low  by a study in 2003 [19]. However, the 
number of reports received by MADRAC more recently has been increasing and these reports are 
mainly submitted by pharmacists [20]. In parallel with MADRAC, the Ministry of Health (MOH) has 
created the Medication Error Reporting System (MERS) in an effort to encourage health care 
professionals to report medication errors and to monitor the reports thus enabling the identification 
of high-risk areas and implementation of safety solutions [21].  
The intention of the Patient Safety Council in initiating programs and strategies to improve patient 
safety is a good start. However, without identifying the extent of the problem and areas that would 
benefit from interventions, these programs may not be able to eradicate the root cause. The reports 
received by MADRAC and MERS are not sufficient or suitable to calculate the incidence or prevalence 
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of ADRs or medication errors (MEs). This is due to incomplete numerators (number of ADEs 
occurring) and denominators (number of patients exposed to a drug). Additionally, they are not able 
to identify other types of ADEs which may also compromise patient safety such as drug overdose 
(DO) and therapeutic failure (TF).  A few small-scale studies have addressed the issue of drug-related 
admissions in Malaysia [22, 23]. However, these studies did not include all types of ADEs and were 
conducted for a short period of time.  The paucity of information regarding the epidemiology of all 
types of ADEs in Malaysia means that there is potential to identify areas to implement preventive 
measures that have not been realised. 
Therefore, this thesis aims to determine the prevalence of ADE-related admissions in Malaysia, the 
extent of this problem and the drugs which are the largest target for potential interventions. It also 
aims to determine the opinions and current practices of health care professionals in Malaysia, and 
identify whether or not education about ADEs is likely to improve their detection and reporting, and 
therefore suggest actions to prevent and resolve ADEs. 
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1.2 Organisation of the study  
This thesis is divided into four chapters. The current chapter provides an introduction to the thesis, a 
brief description about Malaysia and its health care system. Subsequently, it presents the literature 
review on adverse drug events. The chapter ends with the rationale for the study and presents the 
aims and objectives of the study. 
Chapter 2 describes the methods underpinning the first phase of this study. It describes the 
development of the method for the chart review study, the development and testing of a 
classification tool, and implementation of the main chart review study.  It illustrates the data 
collection process, presents the main findings, and discusses the findings. 
Chapter 3 describes the methods used in the second phase of the study. It provides explanation on 
the development and testing of the questionnaire, so as the process of data collection for the main 
survey study. It presents the main findings, and discussion of those findings. 
Chapter 4 summarises the overall findings from both phases of the study and concludes with the 
implications for practice, policy, and research. 
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1.3 About Malaysia 
Malaysia is located in Southeast Asia. It has 13 states and three federal territories. Kuala Lumpur is 
the capital of Malaysia. Geographically, it is divided into two regions: West Malaysia (Peninsular 
Malaysia) and East Malaysia, which are separated by the South China Sea. 
In 2010, Malaysia had a population of approximately 28 million [24], with proportion of men and 
women almost equally distributed (51% versus 49%). The average life expectancy is 74 years, and is 
higher for women than men. Only 5% of the population are aged more than 64 years whilst 27% are 
aged less than 15 years.  The Malays are the largest ethnic group (64%), followed by Chinese (25%), 
and Indian (7%)[24]. Islam is the official religion in Malaysia, and is practiced by 60% of the 
population. Malay language (Bahasa Melayu) is the official language and is spoken in all areas of the 
country. 
1.3.1 Health care in Malaysia 
The responsibility of health care in Malaysia lies with the Ministry of Health (MOH). The health care 
system is divided into two sectors  W public sector and private sector. These sectors are discussed 
below. The majority of Malaysians do not have one single general practitioner (GP) who oversees 
their entire medical care. They can choose to receive medical treatment from several different GPs, 
clinics, or institutions and there may not be any communication between these different health care 
professionals. 
1.3.1.1 Public sector health care 
The government run, public-funded sector is made very affordable to patients because of high 
government subsidies and is free for civil servants, pensioners, and the poor. Other residents are 
charged a small amount of money to receive medical treatment. There are four types of health 
services in the public sector under the MOH: health or community clinics, district hospitals, state 
hospitals and special medical institutions.  
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Health clinics provide primary care services for the following: (a) dental care, (b) maternal and child 
care, (c) family planning, (d) education on health and dietary, (e) elderly health, (f) mental health, (g) 
adolescent health, (h) health screening and diagnostic services for chronic medical conditions and 
provide counselling services on food and nutrition, and smoking cessation, (i) follow-up of patients 
with stable and controlled medical conditions, (j) minor treatment for fever, cough, flu, and other 
minor ailments and (k) minor treatment procedures such as wound cleaning and stitching. There are 
also community health clinics providing services to rural residents, as well as mobile health clinics (a 
van equipped with basic health facilities and personnel) to help the poor and needy residents in rural 
areas [25, 26]. There are about 3,000 health clinics and 2,300 dental clinics in Malaysia[25]. 
The district hospitals have around 100 to 200 beds and are normally run by up to ten medical 
officers. These are secondary care hospitals providing inpatient and outpatient services to the district 
population. Almost all hospitals have basic diagnostic capabilities. They also receive referrals and 
further complement the primary health care services in the district. There are two types of district 
hospitals: with or without specialists. Hospitals without specialists have visiting ones on a regular 
basis.  
State general hospitals have around 500 to 1,500 beds providing tertiary care. Each state in Malaysia 
has one state hospital, the least. These consist of general and teaching hospitals. These hospitals 
provide outpatient and inpatient services in general medicine, general surgery, dermatology, 
ophthalmology, orthopaedics, paediatrics, obstetrics and gynaecology, psychiatry, and pharmacy. In 
Malaysia, there are three hospitals equipped with total hospital information systems (THIS). It is an 
electronic information system designed to manage administrative, financial, and clinical aspects of a 
hospital [25].  
There are six special medical institutions in Malaysia. The special medical institutions provide 
inpatient services for specific medical conditions: (a) National Respiratory Institute (b) National 
Leprosy Control Centre (c) National Cancer Institute, and (d) three Mental Health Institutes. 
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1.3.1.2 Private sector heath care 
The private sector is funded on a non-subsidised, payment-for-service basis. Those who have private 
insurance use the services as well. This insurance can be obtained voluntarily or provided by a private 
company to its workers. Currently, there is no compulsory insurance or national health insurance in 
Malaysia. The types of private health care services are: private hospitals, maternity homes, nursing 
homes, hospices, ambulatory care centres, haemodialysis centres, community mental health centres, 
medical clinics, and dental clinics. 
There are about 6,300 private medical clinics and 1,500 dental clinics in Malaysia[25]. Private clinics 
provide primary care services and the practitioners are registered physicians. Some clinics serve as 
panel clinics in which a company provides insurance coverage to its employees and allow them to 
receive treatment at the appointed clinics.   
In 2009, there were 209 private hospitals, 21 maternity homes, 21 ambulatory care centres, 12 
nursing homes, three hospices, and one community mental health centre in Malaysia. Private 
ŚŽƐƉŝƚĂůƐĂĐĐŽƵŶƚĞĚĨŽƌ ? ?A?ŽĨDĂůĂǇƐŝĂ ?ƐŚŽƐƉŝƚĂůďĞĚƐĂŶĚĂƌĞƵƐƵĂůůǇůŽĐĂƚĞĚŝŶƵƌďĂŶĂƌĞĂƐ[25]. 
At present, patients can go to any health care facilities to receive treatment. Their medical record 
database is not linked between the clinics and/or hospitals. This allows patients to receive treatment 
in any of the clinics or hospitals they prefer, or are comfortable with. However, the disadvantage is 
that, a patient may end up receiving treatments in different clinics or hospitals and poly-pharmacy 
could become a problem, as patient details are not communicated.  
1.3.2 Pharmacy practice in Malaysia 
Malaysia has two types of pharmacy practice  W government and private practice. Government 
pharmacy practice mostly takes place in government hospitals and health care facilities. Pharmacists 
also work at the National Pharmaceutical Control Bureau, pharmacy regulatory units, and 
government universities. There are more than 7,000 registered pharmacists in Malaysia and those 
working in the government sector make up to 59% [27].   
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Private pharmacy practice is mainly represented by chain-community pharmacies and independent 
pharmacies. Besides that, pharmacists also practice in private hospitals, industry, and private 
universities or colleges.  
The job scope of hospital pharmacists is wide. Hospital pharmacists may work in an inpatient 
pharmacy (satellite pharmacy and ward supply pharmacy), outpatient pharmacy, therapeutic drug 
monitoring unit, parenteral nutrition unit, cyctotoxic drug reconstitution unit, drug information 
centre, drug store, and pharmaceutical production and pre-packing unit. Pharmacists in the public 
hospitals usually rotate to different departments regularly. Hospital pharmacists also provide 
services, such as Medication Therapy Adherence Clinics or MTAC (a pharmacist-based adherence 
ĐůŝŶŝĐǁŚŝĐŚƌĞǀŝĞǁƐƉĂƚŝĞŶƚƐ ?ĚƌƵŐŚŝƐƚŽƌǇĂŶĚĂƐƐĞƐƐes their adherence), counselling services for 
inpatients and outpatients, and Methadone Maintenance Therapy (provides direct observation 
therapy, education, and monitoring services to patients who are on methadone). There is a growing 
interest in specialist pharmacists in Malaysia (where pharmacists specialise in certain medical 
condition or unit such as renal pharmacists and intensive care unit pharmacists). 
Hospital pharmacists interact with physicians during medical ward rounds or when there are queries 
about the medication prescribed to patients. Physicians are usually contacted by telephone or are 
met at the wards when the pharmacists need to clarify prescriptions. Pharmacists are also contacted 
by other health care professionals for advice such as the choice of medicine, availability of medicines, 
side effect queries and appropriate administration methods. Hospital pharmacists have direct patient 
contact during dispensing at the outpatient pharmacy department, ward rounds, bedside 
counselling, and patient assessments for clinical monitoring.   
There are more than 3,000 community pharmacists in Malaysia [28]. Community pharmacists, also 
known, as retail pharmacists, provide services such as prescription filling, sales of over-the-counter 
(OTC) medicines dispensing, patient counselling and education, patient therapy management, and 
other patient-focused services (blood pressure or blood glucose monitoring, and cholesterol testing). 
Community pharmacists have minimal interaction with physicians. This is because community 
pharmacy functions as a unit on its own, and does not have link with any health care institution. The 
ĚŝƐƉĞŶƐŝŶŐŽĨƉƌĞƐĐƌŝƉƚŝŽŶŵĞĚŝĐŝŶĞƐŝŶDĂůĂǇƐŝĂƐƚŝůůĨŽůůŽǁƐĂƚƌĂĚŝƚŝŽŶĂů ‘ĚŝƐƉĞŶƐŝŶŐĚŽĐƚŽƌƐ ?
system, in which general practitioners practicing in private clinics are legally allowed to dispense 
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medicines as part of their professional practice. Hence, dispensing by community pharmacists is 
limited. Pharmacists in Malaysia have been seeking to change this situation and move to a model 
where prescriptions are dispensed by pharmacists rather than doctors.  This issue is yet to be 
resolved. However, the growing number of pharmacists may lead to positive changes in the future. 
The pharmacist-population ratio for Malaysia in 2009 was 1: 3,652 [25], which is far from 1:2,000, the 
ideal ratio recommended by the World Health Organisation [29].There are various government and 
private institutions in Malaysia that produce pharmacy graduates yearly. Every year, more than 700 
graduate pharmacists register with the Pharmacy Board of Malaysia [28]. Due to the shortage of 
pharmacists in the country, particularly in the government sector, three- year compulsory service 
was introduced through an amendment to the regulations governing the Registration of Pharmacists 
Act 1951 in 2003 [28]. However due to increasing numbers of pharmacy graduates in recent years, 
this compulsory service has now been reduced to one year [30]. 
1.3.2.1 Pharmacy Board of Malaysia 
The Pharmacy Board was established under the Registration of Pharmacists Act 1951. It consists of 
members from public and private sectors. It is responsible for the registration and deregistration of 
pharmacists and corporate bodies, registration of provisionally registered pharmacists, recognition of 
pharmacy degrees, approval of premises for pharmacist training, setting guidelines and standards 
relating to pharmacy degree, setting and conducting pharmacy jurisprudence examination, and 
conducting inquiries on unethical practices [28]. 
1.3.2.2 Malaysian Pharmaceutical Society 
The Malaysian Pharmaceutical Society (MPS) is a national association for pharmacists in Malaysia. 
The membership of this society is voluntary. It regularly provides updates on the pharmacy 
profession, and scientific research, conducts seminars or conferences for the development of the 
pharmacy profession and provides continuous pharmacy education for its members [31]. It also 
provides a platform for communication between its members. Furthermore, MPS promotes and 
encourages research and publication in the Malaysian Journal of Pharmacy. The society is managed 
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by council members elected during its annual general meetings. In 2010, there were about 2,000 
members in MPS. 
 
1.3.3 Major health problems in Malaysia 
According to the Malaysian National Health and Morbidity Survey III (NHMS III) which was conducted 
in 2006, the prevalence of chronic medical conditions in Malaysia was estimated to be 15.5% [32]. 
Hypertension was reported to have the highest prevalence and followed by diabetes mellitus (DM), 
asthma and heart disease [32]. Over the years, the prevalence of these medical conditions has been 
reported to be increasing [33-36]  W the reasons suggested for this increase include poor dietary 
control and a sedentary lifestyle [36]. For example, the national survey  showed that the overall 
national prevalence of DM among Malaysians aged 30 years and above had increased from 8.3% in 
1996 to 14.9% in 2006 [36]. The Malaysian Health Facts 2010 revealed that diseases of circulatory 
system and of respiratory system were two of the top ten causes of admission to hospitals and these 
two conditions were the two main causes of death in the hospitals [27].  
Across the three main ethnic groups (Malay, Chinese, and Indian), the prevalence of chronic medical 
conditions was reported to be higher among the Indian ethnic group [32], with the prevalence of DM 
being the biggest contributor to this figure [33, 36]. The NHMS III also revealed that a higher 
proportion of people from Malay ethnic group were likely to visit public health facilities compared to 
the other groups, in contrast, people from the Chinese ethnic group were more likely to seek 
treatment from private hospitals and clinics [32]. 
Despite taking drug therapy, more than 70% of patients with chronic medical conditions had poor 
control of these medical conditions [33, 34]. Inadequate self-management skills, and poor knowledge 
about their medical conditions and medicines were some of the reasons quoted as causing this [37]. 
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1.4 Definitions of adverse drug event-related hospital admissions 
In order to conduct a study in drug safety, it is important to understand the commonly used 
terminologies in the literature. A number of studies have attempted to define these terminologies 
[38-42]. One of the problems is that different studies have used different definitions making 
comparison of findings between studies difficult. Commonly used definitions are presented and 
discussed. 
 “Drug related problem ? (DRP) is the broadest terminology in drug safety. It has been defined as: 
 ‘n event or circumstance involving drug treatment that actually or potentially interferes with the 
ƉĂƚŝĞŶƚ ?ƐĞǆƉĞƌŝĞŶĐŝŶŐĂŶŽƉƚŝŵƵŵŽƵƚĐŽŵĞŽĨŵĞĚŝĐĂůĐĂƌĞ ?[42]. 
This can be divided into events that result in injury and that do not result in injury [43]. The former is 
known as drug-related morbidity (DRM) which has been defined as: 
  ‘The failure of a therapeutic agent to produce the intended therapeutic outcome, or the clinical 
biosocial manifestation of unresolved drug related problems ?[42]. 
The injury caused by the unresolved DRP may be minor or severe which could lead to the need for 
more medical attention or hospitalisation. This is interchangeable with terms such as drug-related 
injury [43] and adverse drug event (ADE) [38] . In this thesis, the term ADE will be used.  
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1.4.1 Adverse drug event 
Many attempts have been made to define ADEs (Table 1-1). The American Society of Health-System 
Pharmacists [38], Bates et al. [13] and Gurwitz et al. [44] have defined ADE as an injury due to the use 
of a drug. However, these definitions do not include events related to omission of a drug. Whilst, the 
definition by World Health Organisation (WHO) includes all events occurring during a treatment, 
which does not necessarily have a causal relationship with the treatment. To ensure that all possible 
events that occurred during a drug treatment may be investigated the definition by WHO on ADE is 
adopted in this study.  
Table 1-1: Different definitions for adverse drug events 
Author Definition 
Bates et al., 1995 [13] an injury resulting from medical intervention related to a drug 
American Society of Health-System 
Pharmacists (ASHP)., 1998 [38] 
an injury from a medicine 
World Health Organisation (WHO)., 
2000 [45] 
any untoward medical occurrence that may appear during treatment with a 
pharmaceutical product but which does not necessarily have a causal 
relationship with the treatment 
Gurwitz et al., 2000 [44] an injury resulting from the use of a drug 
Hepler., 2003 [3] a patient injury caused by the drug itself or by an error in how a drug is used 
 
Nebeker et al. [46] have divided ADEs into two major groups; (a)  ‘ŚĂƌŵĐĂƵƐĞĚďǇƚŚĞĚƌƵŐ ?ǁŚŝĐŚ
includes adverse drug reaction (ADR) and drug overdose (DO), and (b)  ‘ŚĂƌŵĨƌŽŵƚŚĞƵƐĞŽĨƚŚĞ
ĚƌƵŐ ?ǁŚŝĐŚŝŶĐůƵĚĞƐƚŚĞƌĂƉĞƵƚŝĐĨĂŝůƵƌĞ ?d& ?ĂŶĚĂĚǀĞƌƐ ĚƌƵŐǁŝƚŚĚƌĂǁĂůƐǇŶĚƌŽŵĞ ?t^ ? ?
Medication errors (ME) overlap in both groups [47]. The relationship between the different types of 
ADEs is shown in Figure 1-1.  
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Figure 1-1: Relationship between terminologies 
 
Adapted from American Society of Health-System Pharmacists (ASHP)., 1998 [38] 
 
 
 
 
 
 
A
B
C
D E
F G
H I
J
A to C : Medication errors
B : Potential medication errors
A + B Medication errors which do not cause harm
D to G : Adverse drug reactions
C + H+ I+ J : Other adverse drug events: medication error, therapeutic failure, 
drug overdose and adverse drug withdrawal syndrome
F to I : Adverse drug event related admission
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1.4.2 Medication error 
An error is defined as: 
 ‘something incorrectly done through ignorance or inadvertence; a mistake, e.g. in calculation, 
judgement, speech, writing, action, etc ? ?[48] 
The National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) in 
United States (US) [49] defined ME as:  
 ‘any preventable event that may cause or lead to inappropriate medication use or patient harm while 
the medication is in the control of the health care professional, patient, or consumer. Such events may 
be related to professional practice, health care products, procedures, and systems, including the 
following: prescribing, order communications, product labelling, packaging, and nomenclature, 
compounding, dispensing, distribution, administration, education, monitoring, and use. ?   
This definition specifies where an error could happen and who could make an error. The Malaysian 
Medication Error Reporting System (MERS) has adopted this definition in its guideline [50]. One of 
the difficulties in this field is the variety of terms used in the definition and classification of ME. 
Another recently proposed definition is: 
 ‘ĂĨĂŝůƵƌĞŝŶƚŚĞƚƌĞĂƚŵĞŶƚƉƌŽĐĞƐƐƚŚĂƚůĞĂĚƐƚŽ ?ŽƌŚĂƐƚŚĞƉŽƚĞŶƚŝĂůƚŽůĞĂĚƚŽ ?ŚĂƌŵƚŽƚŚĞƉĂƚŝĞŶƚ ? 
[51, 52] 
 ‘&ĂŝůƵƌĞ ?signifies that the process has fĂůůĞŶďĞůŽǁĂƐƚĂŶĚĂƌĚ ? ‘dƌĞĂƚŵĞŶƚƉƌŽĐĞƐƐ ?ŝŶĐůƵĚĞƐ
manufacturing or compounding, prescribing, transcribing (when relevant), dispensing, and 
administration of a drug and monitoring. The definition does not specify who is responsible for the 
error. It could be a physician, pharmacist, nurse, care taker, or the patient himself [52]. 
Throughout this thesis, the definition by the NCC MERP will be used due to its being widely accepted 
in Malaysia. ME is interchangeable with preventable ADE [53] or preventable DRM [54]. 
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According to Helper [3], ME can be categorised into three different categories:  
i) An error that has occurred but did not cause any harm to the patient (represented as A + 
B in Figure 1-1) 
ii) An error that has been prevented or corrected in any stages of medication management 
before causing harm to patients which is called as potential ME (represented as B in 
Figure 1-1) 
iii) An error that has occurred and caused harm to the patient (represented as C + D + F + H 
in Figure 1-1) 
In line with the study aims, this thesis will study all types of MEs. Errors can occur at each stages of 
the medication use process [55, 56]. There are five main stages in the medication use process as 
defined by US Pharmacopeia [57]: 
1) Prescribing  W a process of evaluating a patient, establishing the need for a drug, selecting 
the right drug after determining interactions and allergy history, and prescribing the drug.   
2) Transcribing and documenting  W a process of transcribing a prescription order and 
transmitting it to the pharmacy.  
3) Dispensing  W a process of reviewing a prescription order, confirming the transcription, 
contacting the prescriber in case of discrepancies, preparing the drug, and distributing or 
dispensing the drug.  
4) Administering  W a process of reviewing a prescription order, confirming the transcription, 
reviewing warnings, interactions or allergies, evaluating the patient and administering the 
drug. 
5) Monitoring  W a process of assessing a paƚŝĞŶƚ ?ƐƌĞƐƉŽŶƐĞƚŽĂĚƌƵŐ ?reporting and 
documenting the result. 
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Adherence problems can also be classified as ME because non-adherence could result from a human 
error [58]. In this thesis, however, patient non-adherence to drug will be classified under TF (Section 
1.3.4). 
 
1.4.3 Adverse drug reaction 
ADR is represented as D to G in Figure 1-1. The most widely used definition for ADR was developed 
by WHO and is defined as: 
 ‘a response to a drug that is noxious and unintended and occurs at doses normally used in humans for 
prophylaxis, diagnosis or therapy of disease, or for modification of physiological function ?[45].  
This definition has been criticised by Edwards and Aronson [59] because of lack of clarity in the term 
 ‘ŶŽǆŝŽƵƐ ? ?&ŽƌƚŚŝƐƌĞĂƐŽŶ ?ĚǁĂƌĚƐĞƚĂůƉƌŽƉŽƐĞĚĂŶĞǁ Ě ĨŝŶŝƚŝŽŶĨŽƌZ P 
 ‘An appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a 
medicinal product, which predicts hazard from future administration and warrants prevention or 
ƐƉĞĐŝĨŝĐƚƌĞĂƚŵĞŶƚ ?ŽƌĂůƚĞƌĂƚŝŽŶŽĨƚŚĞĚŽƐĂŐĞƌĞŐŝŵĞŶ ?ŽƌǁŝƚŚĚƌĂǁĂůŽĨƚŚĞƉƌŽĚƵĐƚ ?[59].  
 However, ŝƚŝƐĚŝĨĨŝĐƵůƚƚŽĚĞƚĞƌŵŝŶĞǁŚĂƚƚǇƉĞƐŽĨZǁŽƵůĚďĞĐŽŶƐŝĚĞƌĞĚĂƐ ‘ĂŶĂƉƉƌĞĐŝĂďůǇ ?
harmful reaction. The American Society of Health-System Pharmacists has also excluded minor 
reactions [38] in their definition, whilst Strand et al. have included them [41]. 
In this thesis, however, the definition by WHO will be applied due to its wider coverage which 
includes all ADRs no matter how minor, and with the anticipation that all ADRs will be accounted for 
and not missed. 
Some ADRs are unexpected and not preventable, for example, an allergic reaction to an antibiotic 
where the patient is not known to have the allergy [3, 38]. An ADR can also occur due to an error and 
cause harm to a patient [38, 55], for example, ŐŝǀŝŶŐĂƉĂƚŝĞŶƚƉĞŶŝĐŝůůŝŶǁŚĞŶƚŚĞƉĂƚŝĞŶƚ ?ƐŚŝƐƚŽƌǇ
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shows evidence of allergy to the antibiotic.  This type of ADR overlaps with ME and is considered 
preventable [3, 38]. Thus, an ADR occurring due to an error will be classified as ME in this thesis. 
ADRs have been classified as type A or type B reactions by Rawlins and Thompsons [60]. Type A 
reactions (augmented) are predictable especially where the pharmacological properties of the drug 
are known. These reactions are dose-dependent, for example, hypoglycaemia caused by insulin. They 
are also very common and rarely fatal [59]. Type B (bizarre) reactions are rare and unpredictable 
from the pharmacological properties of the drugs, for example, hypersensitivity reaction due to 
penicillin intake. This reaction does not show a clear relationship between the dose and the reaction, 
and can be fatal [59]. 
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1.4.4 Therapeutic failure 
Drug therapy is given to a patient to accomplish a positive therapeutic outcome. There are 
circumstances where the expected outcome is not achieved or accomplished. This is classified as TF. 
/ƚŝƐĂůƐŽŬŶŽǁŶĂƐ ‘ƚŚĞƌĂƉĞƵƚŝĐŝŶĞĨĨĞĐƚŝǀĞŶĞƐƐ ?[61]. Several reports have attempted to define TF as 
described below. 
Hallas et al. [62] defined TF as 
 ‘an absence of therapeutic response that could be linked causally to a prescribed dose that was too 
low, to drug non-compliance, recent dose reduction or discontinuation, interaction, or inadequate 
therapeutic monitoring. ?  
Nelson and Talbert. [63] defined TF as 
 ‘an inadequate therapeutic response to a drug as evidenced by the presence of symptoms of a 
diagnosed disease state or condition. ? 
Both definitions have similar concepts. An uncontrolled disease (absence of or inadequate 
therapeutic response) could occur when the expected outcome of a drug therapy is not achieved 
[63]. This could be due to patient non-adherence to drugs, recent dose reduction or discontinuation, 
interactions, too low a dose prescribed or inadequate therapeutic monitoring [62]. Meyboom et al. 
[64] added that pharmaceutical defect and counterfeit, resistance, and tolerance could also result in 
TF. The definition by Nelson and Talbert [63] however, is wide and not restricted to certain 
conditions like the definition by Hallas et al. [62].  
One of the challenges in the drug safety field is differentiating between various ADE sub-types. TF 
overlap with MEs. For example, omission of necessary medication therapy, inadequate dose, 
interaction, inadequate therapeutic monitoring or pharmaceutical defect and counterfeit which lead 
to TFs can also be classified as MEs. Thus, it is important to have a clear definition for each type of 
ADE so that events will not be missed or underestimated. To be consistent throughout the thesis, the 
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less stringent definition of TF by Nelson and Talbert [63] will be used and TF could result from patient 
non-adherence to drug resistance or tolerance. 
 
1.4.5 Drug overdose 
Camidge et al. [65]  have defined drug overdose as: 
 “the exposure of an individual (by ingestion or inhalation) to an amount of substance associated with 
the significant potential to cause harm. ?  
It occurs when a drug (a pharmaceutical preparation available on prescription or over-the counter) is 
used in an amount that is higher than its normal dose [66]. This definition will be used throughout 
this thesis and can be categorised into accidental poisoning and intentional self-poisoning [65].  
Accidental poisoning may occur when a patient unintentionally consumes an overdose of drugs and 
experiences adverse events. Intentional or deliberate poisoning occurs when a patient intentionally 
consumes an overdose of drugs.  If the intentional DO resulted in death, it is diagnosed as suicide 
[65].  
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1.4.6 Adverse drug withdrawal syndrome 
There are a number of reasons for a drug to be withdrawn: patient experiencing an ADR, 
inappropriate prescribing, or poor adherence [67-69]. All these could lead to adverse withdrawal 
syndrome. Occasionally, withdrawal symptoms are missed due to misdiagnosis. The symptoms may 
mimic a relapse or recurrence of the underlying disease for which the medication was originally 
prescribed [67]. The symptoms may also be misdiagnosed for adverse effects of a new medication or 
for TF [67]. 
Graves et al. [70] defined ADWS as 
  “a clinical set of symptoms or signs that are related to the removal of a drug. ? 
Edwards and Aronson [59] classified drug withdrawal as a type of ADR. However according to WHO 
[45], an ADR is a reaction occurring at normal therapeutic doses. Discontinuation of a drug indicates 
that the drug is not used, which is in contrast to the ADR definition by WHO [45]. Whenever ADWS is 
mentioned in this thesis, the definition by Graves et al., [70] is being used. 
 
1.4.7 Adverse drug event-related admissions 
When a patient experiences an ADE, there are a number of actions which they can take which to a 
large extent, depend on the severity of the event. Many severe ADEs will result in admissions to 
hospitals for treatment (an ADE-related admission), which is represented as F to I in Figure 1.1. These 
admissions can be further classified into ADR, TF, ME, DO or ADWS-related admissions. 
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1.5 Identifying adverse drug events 
There are various ways to detect ADEs depending on the type of events and setting of the studies. 
These include chart review [9-11, 71] , spontaneous reporting [72, 73], computer surveillance [74, 
75], observation [76, 77], intervention documentation [78, 79], and hospital database review [80, 
81].   
 
1.5.1 Chart review 
In this method, patient medical ŶŽƚĞƐ ?ŵĞĚŝĐĂƚŝŽŶĐŚĂƌƚƐ ?ŶƵƌƐĞƐ ?ŶŽƚĞƐ, and laboratory results are 
reviewed manually to identify events. This can be conducted by a health care professional such as a 
research nurse, a pharmacist, or a research assistant. The general rule is to look out for any 
abnormalities in the charts which could indicate an ADE such as, development of new rashes, low 
blood glucose, or a ƉŚǇƐŝĐŝĂŶ ?ƐŽƌĚĞƌĨŽƌĂŶĂŶƚŝĚŽƚĞŽƌƐƵĚĚĞŶĐĞƐƐĂƚŝŽŶŽĨĂĚƌƵŐ[82]. The assessor 
needs to be properly trained in how to detect the anomalies and how to interpret the data. 
A chart review can be conducted prospectively or retrospectively. Prospective reviews [71, 83, 84] 
are conducted while the patient is still in the hospital, and allow additional investigations such as 
patient interviews or new tests to be conducted. For retrospective reviews [15, 85], the patient is not 
available for more information and the researcher is dependent on the information documented in 
the chart. Inadequate or incomplete documentation in the chart is one of the major limitations and 
could result to a wrong interpretation of an event [86-88]. 
The Institute of Healthcare Improvement (IHI) is an independent, non-profit organisation based in 
the US which aims to improve the health care system by developing effective practices and models of 
care in cooperation with patients and health care professionals [27]. This organisation has introduced 
a trigger tool to make chart reviewing simpler [89, 90]. The tool contains a predetermined list of 
ƐƉĞĐŝĨŝĞĚƚƌŝŐŐĞƌƐƚŚĂƚĐĂŶŝŶĚŝĐĂƚĞǁŚĞƚŚĞƌĂŶŚĂƐŽĐĐƵƌƌĞĚ ?ĨŽƌĞǆĂŵƉůĞ ? “ƌŝƐĞŝŶƐĞƌƵŵ
creatinine, ? “ƵƐĞŽĨĂŶƚŝ-emetics, ?Žƌ “ĂďƌƵƉƚĐĞƐƐĂƚŝŽŶŽĨĂĚƌƵŐ ? ? The trigger tool can be used 
during chart review to assist the identification of any abnormalities in the chart. However, this tool 
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may have to be modified to suit the study site. For example, medical wards and paediatric wards may 
have different triggers; or different countries may have different prescribing patterns [89, 91].  
Chart reviewing has been found to detect more ADEs compared to other methods [75, 85, 92].  The 
use of several sources such as medical notes, medication charts, ŶƵƌƐĞƐ ?ŶŽƚĞƐ ?ůĂďŽƌĂƚŽƌǇƌĞƐƵůƚs and 
patient interviews help to compensate for the lack of completeness in each source [93]. Some 
important information that could confirm the causality for certain types of ADE have been found to 
be identifiable ĨƌŽŵŶƵƌƐĞƐ ?ŶŽƚĞƐ[94].  This method also has the advantage of interviewing patients 
for more information or clarification, if conducted prospectively. It is the preferred method for 
research on drug safety as it can accurately document the outcome [95]. It can also be used for a 
more focused review such as about a specific drug or ward. 
However, chart review is labour intensive and a time consuming method. It is costly as the assessors 
may need specialised training. Furthermore, the quality of the information is dependent upon the 
assessors ability to conduct adequate chart reviews  [96]. Although it is a suitable method for this 
type of research, it was found to be not suitable to detect ADEs in outpatient departments because 
most events were not recorded in the notes [97]. 
 
1.5.2 Incident or spontaneous reporting 
This is the primary method which institutions use to identify ADRs. A new drug will only have been 
tested clinically in a few thousands of patients and millions will be consuming it once it is marketed. 
The monitoring of ADR reports is necessary to keep track ŽĨƚŚĞĚƌƵŐ ?ƐƐĂĨĞƚǇƉƌŽĨŝůĞĂŶĚenable the 
authorities to issue any warnings regarding the use of a drug. However, this method will not be able 
to determine the incidence of ADRs due to incomplete numerators (number of ADRs occurring) and 
denominators (number of patients exposed to a drug). Furthermore, the reporting is essentially 
voluntary. The reporter will only report when they feel it is important to do so, or they have 
sufficient interest in reporting ADRs. 
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Ideally, health care professionals would report reactions to the drug authority that is responsible for 
collating all such reports, and the reports would be documented and monitored. The reports should 
also be made by patients and drug companies. The spontaneous reporting system for ADRs is well-
established in many countries including Malaysia [18].  
The Malaysian ADR Advisory Committee (MADRAC) was established under the Drug Control 
Authority (DCA) to monitor safety profiles of drugs registered in Malaysia [18]. It provides the DCA 
with information pertaining to drug safety issues. The National Drug Safety Monitoring Centre, which 
is the secretariat to MADRAC, was accepted as a member of WHO Drug Safety Monitoring Program in 
1990 [18]. Under this program, all ADR reports received and screened by MADRAC are submitted to 
the Uppsala Monitoring Centre in Sweden for inclusion into the WHO database. MADRAC hold 
meetings every two months to conduct causality assessments. Members of MADRAC consist health 
care professionals appointed by the Director General of Health [18]. Initially, pharmacists screen all 
the cases and conduct causality assessments of common ADRs. Only rare or serious reactions are 
presented and discussed during the meetings. MADRAC uses the WHO causality assessment scale 
[98] for all cases and if further investigation is needed for rare or fatal reactions, the Naranjo scale 
[99] is used as a guideline. Other than its monitoring role, MADRAC promotes ADR reporting and 
provides information about ADRs to physicians, pharmacists and other health care professionals.  
Reporting an ADR can be voluntary and generated. Voluntary reports are sent when a reporter 
becomes aware of an incident and decides to make one. Generated reports are made when health 
care professionals or patients are interviewed to seek information on any possible incidents [72, 75]. 
ADR reporting can also be generated by sending reminders to health care professionals to report 
incidents [100]. 
Apart from ADR reporting system, an incident reporting system for ME is also available in some 
countries [101-103] and this was introduced recently in Malaysia [50]. In  2009, the Pharmaceutical 
Services Division under MOH embarked on a reporting system called the Medication Error Reporting 
System (MERS) [50]. The system is managed by a Medication Safety Centre which established a 
database on MEs that includes all error reports related to medication use process. The reporting is 
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done on voluntary basis by health care professionals. All reports are reviewed by National 
Medication Error Committee, which comprises of members from the public and private sectors [50].  
Incidents of DO are also documented in some countries [104-106]. In Malaysia, the National Poison 
Centre is a 24-hour call centre for drug and poisoning information [107]. However poison centres 
usually document the drug queries and do not collect reports related to overdose. Thus, the data 
from the centre may not be able to provide the rate of overdoses. 
Spontaneous incident reporting is cheap and less-time consuming compared to other methods. This 
method has been effective in generating signals where rare and serious ADRs have been identified 
[95]. However, the rate of reporting incidents was found to be low in some countries [108-110]. It is 
dependent on the reporter choosing to report an event and therefore, the rate derived from this 
method is not reliable. Furthermore, this method will not be able to identify all types of ADE such as 
TF and ADWS as there is no system in place to report such incident types. 
 
1.5.3 Computerised surveillance or screening 
This method can only be used where there is a comprehensive patient information system in a 
hospital. This would mean all the records such as clinical, pharmacy, laboratory and administrative, 
are linked to a common database. Such database can be used to screen for events based on certain 
rules such as increased or decreased serum creatinine and blood glucose levels [74, 96]. These rules 
ĂƌĞƐŝŵŝůĂƌƚŽƚŚĞ ‘ƉƌĞĚĞƚĞƌŵŝŶĞĚůŝƐƚ ?ŽĨƚƌŝŐŐĞƌƚŽŽůƐĂŶĚĂƌĞĨůĂŐŐed in the database. Alerts are 
created if any abnormalities occurred. Personnel can see the alerts and perform a targeted chart 
review to verify the alerts. Classen et al. [111] developed a computerised ADE monitor to detect 
ADEs. Each day, a list of all potential ADEs is generated and a pharmacist reviews the medical records 
of all the patients with potential ADEs and interviews them when necessary, to determine the 
accuracy and causality. 
Computerised surveillance is less time-consuming and personnel-intensive compared to chart review 
studies. Jha et al. [74] compared three methods of identifying an ADE and found that a computer 
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search strategy required only 11 person-hours per week compared to 55 person-hours per week for a 
chart review. In addition, Schneider [95] noted that computer screening is capable of detecting errors 
at the prescribing, dispensing, administration, and monitoring levels. Through this method, events 
can be detected at the time they occur [95]. 
However, the disadvantage of this method is that it may not detect events which are not flagged with 
alerts such as subjective symptoms (headache and dizziness). Moreover, it may trigger false positive 
alerts, for example, when a drug is stopped [95]. Thus, the sensitivity and specificity of computer 
alerts depend on the rules or indicators used. 
 
1.5.4 Observational method 
Observational methods involve trained researchers observing a practice in a normal setting. For 
example, an administration of a drug to a patient [76] and documenting the observation. This direct 
observation method is capable of measuring actual errors [95] by identifying errors unknowingly 
committed by a health care professional.  In a study by Barker et al. [76], the preparation and 
administration of drugs by nurses in the ward was witnessed by trained observers. One advantage of 
this method is that researchers can intervene during the drug administration and patient harm could 
be avoided.  
This method can be used to track the performance of an institution [95]. Although it is good for 
quantitative measurement of types of errors, another method is needed to find the underlying 
causes of the errors. Taxis and Barber [112] investigated the errors in the administration of 
intravenous drugs by nurses in a hospital setting through trained observers. They combined the 
observation method with nurse interviews to identify the causes of the errors. 
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1.5.5 Intervention documentation method 
Another method to identify ADEs is to document interventions made by health care professionals. 
These interventions are taken in response to an event. This method has been used in a hospital to 
study the percentage of prescriber contacts documented as pharmacist interventions [113], in an 
emergency department to  determine the pharmacist interventions and potential cost avoidance due 
to the interventions [114], and in a community setting to document the interventions made by 
pharmacy personnel with patients and prescribers [115]. Where interventions are routinely 
documented, it can serve as a method to identify errors and potential errors and determine 
strategies to improve the current system in an institution. However, the rate of errors generated 
from this method depends on the quality of the documentation and whether all interventions were 
recorded [96]. Schneider [95] noted that this method mostly identifies errors made during the 
prescribing process thus a combination of methods is needed to identify other types of ADEs.  
 
1.5.6 Hospital database review 
Hospital databases such as administrative or claims database can be reviewed for ADEs [96]. Using 
selected codes from the International Classification of Diseases (ICD), the database is searched for 
events related to drugs. Waller et al. [116] reviewed a hospital database in England by selecting all 
the 10th International Classification of Disease (ICD-10) codes which included the word  ‘ĚƌƵŐ-
induced, ?ĚŝĂŐŶŽƐĞƐŝŶĚŝĐĂƚĞĚĂƐ ‘ĚƵĞƚŽ ?ĂĚƌƵŐ ?ŽƌĐŽĚĞƐǁŚŝĐŚĐůĞĂƌůǇƐƚĂƚĞĚƚŚĂƚĂŶZŚĂƐ
occurred.  
Hospital database review is less expensive to perform compared to chart review and computerised 
surveillance [96]. However, the quality of data obtained depends on the quality of data recording and 
coding [81]. The events identified through this method were found to underestimate the ADEs rate 
[81, 116] due to incomplete information. 
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1.5.7 Combining methods to identify adverse drug events 
It is challenging to choose the appropriate method to detect ADEs since each method has its own 
strengths and weaknesses. To overcome the limitations, some studies combined identification 
strategies to maximise the detection of ADEs. A study by Jha et al.,[75]  compared computer 
monitoring with chart review and practitioner reporting to identify ADEs in a tertiary care hospital. In 
all the ADEs identified the most effective strategies were chart review (identified 65% of all ADEs) 
and computer-based monitor (identified 45% of all ADEs). There were overlaps of ADEs identified by 
both strategies, whist practitioner reporting identified only 4% of it. Similarly, Gurwitz et al., [44] 
combined chart review with practitioner reporting to identify ADEs in nursing homes. They identified 
546 ADEs, of which 17% were done through reporting and the remainder, using chart review. In both 
studies, chart review was found to have identified more ADEs compared to other methods. In 
addition, Brvar et al. [85] retrospectively reviewed patient charts, hospital information system and 
national spontaneous reporting system for ADRs. The detected frequency of ADR-related admissions 
using chart review was found to be 5.8%, while that using hospital database search was 0.2%. No 
ADR reports for the studied patients had been sent to the national reporting system. This study 
highlighted that physicians document an observed ADR in the medical record but rarely code or 
report it. 
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1.5.8 Identifying adverse drug event-related admissions 
All the methods discussed above can be used to identify ADE-related admissions. However, different 
methods may identify different types of ADEs. The effect of different study designs on the prevalence 
estimates of ADE-related admissions have been explored in a few studies [117-120]. Winsterstein et 
al. [117] explored preventable drug related admissions in a systematic review of 15 papers, whilst 
Beijer and de Blaey [118] explored the impact of study design on ADR prevalence estimates in a 
meta-analysis of 68 studies. Similarly, Kongkaew et al. [120] examined the difference in ADR 
prevalence rates between population groups and methods in 25 studies. Leendertse et al. [119] 
explored the impact of study characteristics on prevalence estimates of drug-related admissions in 
95 studies which included the ones explored by  Winsterstein et al. [117]. According to these studies, 
the prevalence estimates of ADE are influenced by: 
a) Study method 
Winsterstein et al. [117] and Beijer and de Blaey [118] reported that chart review studies 
resulted in higher prevalence rates compared to other methods. Chart review is considered 
ƚŽďĞƚŚĞ ‘ŐŽůĚƐƚĂŶĚĂƌĚ ?ŵĞƚŚŽĚin identifying ADEs. Studies which did not use chart review 
generally reported a lower prevalence of ADEs. Referring to the example given above 
(Section 1.5.7) Brvar et al. [85] reported a prevalence of 5.8% using chart review compared 
to only 0.2% using computer monitoring. Retrospective chart review studies, on the other 
hand, have the tendency to report a lower prevalence rate [121, 122] compared to 
prospective chart review studies [117]. This is attributed to poor documentation in patient 
notes. Prospective studies which have used chart review as their mode of data collection 
have been able to interview patients, relatives, and medical teams for more information, 
where information in the charts was incomplete [9, 11, 123, 124]. Furthermore, studies 
which used this combination of methods (chart review and interview) reported a higher 
prevalence estimates compared to chart reviews alone [120]. In addition, Kongkaew et al. 
[120] reported that studies which have included pharmacists as chart assessors have been 
shown to detect higher rates of ADEs compared to using other health care professionals. 
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b) Study population 
Winsterstein et al. [117] found that inclusion or exclusion of planned admissions or patient 
transfers from other wards or hospitals made little difference to the prevalence estimates. 
Furthermore, they found that studies of patients aged over 70 years reported an almost 
doubled prevalence estimates than those reported studies including only younger patients. 
In addition, Beijer and de Blaey [118] reported that the prevalence estimates for studies of 
elderly patients (aged 65 years and above) were four times higher than those studies of only 
young patients. 
c)  Study sample size 
Beijer and de Blaey [118] reported that studies with a larger number of patients stated lower 
prevalence estimates when compared to those with a lower number of patients (varying 
from 100 to 1,988 hospitalisations). Likewise, Lessing et al. [125] reported that the 
proportion of adverse event decreased with higher number of sample size, where studies 
with more than 20,000 patients found a prevalence of less than 1%. However, they did not 
deny that the quality of data collection methods and publication bias (where smaller studies 
with higher prevalence rate have a greater chance of being published than larger studies 
with lower prevalence rate) may have affected the prevalence rates reported.  
d) Study outcome 
The use of wider definitions of drug-related admissions (including TF and patient non-
adherence) result in a higher prevalence rate [117]. Similarly, Leendertse et al., [119] found 
that studies investigating ADEs reported higher prevalence estimates compared to studies 
which explored only ADRs, unsurprisingly as ADR is one type of ADE. 
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1.6 Epidemiology of adverse drug event-related admissions 
The prevalence and impact of ADEs have been studied with various outcomes reported due to 
variation in the definition, classification, causality assessment and detection methods. Of particular 
interest is the prevalence of ADEs that result in hospital admissions. 
Prevalence is the number of cases in the population at a point in time and is calculated by dividing 
the number of people with the disease or condition at a point in time by the number of individuals 
studied. Prevalence is often expressed as a percentage, calculated by multiplying the ratio by 100 
[126]. Prevalence differs from incidence in that it includes all cases rather than only new cases. 
Some studies have explored ADE-related admissions as a whole whilst others have explored its sub-
types. The prevalence of the sub-types will be discussed first, followed by the prevalence of ADE. 
 
1.6.1 Adverse drug reaction-related admissions 
Studies on ADR are the most extensive and span across a range of different areas, including in-
patients [12, 127, 128], primary care [44], paediatrics [129-131], geriatrics [10, 132, 133], and 
hospital admissions [71, 124, 134].  Table 1-2 lists studies which have investigated the prevalence of 
ADR-related admissions.  The prevalence found in these studies range from 0.7% to 12.8%. The wide 
range of prevalence, to a large extent, was affected by the differences in methods and populations 
studied. 
Chart review was the most common method of data collection and was often done in combination 
with patient or health care professional interview, or incident reporting. Studies that used 
computerised database or surveillance method [74, 80, 81] reported a much lower prevalence, 
between 1.7% and 3.3%. As reported by Brvar et al. [85] chart review was found to be the most 
effective and reliable method in identifying ADRs.  The prevalence of ADRs is reported to be under 
estimated if spontaneous reporting or database review methods were used [119].  
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Most of the studies were conducted prospectively. Only four studies were conducted retrospectively 
[80, 81, 85, 121] and the prevalence reported was between 1.7% and 3.3%. The information 
collected through retrospective review is dependent on the quality of the documentation, thus, this 
mode of data collection probably under-estimates the actual prevalence rate. 
Studies conducted in the medical wards [9, 83, 123, 124] reported a higher prevalence compared 
with studies which included all types of wards within the hospital [80, 81, 121, 135, 136]. Van der 
Hooft et al. [121] and Hopf et al. [135] reported that in their studies the percentage of ADR-related 
admissions was highest in the medical wards. The following could be the possible reasons for this: i) 
medical wards are less likely to have planned admissions compared to other wards such as surgery, 
ii) patients admitted to medical wards could be hospitalised for diverse medical conditions compared 
with other wards and iii) patients presenting themselves to hospital could be initially admitted to 
medical wards and subsequently, after further investigations, are transferred to other specialised 
wards.  
Onder et al. [136] concluded that age per se cannot be regarded as a risk factor for ADRs and 
reported that the increased risks can be attributed to polypharmacy or the number of drugs taken. 
Elderly patients are more likely to suffer from a number of medical conditions and therefore, require 
a higher number of drugs  W thus, increasing the risk of drug-related events. Onder et al. [136] also 
suggested that age is of borderline significance only for those hospital admissions related to severe 
ADRs. Similarly, Zopf et al.,[137] based on a multivariate analysis, found that an increased number of 
drugs was one of the independent predictors for the occurrence of an ADR (other predictors were 
increased temperature, decreased erythrocytes, and low thrombocytes). Other studies have also 
found a similar relationship [138, 139]. 
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Table 1-2: Studies on adverse drug reaction-related admissions
 
Author (country) Patient group 
Admission 
type 
Number of 
patients 
studied 
Method 
Prevalence of 
ADR related 
admission 
Most common drug 
groups 
Carrasco-Garrido et 
al., 2010  
(Spain) [81] 
All patients Hospital 20,712,399 
Retrospective hospital 
admission database 
review 
1.7% 
Antineoplastic and 
immunosuppressive 
agents 
Brvar et al., 2009 
(Slovenia) [85] 
Adult patients 
aged 19-94 
years 
Specialised 
medical 
departments 
520 Retrospective chart 
review 5.8% NSAIDs 
Schwake et al., 2009 
(Germany) [11] 
Patients aged 
>14 years Medical ICU 1,554 
Prospective chart 
review, and interview 6.4% antiplatelets 
Van der Hooft et al., 
2008 
(The Netherlands) 
[121] 
All patients Hospital 2,238 
Retrospective 
computerised medical 
records review 
3.3% anti-thrombotics 
Hopf et al., 2008 
(Scotland) [135] 
All patients 
except 
weekend 
admissions 
Hospital 1,101 Prospective chart 
review 2.7% NSAIDs 
Alexopoulou et al., 
2008 
(Greece) [124] 
All patients 
aged 15-100 
years 
Medical 
wards 548 
Prospective chart 
review, and interview 12.8% NSAIDs 
 
table continued....................... 
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Table 1-2 continued: Studies on adverse drug reaction-related admissions
 
Author (country) Patient group 
Admission 
type 
Number of 
patients 
studied 
Method 
Prevalence of 
ADR related 
admission 
Most common drug 
groups 
Saha et al., 2008 
(India) [140] 
All patients 
aged 18-80 
years 
Internal 
medicine 
department 
1,200 Prospective interview 
and chart review 3.8% NSAIDs 
Rivkin, 2007 
(United States) [84] 
All patients 
except 
weekend 
admissions 
Medical ICU 281 Prospective chart 
review 7.5% antiplatelets 
Van der Hooft et al., 
2006 
(The Netherlands) 
[80] 
All acute, non-
planned 
admissions 
Hospital 668,714 
Retrospective 
computer database of 
hospital discharge 
records 
1.8% anticoagulants 
Pirmohamed et al., 
2004 
(Liverpool, UK) [71] 
Patients aged 
>16 years Hospital 18,820 
Prospective chart 
review 6.5% antiplatelets 
Bhalla et al., 2003 
(Cambrigde, UK) [9] 
All patients 
DJHG\HDUV 
 
Medical 
wards 840 
Prospective chart 
review and interview 6.2% not reported 
Ramesh et al., 2003 
(India) [72] 
All patients 
 
Hospital 3,717 
Prospective chart 
review, interview, and 
stimulated reporting 
0.7% cardiovascular drugs 
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Table 1-2 continued: Studies on adverse drug reaction-related admissions
 
Author (country) Patient group 
Admission 
type 
Number of 
patients 
studied 
Method 
Prevalence of 
ADR related 
admission 
Most common drug 
groups 
Onder et al., 2002 
(Italy) [136] 
All patients 
 
Hospital 28,411 Prospective chart 
review 3.4% diuretics 
Mjorndal et al, 2002 
(Sweden) [123] 
All acute 
admissions 
 
Medicine 
and 
cardiology 
departments 
681 Prospective chart 
review and interview 12.0% antiplatelets 
Jha et al., 2001 
(United States) [74] 
All adults 
 
Multi-
departments 3,238 
Prospective 
computerised and 
targeted chart review 
2.3% antibiotics 
Pouyanne et al., 
2000 
(France) [141] 
All patients 
 
Multi 
institutional 
medical 
departments 
3,137 Prospective chart 
review 3.2% 
cardiac stimulants 
and anti-arrhythmic 
Green et al., 2000 
(United Kingdom) 
[134] 
Randomly 
selected 
patients 
Acute 
medical 
assessment 
unit 
200 Prospective chart 
review 7.5% NSAIDs 
Raschetti et al., 1999 
(Italy) [8] 
All patients 
 
Emergency 
department 1,833 
Prospective chart 
review 0.8% cardiovascular drugs 
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Table 1-2 continued: Studies on adverse drug reaction-related admissions
 
Author (country) Patient group 
Admission 
type 
Number of 
patients 
studied 
Method 
Prevalence of 
ADR related 
admission 
Most common drug 
groups 
Schoenemann et al., 
1998 
(Germany) [73] 
All patients 
 
Medical & 
ICU 4,032 Prospective reporting 2.4% NSAIDs 
Ahmed et al., 1997 
(Saudi Arabia) [142] 
All patients 
 
Medical 960 Prospective chart 
review 5.8% NSAIDs 
Hallas et al., 1992 
(Denmark) [83] 
All patients 
 
Medical 1,999 Prospective interview, 
and chart review 8.4% NSAIDs 
Hallas et al., 1990 
(Denmark) [62] 
All patients 
 
Medical 333 
Prospective patient 
interview, and chart 
review 
8.1% insulin 
Bergman et la., 1981 
(Sweden) [143] 
All patients 
aged16-97 
years 
 
Internal 
medicine 285 Prospective interview 5.6% cardiovascular drugs 
Hurwitz et al., 1969 
(Northern Ireland) 
[1] 
All patients 
 
Hospital 1,268 Prospective chart 
review and, interview 2.9% antimalarial 
Carrasco [81]Brvar [85]Schwake [11]Van der 2008 [121]Hopf [135]Alexopoulou [124]Saha [140]Rivkin [84]Van der 2006 [80]Pirmohamed [71]Bhalla [9] 
Ramesh [72]Onder [136]Mjorndal [123]Jha 2001 [74]Pouyanne [141]Green [134]Raschetti [8]Schoenemann [73]Ahmed [142]Hallas 92 [83]Hallas 90 
[62]Bergman [143]Hurwitz [1] 
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Several studies have found that more women than men experienced ADRs [71-73, 80, 83, 136, 141, 
143]. The following reasons were given for this: i) sex affects the drugs to which a patient might react 
due to their differing health conditions [144], ii) women have increased bioavailability of drugs and 
greater sensitivity of target organs [145] and iii) women are more aware of the status of their 
medical conditions [34], thus, seek medical attention more frequently compared to men. The slower 
and lower renal clearance of drugs in women was also suggested as one of the possible reasons for 
the higher rate of reaction [144].   
Drugs associated with adverse drug reaction-related admissions  
The most common drug groups associated with ADR-related admissions include non-steroidal, anti-
inflammatory drugs (NSAIDs), and anti-platelets. These drugs were responsible for 70% to 80% of 
ADR-related admissions. The system most commonly affected by an ADR was gastrointestinal (GI), 
resulting in GI bleeding. Aspirin was reported the most common single drug causing GI bleeding [11, 
71, 84, 123].  
1.6.1.1 Studies in Malaysia 
There was only one study of ADR-related admissions in Malaysia (not listed in Table 1-3 because of 
lack of information as published only in abstract form). This study reported that of 110 patients 
admitted to medical wards due to DRPs, 34% was as a result of ADRs [22]. NSAIDs induced gastritis 
was the most common cause of these admissions (the percentage was not reported). 
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1.6.2 Medication error-related admissions 
ME-related admissions are also known as preventable drug-related admissions (PDRA) [54] or 
preventable ADE-related admissions [53]. Up to 92% of all drug-related admissions have been found 
to be preventable [146]. Table 1-3 summarises studies investigating ME-related admissions. The 
prevalence of ME-related admissions from these studies was between 1.2% and 10.6%.  
All studies were conducted prospectively and chart review was the main mode of data collection 
(Table 1-3). At least three studies have investigated admissions related to all types of MEs [139, 147, 
148], giving prevalence from 1.2% to 4.3%. Studies by Green et al. [134] and Pirmohamed et al. [71] 
investigated ADR-related admissions and their preventability, whilst, other studies investigated 
admissions related to ADR, TF, drug-drug interactions, and drug-alcohol interactions. Thus, 
comparison and among studies is difficult and may not reflect the prevalence of all types of MEs. 
Drugs associated with medication error-related admissions  
Four studies [83, 134, 147, 148] reported NSAIDs as the drug most frequently associated with ME-
related admissions, the most common event being GI bleeding. These errors were reported to have 
been caused by ignorance of patients and physicians about the said drug. Hardmeier et al  [148] 
divulged that 10% of the patients admitted due to MEs took NSAIDs without consulting a health care 
professional  resulting in GI complications. In contrast, Howard et al. [147] reported that the failure 
to prescribe a GI prophylaxis in high-risk patients resulted in 12% of ME-related admissions. 
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Table 1-3: Studies on prevalence of medication error-related admissions 
 
Author (country) 
Patient 
group 
Admission 
type 
Number of 
patients 
studied 
Method Type of MEs 
Prevalence of 
ME-related 
admissions 
Most common 
drug group 
Leendertse et al., 
2008 (Netherlands) 
[139] 
Adults 
 ?A? ? ?years) Hospital 12,793 
Prospective chart 
review, trigger tool, 
and physician report 
Prescribing 
and 
administrative 
errors 
2.6% Anticoagulants 
Zargarzadeh et al., 
2007 (Iran) [146] 
Sampled 
patients 
 ?A? ? ?years) 
Hospital 1,000 
Prospective chart 
review 
Preventable 
ADRs and TFs 
10.6% 
Cardiovascular 
drugs 
Hardmeier et al., 
2004 
(Switzerland) [148] 
All patients 
Internal 
medicine 
department 
6,383 
Prospective hospital 
ĚĂƚĂďĂƐĞ “ĞǀĞŶƚ ?
review, and 
physician monitoring 
All types of 
MEs 
1.2% NSAIDs 
Howard et al., 2003 
(England) [147] 
All patients 
Medical 
admission 
unit 
4,093 
Prospective chart 
review, and patient 
and physician 
interview 
All types of 
MEs 
4.3% NSAIDs 
Pirmohamed et al., 
2003 (England) [71] 
Adults 
(>16) 
Medical and 
surgical 
wards 
18,820 
Prospective chart 
review, and 
interview 
Preventable 
ADRs 
4.7% Not reported 
Green et al., 2000 
(England) [134] 
Random 
selection of 
200 patients 
Acute 
medical 
admissions 
200 
Prospective chart 
review, and 
interview 
Preventable 
ADRs 
6.0% NSAIDs 
table continued.......... 
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Table 1-3 continued: Studies on prevalence of medication error-related admissions 
 
Author (country) 
Patient 
group 
Admission 
type 
Number of 
patients 
studied 
Method Type of MEs 
Prevalence of 
ME-related 
admissions 
Most common 
drug group 
Raschetti et al., 
1999 (Italy) [8] 
Adults Hospital 1,883 
Prospective chart 
review 
Preventable 
ADRs, TFs, drug-
drug 
interactions and 
alcohol-drug 
interactions 
1.4% Not reported 
Nelson and 
Talbert, 1996 
(US) [63] 
All patients 
Coronary 
and medical 
intensive 
care unit and 
internal 
medicine 
unit 
452 
Prospective chart 
review, and 
medical team 
interview 
Preventable 
ADRs, TFs, and 
DOs 
9.6% Not reported 
Hallas et al., 1992 
(Denmark) [83] 
Adults 
Medical 
wards 
1,999 
Prospective chart 
review, and 
interview 
Preventable 
ADRs and TFs 
3.4% Not reported 
 
Leendertse [139]Zargarzadeh [146]Hardmeier [148]Howard [147]Pirmohamed [71]Green [134]Raschetti [8]Nelson [63]Hallas 92 [83]
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1.6.2.1 Studies in Malaysia 
The number of studies which investigated ME-related admissions in Malaysia is small. Three studies 
which have explored different types of ME in hospitals [149-151] reported prevalence of ME 
between 11% and 25%. However, these studies did not investigate admissions related to ME. 
Another study which investigated admissions related to drugs reported that 92% of it was 
preventable [22]. However, no further details on the types and causes of these preventable 
admissions were given. 
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1.6.3 Therapeutic failure-related admissions 
Comparison between studies that have investigated TF is complicated because of the use of different 
definitions. As TF overlaps with ME, some of the categories in TF could also be classified as ME.  
The studies that have investigated TF are summarised in Table 1-4. All studies were conducted 
prospectively. Chart review and patient interview were main modes of data collection. Based on 
these studies, it is estimated that the prevalence of TF-related admission is between 1.1% and 9.3%. 
TF has many causes including patient non-adherence to drugs, dose reduction or discontinuation, 
interactions, too low a dose prescribed or inadequate therapeutic monitoring [62], [146]. A study in 
Iran reported that up to 80% of the drug-related admissions were due to therapeutic failure and this 
was attributed to low literacy among patients.  Zargarzadeh et al. [146] explained that a lack of ability 
to read drug instructions and failure to seek information about it may have resulted in the high level 
of therapeutic failure. Other causes reported were drug-drug interactions, inadequate monitoring, 
dose reduction or discontinuation, too low a dose being prescribed and overdose [8, 9, 83, 152]. In 
this thesis, drug-drug interactions, inadequate monitoring, dose reduction or discontinuation and too 
low dose prescribed are classified as MEs. 
A few factors increase the risk of admission related to non-adherence including poor recall of drugs 
taken by patients, seeking medical advice from numerous physicians, female gender, polypharmacy, 
expensive drugs, and seeking alternative medication or treatment [153]. In addition, Davidsen et al. 
[154] reported ADRs and discontinuation of the use of drugs (either because patients ran out of it, or 
felt there was no further need for it) as the reasons for non-adherence [154].  
 
Drugs associated with therapeutic failure -related admissions  
Cardiovascular drugs were the most common drug group associated with therapeutic failure 
probably because they are used widely in clinical practice. Cardiovascular complications such as 
arrhythmias and congestive heart failure were the most common conditions resulting in admissions 
[147, 152].
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Table 1-4: Studies on prevalence of therapeutic failure-related admissions 
 
Author (country) 
Patient 
group 
Admission type 
 
Number of 
patients 
studied 
Method 
Prevalence of 
TF-related 
admissions 
% of highest cause 
for TF 
Most common 
drug group 
Zargarzadeh et 
al., 2007 
(Iran) [146] 
Selected 
patients 
Hospital 1,000 
Prospective 
quota sampling 
9.3% 
80 %: Non-
adherence 
Cardiovascular 
drugs 
Franceschi et al., 
2004 
(Italy) [152] 
All 
patients 
Emergency 
department 
607 
Prospective 
patient interview 
6.8% 
78%: Non-
adherence 
Cardiovascular 
drugs 
Bhalla et al., 2003 
(England) [9] 
All 
patients 
ĂŐĞĚA? ? ?
years 
Medical wards 840 
Prospective chart 
review and 
interview 
2.7% 
48%: Non- 
adherence 
Not reported 
Howard et al., 
2003 (United 
Kingdom) [147] 
All 
patients 
Medical 
admissions unit 
4,093 
Prospective chart 
review, and 
patient/GP 
interview 
1.3% 
(non-adherence 
cases only) 
Cardiovascular 
drugs 
Malhotra et al., 
2001 
(India) [153] 
Elderly 
patients 
ĂŐĞĚA? ? ? 
Medical 
emergency 
department 
578 
Prospective 
interview, and 
chart review 
7.6% 
(non-adherence 
cases only) 
Cardiovascular 
drugs 
Raschetti et al., 
1999 
(Italy) [8] 
All 
patients 
Emergency 
department 
1,883 
Prospective chart 
review 
1.4% Not reported Anti-diabetics 
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Table 1-4 continued: Studies on prevalence of therapeutic failure-related admissions 
 
Author (country) Patient group 
Admission 
type 
 
Number of 
patients 
studied 
Method 
Prevalence of 
TF-related 
admissions 
% of highest 
cause for TF 
Most common 
drug group 
Nelson and Talbert, 
1996 
(US) [63] 
All patients 
Coronary, 
medical ICU 
and internal 
medicine unit 
452 
Prospective chart 
review, and 
medical team 
interview 
8.9% 
Not reported Not reported 
Hallas et al., 1992 
(Denmark) [83] 
All patients Medical 1,999 
Prospective 
interview, and 
chart review 
2.8% 
64 %: non-
adherence 
Cardiovascular 
drugs 
Hallas et al., 1990 
(Denmark) [62] 
All patients Medical 333 
Prospective 
interview, and 
chart review 
2.7% 
56 %: non-
adherence 
Not reported 
Davidsen et al., 1988 
(Denmark) [154] 
All patients Cardiology  426 
Prospective chart 
review 
3.8% Not reported 
Cardiovascular 
drugs 
Bergman and 
Wiholm, 1981 
(Sweden) [143] 
All patients 
Internal 
medicine  
285 
Prospective 
interview, and 
observation 
6.7% 
58%: non-
adherence 
Cardiovascular 
drugs 
Zargarzadeh [146]Franceschi [152]Bhalla [9]Howard [147]Malhotra [153]Raschetti [8]Nelson [63]Hallas 92 [83]Hallas 90 [62]Davidsen [154]Bergman [143] 
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1.6.3.1 Studies in Malaysia 
There are no studies in Malaysia specifically investigating TF resulting in hospital admissions. 
However, there are studies investigating adherence. These studies focused on specific medical 
conditions, such as hypertension [155-158], diabetes mellitus [23, 158], tuberculosis [159, 160], renal 
disease [161], and asthma [158]. The percentage of patients with poor adherence in these studies 
was between 26% and 56%. TŚĞŵŽƐƚĐŽŵŵŽŶƌĞĂƐŽŶƋƵŽƚĞĚĨŽƌƉŽŽƌĂĚŚĞƌĞŶĐĞǁĂƐ ‘ĨŽƌŐĞƚƚŝŶŐƚŽ
ƚĂŬĞĚƌƵŐƐ ?[158, 161]. Other reasons were side effects [161], a decision not to take the drugs [161], 
inability to read instructions on drug labels [158] , and complex, costly or ineffective drug regimens 
[155]. In addition, in the abstract, Farooqui et al. [22] reported that patient non-adherence 
accounted for 39% of the identified admissions related to drugs. This study found that patient intent 
to seek alternative medicine was the main cause for poor adherence. 
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1.6.4 Drug overdose-related admissions 
Drug overdoses whether intentional or not cause significant morbidity and mortality. Poisoning 
accounted for 3.6% of all deaths registered in England and Wales in 2009 [162]. Drug poisoning 
mortality rates rose 62% from 1999 to 2004 in US [163].  
Studies that have investigated DOs or poisoning-related admissions are summarised in Table 1-5. The 
prevalence of overdose-related admissions in these studies is estimated between 0.1% and 17.3%. 
The low prevalence estimates of 0.1% [122], 0.2% [164], and 0.4% [165] were probably due to the 
study design  W retrospective review of patient records. All other studies were prospective. Schwake 
et al. [11] reported the highest prevalence (17.3%). This was because of the study site (intensive care 
unit) which serves as a regional toxicology unit, thus, all poisoning cases are treated in this unit 
before getting transferred to an appropriate ward. Nevertheless, this study raises concerns about the 
high level of self-poisoning. 
Intentional overdoses were reported to be the most common mode of poisoning in some studies 
[166, 167], although accidental overdoses were found the be more common in children [164]. Most 
of the studies reported that women and younger patients were found to be at a higher risk of being 
admitted due to DO. Family conflict was found to be the main risk factor for intentional overdoses in 
women [142], whilst in young patients, personal and family relationship problems were regarded as 
causes for intentional overdoses [167]. Ahmed et al. [142] revealed that 70% of DO patients used 
drugs that had been originally prescribed for another member of the family. 
Drugs associated with drug overdose-related admissions  
The most common drug groups associated with overdose were analgesics and psychotropics, and 
these drug types have not changed over the decade. Paracetamol was the most common single 
causative drug. This is because paracetamol is easily available as an OTC drug. Due to high incidence 
of paracetamol overdose, the quantity available for individual sale is restricted in some countries 
[168]. For example, in the United Kingdom (UK), general outlets are limited to selling only 16 tablets 
of 500mg whereas in pharmacies, only 32 tablets of 500mg can be sold. However in the latter, after 
further assessment and approval from a pharmacist, the said tablets can still be sold up to 100. There 
is no restriction on the amount of paracetamol that can be sold in Malaysia. However, they are sold 
in blister strips.
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Table 1-5: Studies on prevalence of drug overdose-related admissions
 
Author (country) 
Patient 
group 
Admission type 
Number of 
patients studied 
Method 
Prevalence of 
DO-related 
admissions 
Most common drug 
group 
Liisanantii et al., 
2011 (Finland) [169] 
All patients ICU 61,527 
Retrospective 
computer database 
4.5% Not reported 
Buykx et al., 2010 
(Australia) [170] 
All patient 
Emergency 
department 
521 
Retrospective 
computer database 
1.4% Not reported 
Oguzturk et al., 2010 
(Turkey) [166] 
All patients 
aged >15 
years 
Emergency 
department 
25,070* 
Retrospective 
computer database 
and, chart review 
0.7% Multiple drugs 
Schwake et al., 2009 
(Germany) [11] 
All patients 
aged >14 
years 
Medical ICU 1,883 
Prospective chart 
review, and 
interview 
17.3% Psychotropic drugs 
Rajasuriar et al., 
2007 
(Malaysia) [165] 
All patients Hospital 5,049,767* 
Retrospective 
computer database 
review 
(3 years of computer 
records) 
0.4% 
(including non-
medicinal 
poisoning) 
Analgesics 
Al-Jahdali et al., 
2004 
(Saudi Arabia) [122] 
All patients Hospital 84,946 
Retrospective chart 
review 
(3 years of records) 
0.1% Analgesics 
Bhalla et al., 2003 
(England) [9] 
All patients 
aged A? ? ?
years 
Medical wards 840 
Prospective chart 
review, and 
interview 
2.4% Analgesics 
     
*estimated by researcher                     table continued............... 
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Table 1-5: Studies on prevalence of drug overdose-related admissions
 
Author (country) 
Patient 
group 
Admission type 
Number of 
patients studied 
Method 
Prevalence of 
DO-related 
admissions 
Most common 
drug group 
Ab Rahman AF, 
2002 
(Malaysia) [164] 
All patients Hospital 234,500* 
Retrospective chart review 
(9 years of computer 
records) 
0.2% 
(including non-
medicinal 
poisoning) 
Psychotropic 
drugs 
Tountas et al., 
2001 
(Greece) [171] 
All patients 
Internal 
medicine 
department 
1,705 Not available 8.5% 
Psychotropic 
drugs 
Ahmed et al., 1997 
(Saudi Arabia) 
[111] 
All patients Medical wards 960 Prospective chart review 5.2% Analgesics 
Nelson and 
Talbert, 1996 
(US) [63] 
All patients 
Coronary, 
medical ICU and 
internal 
medicine unit 
452 
Prospective chart review, 
and medical team interview 
2.0% Not reported 
Bergman and 
Wiholm, 1981 
(Sweden) [143] 
All patients 
Internal 
medicine 
285 
Prospective interview, and 
observation 
3.5% 
Psychotropic 
drugs 
Hurwitz et al., 
1969 
(Northern Ireland) 
[1] 
All patients Hospital 1,268 
Prospective chart review, 
and interview 
2.1% 
Psychotropic 
drugs 
* estimated by researcher Liisanantii et al., 2011 [169]Buykx et al.,2010 [170]Oguzturk et al., 2010 [166]Schwake et al., 2009 [11]Rajasuriar et al., 2007 [165]Al-Jahdali et al., 2004 [122]Bhalla et al., 2003 
[9]Ab Rahman AF, 2002 [164]Tountas et al., 2001 [171]Ahmed et al., 1997 [142]Nelson and Talbert, 1996 [63]Bergman and Wiholm, 1981 [143]Hurwitz et al., 1969 [1]
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1.6.4.1 Studies in Malaysia 
In Malaysia, three studies have investigated all types of poisoning resulting in admission to hospitals 
[164, 165, 172]. Three further studies have investigated other aspects of poisoning  W one explored 
self-poisoning cases [173], the second, the factors associated with adult poisoning [167], and the 
third the trend of inquiries received by the national poison centre [174]. Poisoning accounted for 
between 0.2% and 0.4% of admissions [164, 165] and the predominant mode of poisoning was 
accidental.  A study by Fathelrahman et al. [172] conducted in Northern Malaysia estimated an 
annual incidence rate of poisoning admissions to be 25 per 100,000 persons. They have reported that 
intentional poisoning was the most common mode of poisoning. The annual rate of self-poisoning 
was reported to be 15 per 100,000 persons in another study, with an average of 8 patients admitted 
monthly due to self-poisoning [173].  
In the study of self-poisoning, 62% were due to DO [173], but even in studies where accidental 
poisoning was pre-dominant, more than 45% of cases involved DO [164, 165]. The types of drug 
classes reported to be involved with DO were non-opioid analgesics, antipyretics, anti-rheumatics, 
antipsychotics and benzodiazepines [164, 165, 173].  
Most admissions occurring due to poisoning involved women. However, the poisoning was more 
likely to be fatal in men [165, 167, 173]. This is due to the differences in types of substances 
consumed by each group. Chemical poisoning such as detergent and weed killer was most commonly 
implicated in men, whereas women were most likely to use medicines. On the other hand, Indian 
and Chinese ethnicity were found to be significantly associated with poisoning [167]. Rajasuriar et al. 
[165] added that the fatality rate was highest among Indian ethnicity because they were more likely 
to use weed killers. 
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1.6.5 Adverse drug withdrawal syndrome-related admissions 
ADWS-related admissions could be due to patient abruptly discontinuing medications or health care 
professionals discontinuing medications which were found inappropriately prescribed, without 
tapering down the dose [67, 175]. 
Studies related to ADWS are not extensive. A systematic review concluded that the withdrawal of 
some of the drugs such as opioids, beta-adrenoceptor blockers, levodopa and corticosteroid can 
cause patient morbidity and mortality but studies involving these drugs are lacking [176]. Other than 
these drugs selective serotonin reuptake inhibitors [67] and other antihypertensives [177] could also 
cause withdrawal syndromes. 
 The studies that investigated ADE-related admissions did not include ADWS as one of their study 
outcomes. This could indicate that the frequency of ADWS could be too small to be identified, or it is 
difficult to recognise an ADWS. In their study, Mita el at. [175] found that ADWS was not frequently 
detected and only 0.8% admissions experienced it. Almost half of drug discontinuation cases in the 
study by Gerety et al. [178] resulted in ADWS but the events were not as serious as other ADEs. 
Among the 62 patients in a nursing home who experienced ADWS, one was hospitalised and none 
resulted in death [178]. 
The issue with drug withdrawal syndrome is that it mimics the medical condition for which the drug 
was prescribed [67, 178-180]. For example, the withdrawal of antihypertensive agents may produce 
sympathetic over-activity such as nervousness, tachycardia, headache, agitation, nausea, and rapid 
increase in blood pressure [177]. However, this syndrome is more common in withdrawals of long-
term therapy than short-term [177] . Furthermore, it is difficult to identify which drug has caused the 
withdrawal syndrome if a patient was prescribed with multiple drugs, or was on alcohol influence or 
other illicit drugs , since the pharmacological effects of some agents overlap [178, 180]. For example, 
withdrawal symptoms of alcohol and barbiturates overlap such as seizure and delirium [180].  
1.6.5.1 Studies in Malaysia 
No study was found that investigated the rate of ADWS or its related admissions in Malaysia. 
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1.6.6 Adverse drug event-related admissions 
Of the studies listed in Table 1-2 to Table 1-5, only 11 studies have investigated more than one sub-
type of ADEs. These studies are listed in Table 1-6. The prevalence of ADE-related admissions has 
been found to be between 0.7% and 30.4% (these include studies which have investigated only one 
ADE sub-type as listed in Table 1-2 to Table 1-5). For studies which have investigated more than one 
type of ADEs, the prevalence of ADE-related admissions was 2.5% to 30.4% (Table 1-6). The lowest 
rate of 2.5% is likely due to the study site (emergency department) where the researcher depended 
ŽŶƉŚǇƐŝĐŝĂŶƐ ?ĚŝĂŐŶŽƐĞƐƚŽŝĚĞŶƚŝĨǇƐ[8]. This study used a prospective chart review method. 
Whilst the highest rate of 30.4% is likely due to the study population (elderly patients aged more 
than 75 years) and this study combined prospective chart review and patient interview in identifying 
patients[10].  
Comparison between studies in Table 1-6 is difficult because of the difference in the types of ADEs 
investigated and definitions used. For this reason, each type of ADEs, the prevalence, and drugs 
associated were discussed separately in the previous sections.  
 
 
 
 
 
 
 
 
 
 
Schwake [11]Saha [140]Bhalla [9]Malhotra [153]Chan [10]Raschetti [8]Ahmed [142]Hallas 92 [83]Hallas 90 [62]Bergman [143]Hurwitz 
[1] 
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Table 1-6: Studies on prevalence of adverse drug event-related admissions  
 
Author (country) 
Admission type 
(patient group) 
Number of patients 
studied 
Method 
Type of ADEs 
investigated 
Prevalence of 
ADE-related 
admissions 
Schwake et al., 2009 
(Germany) [11] 
Medical ICU 
(all patients aged >14 
years) 
1,554 
Prospective chart 
review, and interview 
x ADRs 
x Deliberate self-drug 
poisoning 
23.7% 
Saha et al., 2008 
(India) [140] 
Internal medicine 
department 
(all patients aged A? ? ? 
years) 
1,200 
Prospective interview, 
and chart review 
x ADRs 
x Drug-drug interaction 
x Non-compliance 
x Accidental or 
intentional overdose 
4.2% 
Bhalla et al., 2003 
(Cambrigde, UK) [9] 
Medical wards 
( All patients aged A? ? ? 
years) 
1,000 
Prospective chart 
review, and interview 
x ADRs 
x DTFs 
x Overdose or abuse 
10.1% 
Malhotra et al., 
2001 
(India) [153] 
Medical emergency 
department 
 ?ůĚĞƌůǇ ?ĂŐĞA? ? ? ? 
840 
Prospective interview, 
and chart review 
x ADRs 
x Non-compliance 14.4% 
Chan et al., 2001 
(Australia) [10] 
Acute medical units 
( Elderly; 
ĂŐĞA? ? ? ?
578 
Prospective chart 
review, and interview 
x ADRs 
x Non-compliance 30.4% 
 
table continued.......... 
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Table 1-6 continued: Studies on prevalence of adverse drug event-related admissions
 
Author (country) 
Admission 
type 
(patient group) 
Number of 
patients studied 
Method Type of ADEs investigated 
Prevalence of 
ADE-related 
admissions 
Most common 
type of ADE (%) 
Raschetti et al., 
1999 
(Italy) [8] 
Hospital 
(all patients) 
240 
Prospective chart 
review 
x ADRs 
x DTFs 
x Drug-drug interactions 
x Drug and alcohol interactions 
2.5% 
TF  
(56%) 
Ahmed et al., 
1997 
(Saudi Arabia) 
[142] 
Medical 
(all patients) 
1,833 
Prospective chart 
review 
x ADRs 
x Drug overdose 11.0% 
ADR 
 (53%) 
Hallas et al., 
1992 
(Denmark) [83] 
Medical 
(all patients) 
960 
Prospective 
interview, and 
chart review 
x ADRs 
x DTFs 
x Intentional overdose 
11.4% 
ADR  
(74%) 
Hallas et al., 
1990 
(Denmark) [62] 
Medical 
(all patients) 
452 
Prospective 
patient interview, 
and chart review 
x ADRs 
x DTFs 10.8% 
ADR  
(75%) 
Bergman and 
Wiholm 1981 
(Sweden) [143] 
Internal 
medicine 
department 
(all patients) 
1,999 
Prospective 
interview 
x ADRs 
x TF 
x Poisoning 
15.7% 
TF  
(45%) 
Hurwitz et al., 
1969 
(Northern 
Ireland) [1] 
Hospital 333 
Prospective chart 
review, and 
interview 
x ADRs 
x Overdose 5.0% 
ADR  
(58%) 
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1.7 Role of health care professionals in adverse drug events 
Health care is an integrated process by which physicians, pharmacists, nurses and other health care 
professionals provide care to patients according to their expertise, and thus patient safety is not an 
individual responsibility. A health care professional is responsible for recognising and resolving ADEs 
that occur, monitoring those and developing educational packages to reduce future occurrences.  
 
1.7.1 Recognising adverse drug events 
The initial step in identifying ADEs is to be alert to the possibility that a patient may be experiencing 
one. The next step is to decide the type of interventions. However, it is not an easy task to identify 
whether or not a patient is experiencing an ADE. Health care professionals sometimes fail to 
recognise that an ADE has occurred by misinterpreting ƉĂƚŝĞŶƚƐ ?ĐŽŵƉůĂŝŶƚƐŽƌƐǇŵƉƚŽms as minor 
and irrelevant, or related to the progression of their medical conditions. This may explain why many 
ADEs are never recognised [181]. 
It is important to listen to the patients as their concerns and complaints may indicate a drug-related 
problem. The key information for detecting ĂŶƐŚŽƵůĚďĞĂǀĂŝůĂďůĞŝŶƚŚĞƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐĂůĂŶĚ
drug history [88].  Health care professionals need to be thorough and comprehensive in taking 
histories and should include OTC drugs and herbal remedies. If an ADE is suspected, they should 
investigate whether or not there is sufficient information to link the event to a drug [59, 182]. This 
can be determined by identifying time relationship between drug intake and the occurrence of the 
event, and the pattern of the event (whether it is related to a pharmacological effect, an allergy, an 
insufficient use of a drug, or an error) [59]. Additionally, known drug effects and further 
investigations such as laboratory tests may caution or rule out a diagnosis. In case of an ADR, an 
option to confirm that it is an ADR is re-challenging the suspected drug in the patient if the effect is 
not severe [59, 182, 183].  
When these empirical findings fail to produce any causal relationship, algorithms can be used to 
assist in the assessment of an ADE-probability. Widely used algorithms include EĂƌĂŶũŽ ?ƐĂůŐŽƌŝƚŚŵ
[99], and that of Hallas et al. [62]. EĂƌĂŶũŽ ?ƐĂůŐŽƌŝƚŚŵŝƐƵƐĞĚĨŽƌƚŚĞĂƐƐĞƐƐŵĞŶƚŽĨƐƵƐƉĞĐƚĞĚZƐ
whilst the latter is used to assess suspected TF. 
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Evidence suggests that inappropriate prescribing (IP) is associated with an increased risk of ADE [184, 
185]. This is reported to be relatively common especially in older patients [186]. IP involves the use 
of medicines that pose more risks than benefits especially when safer alternatives are available. It 
also involves misuse of medicines (inappropriate dose or duration), prescription of medicines with 
clinically significant drug-drug and drug-disease interactions, and importantly, the underuse of 
potentially beneficial medications [185]. In 1992, a UK-based study found that nearly 50% of ADRs 
were due to inappropriate prescribing, either due to drugs that were contraindicated or were 
unnecessary [184]. Because older adults are more sensitive to its certain adverse effects, various lists 
of medicines have been created to guide clinicians. These lists used explicit (criterion-based) or 
implicit (judgement-ďĂƐĞĚ ?ƉƌĞƐĐƌŝďŝŶŐŝŶĚŝĐĂƚŽƌƐ ?ǆĂŵƉůĞƐŽĨĞǆƉůŝĐŝƚŝŶĚŝĐĂƚŽƌƐĂƌĞƚŚĞĞĞƌ ?Ɛ
criteria which is widely used in the US, and the most recent criteria, STOPP (Screening Tool of Older 
WĞƌƐŽŶƐ ?ƉŽƚĞŶƚŝĂůůǇŝŶĂƉƉƌŽƉƌŝĂƚĞWƌĞƐĐƌŝƉƚŝŽŶƐ ?[186]. Both criteria list the medicines to be avoided 
in older people. An example of implicit criteria is the Medication Appropriateness Index (MAI) which 
measures prescribing appropriateness according to ten criteria including indication, effectiveness, 
dose, administration, drug-drug and drug-disease interactions, and cost [186]. 
 
1.7.2 Resolving adverse drug events 
Preventing an ADE is a much better option than finding a way to resolve it. However, this may not 
always be possible because some events occur unexpectedly, particularly ADRs. Surveys have 
reported that physicians and nurses expect the pharmacists to take the responsibility to resolve drug-
related problems [187, 188] and educate patients about safe and appropriate use of drugs [189, 
190]. Due to their expertise and knowledge of pharmacology, proactive involvement of pharmacists 
not only helps in resolving ADEs but in preventing them. 
The types of DRP that pharmacists report observing most commonly are related to dosing or drug 
choice problems [113, 114, 191-193]  W inadequate dose or drug, need for dosage adjustment and 
inappropriate drug selection. Pharmacists most often contacted physicians to resolve these problems 
[113, 191, 194], however, some managed to do them alone [115, 195]. The most common reasons 
for pharmacists to contact physicians were to recommend changes to ĂƉĂƚŝĞŶƚ ?ƐĚƌƵŐƚŚĞrapy such 
as addition of a new drug, changes in dosage or stopping to use a drug [113, 114, 191]. Additionally, 
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pharmacists were reported to be responsible for providing information about drugs to other health 
care professionals [114, 192] and answering queries from nurses [114].  
Patient adherence problems were the primary problem pharmacists reported managing by 
themselves [195]. Two studies reported that patient counselling and education was the most 
common intervention used [115, 191]. It is important to highlight that both these studies [115, 191] 
were conducted in a community setting where pharmacists are not obliged to report to or discuss 
with other health care professionals. Upon identification of a problem, the interventions 
recommended by pharmacists in solving a DRP are usually accepted by physicians  W the acceptance 
rate of which was reported to be up to 98% [196]. This high acceptance rates demonstrates the 
important role of pharmacists in solving DRPs  W particularly where this prevents DRP reaching the 
patient. 
 
1.7.2.1 Studies in Malaysia 
Three studies carried out in Malaysia relating to interventions by pharmacists were found. One study 
was conducted at an outpatient pharmacy department [197], and two were conducted in intensive 
care units or ICU [198, 199]. 
Of the 6360 prescriptions received during the one-week study at the outpatient pharmacy 
department, only 43 required an intervention [197]. Most of these prescriptions had one similar 
problem, errors of omission of a quantity or dose to be supplied. The most common intervention 
taken was contacting the physician.  
Both studies in ICUs reported that more than 90% of ƉŚĂƌŵĂĐŝƐƚƐ ?recommendations were accepted 
by the team [198, 199]. The most common problem identified by the pharmacists was unnecessary 
drug therapy [198, 199]. This study has also shown that the interventions from pharmacists have 
resulted in cost-savings [199]. 
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1.7.3 Preventing or reducing adverse drug events 
A significant proportion of ADEs are considered to be preventable, thus, approaches to improve 
patient care and reduce the occurrence of ADEs should focus on this area. The strategies in 
preventing ADEs can be divided into two types: strategies to improve existing patient care and 
strategies targeted at high-risk patients of ADE.  
A study conducted in  paediatric wards evaluated the effectiveness of several prevention strategies in 
MEs and identified that, i) computerised physician order entry (CPOE), ii) ward-based clinical 
pharmacists, and iii) improved communication between physicians, pharmacists and nurses have the 
potential to reduce MEs [200]. Similarly, the studies which assessed the preventability of ADEs in 
adult patients [13, 78, 128, 201] found pharmacists participation in the rounds [78], and CPOE [201] 
as the two most effective prevention strategies. These strategies can be targeted to identify DRPs 
during the process of drug use and may help highlighting problems which could be improved so that 
ADEs could be minimised. 
One of the methods being widely used in the US is the computerised systems in the health care. 
Computerised systems can be introduced into different stages of the drug use process in order to 
reduce the probability of an error. CPOE is an electronic system where physicians enter the 
prescrŝďŝŶŐŽƌĚĞƌĨŽƌĂƉĂƚŝĞŶƚ ?ƐƚƌĞĂƚŵĞŶƚ ?dhe orders are received by the staff (in the pharmacy, 
laboratory or ward), through a computer network and they are responsible for completing the 
orders. Some systems also have a clinical decision-support system (CDSS) which produces drug 
allergy or drug-drug interaction warnings. Bates et al. [201] evaluated the efficacy of this system and 
revealed that it was able to show a significant decline in preventable and non-intercepted, potential 
ADEs  W from 10.7 event per 1000 patient-days to 4.68 events.   
Pharmacy-led intervention may also help in preventing ADEs ĚƵĞƚŽƚŚĞƉŚĂƌŵĂĐŝƐƚƐ ?ĞǆƉĞƌƚŝƐĞĂŶĚ
knowledge in pharmacology. Studies have found that pharmacists are capable of reducing the rate of 
ADEs and their involvement was found to bring positive outcomes to health of patients [6, 78, 79, 
196]. Leape et al. [78] conducted a controlled clinical trial that included a pharmacist in a ward round 
team. They found that the pharmacist was able to reduce the rate of ADEs by preventing and 
intercepting them. The pharmacist provided information on doses, interactions, indications and drug 
alternatives to physicians at the time of ordering and 99% of the recommendations were accepted 
[78]. Similar findings were also observed in a study by Kucukarslan et al. [196] which investigated the 
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effect of pharmacists in a round team. The rate of ADEs in this study was reduced by 78%. Of the 150 
recommendations by the pharmacists, 98% were accepted by the ward round team [196]. 
These two strategies (CPOE and pharmacists participation in the rounds) may be feasible in hospital 
settings (provided that the hospital has a computerised system and adequate number of 
pharmacists), but not in private clinics or community pharmacies. Other examples of strategies 
where pharmacists can participate to prevent ADEs are pharmacy-led medication review and patient 
counselling. 
DĞĚŝĐĂƚŝŽŶƌĞǀŝĞǁŚĂƐďĞĞŶĚĞĨŝŶĞĚĂƐĂ ‘structured, critical examination of a patient's medicines 
with the objective of reaching an agreement with the patient about treatment, optimising the impact 
of medicines, minimising the number of medication-related problems and reducing waste' [202].  
One example of which is a randomised controlled trial of medication review by pharmacists in care 
homes that was conducted by Zermansky et al. [203]. A comparison was made between a control 
group (with usual GP care) and intervention group (where pharmacists conducted medication 
review). This study concluded that the number of drug changes in the intervention group was high. 
Furthermore, a significant reduction in the number of falls in the elderly was found. This was 
achieved by stopping the use of drugs which may cause confusion, sedation, or hypotension and, 
adjusting or starting a drug that improves mobility (which was thought to have been responsible for 
this reduction). Additionally, this study reported that the GP reviews occured less frequently than 
pharmacist reviews (only 19% of patients had a review by the GP during the study).  
Pharmacists are not the only professional responsible for conducting medication reviews, but 
physicians and nurses are equally responsible. GP-made reviews has been found to be as effective as 
pharmacist-led reviews [204]. One study evaluated the quality of GP and nurse medication reviews 
during training by a practice pharmacist [205]. It was reported that the quality of review before the 
training was poor in GP ?s but the documentation of DRP was improved following the training. The 
study also found that the nurse reviews were able to identify discrepancies in repeat prescriptions. 
This study has shown that GPs and nurses are capable of identifying DRP if given the appropriate 
training. 
Although medication review was reported to have produced some health benefits to patients and 
health care system, the effectiveness of this intervention is still not well-proven. A meta-analysis of 
32 studies by Holland et al. [206] revealed that there are some mixed findings from different studies 
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about medication review (example: one study reported to have reduced hospital admission, while 
some have shown no significant reduction). Further investigations and improvement may be needed 
to optimise the benefits of medication review. 
One of the important responsibilities of pharmacists is counselling patient on proper medication use. 
A study by Schnipper et al. [6] evaluated the effects of counselling and follow-up by pharmacists on 
the rate of preventable ADEs and medication non-adherence after 30 days patients were discharged 
from a hospital. Only 1% of patients who were in the intervention group experienced ADEs whereas 
11% of patients in the control group (no intervention) experienced such [6]. 
The time spent by pharmacists with each patient might limit the opportunity of implementing 
pharmacy-led medication review and patient counselling in real life. It may be practical that 
pharmacists focus on identifying high-risk patients and approach them to tackle the problems. 
Apart from the strategies discussed above, inappropriate prescribing which could also contribute to 
ƚŚĞŽĐĐƵƌƌĞŶĐĞƐŽĨƐŚŽƵůĚĂůƐŽďĞƚĂĐŬůĞĚ ?ƋƵĂůŝƚĂƚŝǀĞƐƚƵĚǇŝŶh<ƋƵŽƚĞĚƚŚĂƚ ‘prescribers 
need education in how to avoid prescribing when it is not clinically indicated ?[207]. Education is the 
main strategy to ensure that prescribers are equipped to prescribe appropriately [208]. For many 
years, guidelines have been created to help prescribers in choosing appropriate therapy for specific 
conditions. However these guidelines will not be effective unless the users are educated about their 
use. In UK, an education about the use of guidelines on prescribing nutritional supplements 
significantly reduced total prescribing by 15% and reduced inappropriate prescribing from 77% to 
59% [209]. The study also reported that prior to the educational programme, there was a low level of 
knowledge and practice in identifying those at risk of malnutrition and their nutritional management.  
In an attempt to prevent ADEs, it is important that prescribers know the most common medications 
involved and the demographic patterns of patients who are susceptible to them. These patterns may 
change over time due to increased numbers of newly marketed medicines and changes in disease 
patterns. Thus, all this information should be regularly disseminated to the prescribers, accompanied 
by education on appropriate prescribing. 
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1.7.3.1 Studies in Malaysia 
In Malaysia, pharmacists provide individual or group counselling for outpatients, inpatients and 
discharged patients. This approach aims to help patients achieve the intended health outcomes 
through better adherence and providing information about possible ADEs. In 2009, more than 
200,000 counselling services have been provided to patients [210]. The number of patients who have 
received this service has increased by 53% since 2008 [210]. However, to date, there has been no 
evaluation of the effectiveness of this service. 
MTAC has also been introduced in outpatient services. It aims to optimise drug therapy in the 
management of chronic medical conditions such as diabetes mellitus, asthma, retroviral disease, and 
warfarin therapy [210]. Patients are selected by pharmacists or referred by physicians. Patients are 
scheduled to meet pharmacists every one or two months for a total of eight visits and are given 
individualised counselling and education [211]. During each visit, patienƚ ?ƐĂĚŚĞƌĞŶĐĞǁŝůůďĞ
assessed and pharmacists provide recommendations to physicians (for example, addition of a drug, 
or dosage changes) if necessary. One study has investigated the effectiveness of the Diabetes MTAC 
(DMTAC) in Malaysia [211]. Patients ? medical records and DMTAC forms were assessed 
retrospectively. The blood sugar control, lipid parameters and medication adherence of patients who 
had completed all eight visits significantly improved indicating that the service was effective in 
improving boƚŚƉĂƚŝĞŶƚƐ ?adherence and outcomes of their condition.  
Zaidi et al. [199] have investigated clinical pharmacists ? participation in the ICU. The majority of DRPs 
detected were related to unnecessary drug therapy. The overall recommendations provided by the 
pharmacists were found to have resulted in a net cost saving of RM 15,277 in the ICU (USD 4,007). 
Most reduction in the cost resulted from the discontinuation of drug use (70%). This study has 
provided evidence that a clinical pharmacist in the ICU has the potential to minimise the health 
service expenditure. 
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1.7.4 Monitoring adverse drug events 
Incident reporting serves as an important tool for monitoring ADEs. Research findings related to 
ADEs could also provide details of the extent of a problem and lead to changes in practice or 
increases occurrences of likely problems. Furthermore, computerised systems can also be used to 
monitor ADEs. An important role of health care professionals in ADE monitoring is reporting an ADE 
incident after actions are taken to resolve patients ? problems, so that they build a database of 
information that can be used for future prevention or precaution. 
Reporting ADRs is important to drug safety surveillance. A drug undergoes clinical trials before it can 
be submitted for marketing authorisation. Clinical trials are not able to detect all ADRs because they 
are often conducted over short periods of time and in selected population groups. Once the drug is 
marketed, it is exposed to a wider population and part of safety monitoring is the spontaneous ADR- 
reporting system. This system also produces signals for new potential ADRs and is one of the 
cheapest ways to monitor the safety profiles of all marketed drugs. 
In UK, reports of suspected ADR are sent to the Medicines and Health Products Regulatory Agency 
through thĞ “zĞůůŽǁĂƌĚ^ĐŚĞŵĞ ?[212]. A similar approach is also practiced in many other countries 
[18, 213, 214]. Although such reporting systems have been established for many years, under-
reporting is a major limitation in many countries. Thus, to identify the reasons for under-reporting, 
many studies have investigated the possible factors that encourage and discourage ADR-reporting 
among health care professionals [215-228] . The most common factor encouraging health care 
professionals in reporting ADRs is a serious or unusual reaction [215-219, 224, 225], followed by 
reactions involving newly marketed drugs [217, 219].  The most common factors discouraging health 
care professionals from reporting ADRs include well known reactions [220, 223, 225, 228] , 
uncertainty of an association between the reaction and the drug [215, 221], and a lack of time [217, 
219, 227]. The lack of availability of reporting forms [219], reactions not being clinically significant 
[216], and a lack of knowledge about the reporting process [222, 226] were other reasons found that 
discourage health care professionals from reporting ADRs. 
Health care professionals were more likely to report a reaction if they could ascertain that the drug 
has caused the ADR and the reaction was not well-known. However, national pharmacovigilance such 
as MADRAC in Malaysia, urge health care professionals to report any suspected ADRs. Causality 
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assessment is usually conducted in the pharmacovigilance unit to determine whether or not there is 
causal relationship between a drug and an ADR and health care professionals should be made aware 
of this. Proper communication between the pharmacovigilance unit and health care professionals 
could clarify this misconception. 
More than 40% of hospital pharmacists in UK reported lack of time in completing ADR reports [134]. 
A survey of community pharmacists in Iran found that lack of time was not a major issue [215] and 
concluded that different working practices (community compared to hospital) could influence the 
factors for ADR reporting. However, Herdeiro et al. [229]  reported that hospital pharmacists were 
more likely to report ADRs compared to community pharmacists. Such differences in working 
practices might be due to the former working closely with other health care professionals and having 
access to patient notes so they are in a better position to determine whether or not an ADR has 
occurred. Community pharmacists are reliant on patients informing them of their medical problems.  
Pharmacists agree that ADR reporting is a professional obligation [217, 221, 226, 229]. They play an 
important role in pharmacovigilance, both in hospital and community settings. Greater participation 
by pharmacists in ADR reporting could considerably reduce the problem of under-reporting [230] and 
therefore provide better information for the regulators. Several studies concluded that positive ADR 
reporting attitudes are associated with increased reporting [229] and changing the wrong beliefs and 
attitudes of pharmacists about the purpose of reporting ADRs could improve it. In some studies, 
pharmacists suggested that education or training could improve ADR reporting [218, 220, 226, 231]. 
Granas et al. [232] evaluated the effects of a training on attitudes towards ADR reporting.  Compared 
with a control group that received no training, there was an increase in the percentage of ADR 
reporting by the pharmacists that received one.  
The aims of monitoring spontaneous ADR reporting are to identify previously unrecognised ADRs, 
identify risk factors that may predispose the development of an ADR, and to maintain a database for 
sharing of information [18]. These aims were correctly identified by health care professionals in some 
studies [219, 224]. However, in some studies, it was a matter of concern that they revealed 
monitoring of ADR reports is able to measure the incidence of ADRs [215, 216]. ADR reporting system 
is unsuitable to measure such incidence due to incomplete numerators (number of ADR reports) and 
denominators (number of patients exposed to a drug).  
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A few countries have developed a ME reporting system or ME reporting program (MERP) at national 
or hospital level [102, 233, 234]. The Institutes of Safe Medication Practices (ISMP) in the US has 
listed examples of the impact of the MERP [235] and they were: producing national hazard alerts 
(e.g. changes in packaging of drugs that could lead to look-alike confusion), disseminating trends of 
errors and the strategies to reduce them, recommending changes (in drug packaging or labelling, 
system and individual practices), establishing standards (e.g. national safety guidelines) and 
promoting public policy advocacy (e.g conducting conferences for health care professionals and 
participating in national policy discussions). Although the collection of MEs has the potential to 
reduce future occurrences, a number of factors have discouraged health care professionals from 
reporting incidents. One study highlighted that the type and severity of a ME influences the 
likelihood that an error will be reported [236]. Nurses [237, 238] and pharmacists [239] have greater 
awareness of error-reporting systems and therefore, were more likely to report an incident 
compared to physicians. Physicians were more likely to report a ME with a severe patient outcome 
whilst pharmacists and nurses reported all types of MEs [236]. However, most claimed that they 
would only report a ME that caused harm to the patients [237, 240].  Health care professionals 
reported that lack of feedback after reporting, the long process of reporting, and incidents that 
seemed too trivial to report as main barriers to reporting an incident [237]. Other reasons quoted 
were forgetting to report [237] and not being aware of the occurrence of an error [240]. 
 
1.7.4.1 Studies in Malaysia 
Malaysia like many countries collects ADR reports on voluntary basis from doctors, pharmacists and 
nurses. Since 2007, reports from patients have also been accepted. The reports are reviewed and 
assessed by MADRAC every two months. All are then submitted to the International Centre of Drug 
Monitoring (WHO) in Uppsala, Sweden [18, 19]. In 2009, the total number of ADR reports received by 
MADRAC was 5850, which was an increase of 90% since 2007 [241]. A high percentage of reports 
(57%) were submitted by pharmacists in 2009 and the high number of graduate pharmacists in 
hospitals due to the three-year compulsory service was suspected to be the reason for the increase. 
At least three studies have explored the views of health care professionals to ADR reporting in 
Malaysia. One investigated the attitudes of physicians towards ADR reporting [223] whilst the other 
two qualitatively investigated the views of community pharmacists about ADR reporting [226, 231]. 
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Aziz et al. [223] conducted face-to-face interviews using a structured questionnaire among the 
physicians working in a teaching hospital. More than 80% of the physicians have suspected an ADR 
but did not report it and 40% were not aware of the existence of a national reporting system. The 
most common reason for not reporting was either because the ADR was well known or too trivial. 
Ting et al. [231] and Elkalmi et al. [226] interviewed community pharmacists and both studies 
reported that most of them were not aware of the existence of a national reporting system and had 
not reported an ADR. The reason given for the latter was that the reaction was common and mild. 
When asked to suggest ways to improve ADR reporting, pharmacists from both studies agreed that 
education and training would improve reporting rates. These three studies have shown that many 
health care professionals are not aware of the existence of a national reporting system and their 
obligation to report ADRs. 
MERS was established in Malaysia in 2009 [21] and a total of 2,572 ME reports have been received to 
date [242]. As yet, there has been no published evaluation of the system.  
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1.8 Rationale for study 
A review of the literature has shown that ADEs are a significant problem in many countries and can 
result in patient harm and hospitalisation. The findings from research on ADEs have produced several 
preventive strategies. Thus, in order to reduce the number and severity of harm related to 
medication, and to implement the preventive strategies, it is important to measure and describe the 
epidemiology of ADEs.  
It is evident that the health care professionals have an important role in recognising, resolving, 
preventing and monitoring ADEs. Various interventions have been introduced to improve patient 
safety.  The two most effective interventions found were CPOE and the involvement of pharmacists 
in rounds. The concept of clinical pharmacy involves assessment of DRPs and pharmacists play an 
important role in detecting, solving and preventing the problems. They are well trained in 
therapeutics and can play a key role in drug surveillance. Changing habits are difficult, thus any 
attempt to influence the current practice as a means of preventing ADEs should be based on 
thorough understanding of the current practices of health care professionals in improving patient 
ƐĂĨĞƚǇ ?DĂŶǇƐƚƵĚŝĞƐŽĨŚĞĂůƚŚĐĂƌĞƉƌŽĨĞƐƐŝŽŶĂůƐ ?ŝŶƚĞƌǀĞŶƚŝŽŶƐŚĂǀĞƐŚŽǁŶŐŽŽĚƌĞƐƵůƚƐĨŽƌƉĂƚŝĞŶƚ
safety but how this translates to usual practice is uncertain. Therefore, a study to determine the 
experiences of Malaysian health care professionals related to ADEs was proposed as part of this 
thesis.  
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1.9 Research aims and objectives 
This study aimed to determine the occurrence of ADE related admissions to a Malaysian hospital and 
also investigate experiences of pharmacists of ADEs in the Malaysian health care setting. 
The specific objectives of the study are divided into two phases: 
Phase 1  W ADE-related admissions 
i) To determine the prevalence of ADE-related medical admissions in a public tertiary 
hospital in Malaysia 
ii) To determine the types of ADE-related cases in those medical admissions 
iii) To determine the types of drug associated with ADEs 
Phase 2  W survey of ADE experiences of pharmacists in Malaysia 
i) To investigate whether or not pharmacists are able to observe ADEs during their daily 
activities in both community and hospital settings 
ii) To identify the strategies taken by pharmacists in resolving the ADE-related problems 
observed 
iii) To evaluate whether or not pharmacists are aware about the role of MADRAC and ADR 
reporting system 
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1.10 Methodological issues 
It was proposed to conduct a study to measure the occurrences of ADEs and determine the drugs 
associated with them. Following this, a survey was proposed to find about the ADE-related 
experiences of health care professionals in Malaysia. 
 
1.10.1 General design 
1.10.1.1 Prevalence of adverse drug event-related admissions 
Data derived from records of ADR reporting can be a useful tool in identifying areas for intervention. 
However, the low spontaneous ADR reporting rates may under-estimate the extent of the problem. 
Furthermore, they may not provide information about other types of ADE  W TF, ME and DO. 
Detecting ADEs through computerised systems is another option. However, the potential study sites 
like many other Malaysian hospitals, are not equipped with a computerised system and have 
handwritten documentation. 
The most comprehensive method determining the prevalence of ADEs is one which allows detection 
of ADEs, calculation of prevalence, identification of the type of drugs associated with an ADE, and 
patient characteristics.  All these information can be obtained using the chart review method. Chart 
review study allows a complete review of patient medical notes and charts. Information gathered 
from this method is useful in identifying ADEs and classifying them into sub-types. It has the 
advantage of being able to search for more information in the charts when the initial information is 
not enough to classify an ADE. Conducting a prospective chart review study also enables the 
collection or clarification of data from patients and health care professionals. 
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1.10.1.2    The experiences of health care professionals about adverse drug events 
The survey aimed to answer few questions: do health care professionals observe ADEs during their 
daily work activities? If they do, what types of ADEs were observed and what were the interventions, 
if needed, taken to solve the ADEs?  The best way to understand these experiences is to ask them. 
This can be done through interviews or survey questionnaires. Interview allows for a two-way 
communication, where the interviewer is able to clarify answers given by a respondent and the 
respondent is able to seek more explanation on the questions. However, it is costly and time- 
consuming to conduct them in a large population yet a smaller sample may not be enough to reflect 
the views of the population. Hence, a self-administered survey is comparably efficient in collecting 
information about the types of ADEs observed, the associated drugs, and actions taken in response 
to those ADEs. Due to high number of physicians and nurses, and with concerns about cost and time, 
it was decided that the researcher should personally distribute the questionnaires to all physicians 
and nurses in all medical wards of the studied hospital (including the wards where the chart review 
study was conducted). This was planned to be carried out during their weekly meetings.  
An email-based survey was felt to be the most effective method to obtain information from the 
Malaysian pharmacists. To enable the views of both community and hospital pharmacists, the MPS 
was approached to supply details of their members. However, their data confidentiality 
arrangements meant that they were only able to support a postal survey. Therefore, it was decided 
to change the method to the latter. 
 
1.10.2 Strengths and limitations 
Although chart review is able to provide a complete review of all the notes and charts, the quality of 
the data in the notes is dependent on a physician ?ƐĂĐĐƵƌĂĐy of recorded details. This can be 
overcome by adding patient interviews to the chart review where needed. However, chart review is 
time-consuming, as a researcher must review and record patient notes individually. 
Postal surveys use self-completion questionnaires and this method enables the collection of data 
from a large population within a short time scale. They allow respondents the opportunity to answer 
the questionnaire at a convenient time. One of the disadvantages of postal survey is the poor 
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response rate. However, this can be overcome by sending reminders to the respondents. Additionally 
on the downside, there is lack of control about who completes the questionnaire. Unlike in face-to-
face interviews, respondents are not able to clarify immediately from the researcher when they are 
unsure of question meanings and so, interpretations of such may vary. To minimise this setback, the 
researcher can provide their contact details in the questionnaire. 
 
1.10.3 Case definition 
ADEs as whole have substantial effect on patient morbidity. Rather than investigating one type of 
ADE, it was decided to investigate all types of ADEs. The reason being that, the sub-types of ADEs 
overlap with each other and it is difficult to separate one from another. Restricting the study to one 
type of ADE may result in an under- or over-estimate of the rate due to misclassification of events. 
Furthermore, the type of drugs associated with different types of ADEs may vary and this information 
will be useful in developing strategies to improve the current health care system. For the same 
reasons, health care professionals were asked to report their experiences in observing all types of 
ADEs.  
A chart review study was therefore designed to collect information relating to ADEs in two medical 
wards in a tertiary public hospital. Following a pilot study, a classification tool was designed to assess 
and classify the ADEs. The criteria were used in the main chart review study which was conducted 
over 24 weeks. 
 
1.10.4 Choice of previously published instrument 
There was no existing questionnaire ĞǆƉůŽƌŝŶŐƉŚĂƌŵĂĐŝƐƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐŽĨ ADEs. However, there are 
a number of surveys which have investigated ŚĞĂůƚŚĐĂƌĞƉƌŽĨĞƐƐŝŽŶĂůƐ ?attitudes towards and 
awareness of spontaneous ADR reporting [215-228]. 
The questionnaire by Consentino et al. [216] was developed to ŝŶǀĞƐƚŝŐĂƚĞƉŚǇƐŝĐŝĂŶƐ ?ĂƚƚŝƚƵĚĞƐƚŽ
ZƐƉŽŶƚĂŶĞŽƵƐƌĞƉŽƌƚŝŶŐƐǇƐƚĞŵ ?/ƚĞǆƉůŽƌĞĚƚŚĞƉŚǇƐŝĐŝĂŶƐ ?ĂǁĂƌĞŶĞƐƐŽŶƉƵƌƉŽƐĞƐŽĨZ
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reporting, what types of ADR to report and factors encouraging and discouraging ADR reporting. This 
questionnaire has also been used in a hospital-based study [243]. Similar criteria were explored in 
other studies investigating the attitudes towards ADR reporting among health care professionals  W 
experiences of reporting ADRs, aims for ADR reporting system, types of ADR that should be reported, 
barriers to and factors encouraging ADR reporting [217, 219, 227, 232].  
A questionnaire was therefore designed following a discussion with research supervisors to collect 
information ŽŶƉŚĂƌŵĂĐŝƐƚƐ ?-related experiences. Following a pilot study, the questionnaires 
were mailed to all hospital, clinic, and community pharmacists who were members of MPS. 
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2 CHAPTER 2: A CHART REVIEW STUDY OF MEDICATION-RELATED ADMISSIONS TO A 
HOSPITAL 
CHAPTER 2 
 
A CHART REVIEW STUDY OF MEDICATION-RELATED ADMISSIONS TO 
A HOSPITAL 
This chapter describes the development of the method for the chart review study. A preliminary 
study was conducted to determine the type of information available in patient charts, design the 
data collection form, and modify trigger tool according to the Malaysian context and study 
objectives. This was followed by a pilot study to design the method for the main chart review study, 
modify the data collection form, where necessary, and estimate the number of admissions to the 
study site. Finally, this chapter describes the chart review study which was conducted in two medical 
wards in a tertiary public hospital. It addresses the prevalence of ADEs, its sub-types, and the drug 
associated with these occurrences. 
 
2.1 Objectives 
The objectives of this study were to: 
i) To determine the prevalence of ADE-related medical admissions in a public tertiary 
hospital in Malaysia 
ii) To determine the types of ADEs related to those medical admissions 
iii) To determine the types of drugs associated with these ADEs 
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2.2 Method 
2.2.1 Study design 
The chart review study was conducted in two medical wards in a tertiary public hospital. It is an 800-
bed hospital with 20 clinical disciplines. Patients admitted to emergency department are stabilised 
and admitted to the wards whilst elective admissions are directly admitted to the wards. The 
personal data of patients admitted to the hospital is entered into a computer system which is 
available at the registration counter. Patients or family members of non-civil servants are required to 
pay a deposit prior to admission and full payment upon discharge, whilst civil servants should provide 
a guarantee letter from their employer to be exempted from payment. There are a few classes of bed 
in the public sector  W first class, second class and third class. The choice of a class relies upon the 
salary scale of a civil servant (servants from higher salary scale are eligible for first or second-class 
wards) or the ability of a non-civil servant to make the full payment. However the choice of wards 
also depends on their availability. The third-class wards are usually over-crowded, prompting the 
addition of extension beds if existing beds are fully occupied (40- 50 beds). First and second-class 
wards have fewer beds (1-6 beds) and more privacy for the patients. This is a typical scenario in 
almost all the tertiary public hospitals in Malaysia. 
There were seven medical wards in the study hospital. The hospital is situated in Selangor state and 
is the main referral hospital for the surrounding area. Patients admitted to the medical wards were 
treated for various medical conditions such as cardiovascular diseases, diabetes mellitus, respiratory 
diseases, renal diseases, haematological conditions, and liver diseases. The majority of adult medical 
admissions to the hospital were admitted to the medical wards before transferred to the appropriate 
specialist ward. The selected study site is typical of public hospitals in Malaysia. Two medical wards 
were selected by the head of medical department in the hospital for the study as they were 
considered the busiest wards. Patients are usually admitted in these two wards (3rd class wards) 
before transferred to other wards (2nd class or 1st class wards). 
The preliminary and pilot study was conducted between June and July 2008. The main study was 
conducted between November 2009 and April 2010. 
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2.2.2  Development of the method 
To maximise the sensitivity of the study, a prospective chart review method was chosen. Initially, the 
preliminary study was conducted to review the medical records. It was then followed by a pilot study 
to test and develop the chart review method. The following section describes the preliminary and 
pilot studies which contributed to the development of the main method used for this research. 
2.2.2.1 Preliminary study 
Prior to the pilot study, a two-day preliminary study was conducted in one medical ward. The 
preliminary study addressed the following objectives: 
x To allow familiarisation with the types of information contained in patient notes on the ward 
and therefore assist in designing a suitable data collection form 
x To test the suitability of a published ADE trigger tool [90] for the Malaysian context 
During this preliminary study, all charts of patients admitted over two days were reviewed.  The type 
of information that can be retrieved from patient charts and the location of the different types of 
information were recorded. 
During this, it was noted that patient information such as gender, age, and ethnic group were 
ĂǀĂŝůĂďůĞŝŶƉĂƚŝĞŶƚƐ ?ŵĞĚŝĐĂůŶŽƚĞƐ ?ĂƐǁĞůůĂƐƚhe initial diagnosis upon admission, confirmed 
diagnosis and the investigations carried out. Information about the drugs upon admission and those 
administered in the ward were available in the medication charts.  
All of these information were easily available from the charts. Laboratory test results were not 
usually updated immediately. However, the results were available the following day. 
Based on the information from this preliminary study, the literature, and discussion with research 
supervisors, a data collection form was designed (Appendix 1). The data collection form was 
subsequently created in a mobile device called a Personal Digital Assistant (PDA). 
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The trigger tool developed by Institute of Health Improvement was adapted [90] and it served as a 
quick check list of important triggers to look out for in screened patients that could lead to 
identification of ADEs. Some items were added to the list to make it more useful in the Malaysian 
context and to meet the study objectives. The modified trigger tool is in Appendix 2 and the items 
added were:  
x T1 Antihistamines: a wider range of anti-histamines were listed in T1 compared to 
only diphenydramine in the original trigger tool 
x T4 Anti-emetics: anti-emetics commonly used in Malaysia were added 
x T5 Anti-diarrhoeals: anti-diarrhoeal drugs commonly used in Malaysia were added 
x T7 Antacids: the original trigger list did not contain antacids. Since gastrointestinal 
disorder was one of the most common ADEs reported in many studies, it was 
deemed appropriate to add this trigger in the list 
x T10 Abnormalities in laboratory data: all the abnormalities in the laboratory data 
were grouped under T10, compared with the original trigger tool which listed limited 
laboratory tests 
x T13 Uncontrolled disease/ recurrent/ worsening of a disease: this was not listed in 
the original tool but was added in accordance with the study objectives 
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2.2.2.2 Pilot study 
Pilot study was conducted prospectively over four weeks between June and July 2008. It addressed 
the following objectives: 
x Assess the feasibility of the chart review method and use the trigger tool to identify ADEs in 
medical wards of a public hospital in Malaysia 
x Determine the availability of charts for review and number of charts that can be reviewed in 
a day 
x Determine the optimum timing of visits to the wards 
x Determine the completeness of information in the patient charts 
x Determine whether the data collection form is suitable and able to collect the information 
needed to assess the occurrence of an ADE 
x Determine whether any changes should be made to data collection form 
x Estimate the number of admissions to medical wards and prevalence of ADEs during the time 
period of the pilot study 
x Determine whether or not the PDA is a suitable way to collect data 
 
Medication charts and medical records of all patients who were admitted to the wards during the 
previous 48 hours, if available were reviewed. Patient information was initially entered into the PDA 
and was later uploaded into a Microsoft Access database. The modified trigger tool was used to 
assist in detecting suspected ADEs during the patient chart review. 
All the clerked cases were classified into 2 main categories: 
(i) Suspected ADE cases  W admissions that were suspected to have been caused by one or 
more drugs 
(ii) Admissions not related to ADE (no ADE)  W admissions that were not related to any drug 
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A random sample consisting of 10% of all the clerked cases were checked by an assessor (first 
assessor  W FA), to ensure the identification of any ADE cases was appropriate (Figure 2-1). The 
assessor was one of the research supervisors, who has experience in pharmacovigilance. All 
suspected ADR cases were sent to a second assessor (SA), a senior pharmacist in MADRAC, to 
determine the causality. Causality assessment was carried out on all suspected ADR cases using the 
WHK ?ƐĐĂƵƐĂůŝƚǇƐĐale (Appendix 3). 
Figure 2-1: Flow chart of the research process 
Suspected ADE cases
Researcher
10% randomly selected ADE and no 
ADE cases
All ADR cases
Screened cases
Assessor 1 (FA) Assessor 2 (SA)
4 weeks of data collection on medical wards
 
 
 
 
 
 
 
Chapter 2 
 
 
77 
 
(a) Chart review 
 
During the pilot study, 374 patients were admitted to the medical wards. Of these, 136 (36%) charts 
were screened.  From the information collected, it was possible to determine definite ADEs in 52 
cases, no ADEs were suspected in 14 cases, and for the remaining 70 cases classification was not 
possible. The reason for this was a lack of information in the cases mentioned last. Information such 
as past medical and medication history, confirmed diagnosis and laboratory results were incomplete 
or missing. It is important to know which drugs the patients were taking prior to admission, how long 
they have been taking them, and for what condition to establish whether or not the presenting 
complaints are related to the drug consumed. Side effects, contraindications, choice of drug, doses 
and mode of administration need to be assessed to gauge their relation to any event experienced by 
patients.  
Patients without past medication history were considered as admissions not related to drugs by 
assuming that they were not on any medications. This may not be true in all patients as sometimes, 
this information may not have been recorded in the chart. Moreover, the patients could not have 
possibly recalled the information, or that they did not bring their drugs to the hospital.  
 
(b) Completeness of information in the patient charts 
 
As this study relied on patient charts and medication records, incomplete information and poor 
documentation were major limitations. Interviewing patients though, may have provided some 
missing information. However, quality of data would depend on their ability to recall information, 
their willingness to be interviewed, or their physical or health condition (for they may be too sick to 
even engage in an interview).  Count in the fact that patients in Malaysia may visit more than one 
general practitioner, and so clarifying any medication history from these very patients may have 
been complicated.  
 
 
Chapter 2 
 
 
78 
 
(c) Availability of charts for review and number of charts reviewed daily 
 
During the four-week period, the mean number of charts reviewed per day was six (ranging from 
three to 12). Some charts were not available for screening for a number of reasons including patients 
being away from the ward for procedures such as scans and X-rays, or them being discharged or 
transferred to another ward. 
The advantages of reviewing patients admitted in the previous 48 hours was that the information in 
the charts was more likely to be complete, with laboratory results, diagnosis, and further 
investigations. The disadvantage, however, was that patients admitted for short periods of time or 
were quickly transferred to other wards were missed. The only available record of all admitted 
patients was a daily record book which had minimal information on patients. Therefore, clerking 
patients admitted previous 24 hours will increase the number of cases screened per day. In case of 
missing or incomplete information, the case can be followed up the next day. 
(d) Trigger tool 
The list of triggers which was modified from the IHI trigger tool was not able to detect all ADEs. There 
were no triggers for MEs, DOs or ADWS. It would have been possible to add more triggers to the list 
to include all the possible ADEs. However, the usefulness of a trigger tool may reduce as the number 
of items for checking increases. 
(e) Visiting time 
Both the wards in the study had a routine of patient care. In the morning physicians and specialists 
conduct their ward rounds. During this time, patient charts were placed by ƚŚĞĨŽŽƚŽĨƉĂƚŝĞŶƚƐ ?ďĞĚƐ
to aid review of patients during the rounds. However, later in the afternoon, charts were moved to 
ƚŚĞŶƵƌƐĞƐ ?ƐƚĂƚŝŽŶĨŽƌĨŝnal review and duty hand-over, thus, making this the best opportunity to gain 
access to the medical charts.  
During the study, the researcher visited each ward on alternate days. However, during the case 
assessment at the end of each day, there was a need to clarify incomplete information. Information 
such as confirmed diagnosis and laboratory data were either not available or incomplete. For this 
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reason, the researcher visited the same ward the next day to clarify the incomplete information and 
increased the time needed to review each patient.  
(f) Suitability of the data collection form 
The data collection form was able to collect basic information. However, in order to conduct an ADR 
causality assessment and classify cases into ADE category, more information is needed. Additional 
information needed were: dates when past medication were started and stopped, changes in vital 
signs and laboratory results, other laboratory findings (such as computerised tomography (CT) scan, 
X-ray, and drug therapeutic monitoring), and progress of patients after any medical intervention. 
 
(g) Suitability of Palm PDA to collect data 
 
The PDA delayed the data collecting process because it did not always recognise handwriting, so data 
needed to be entered more than once before it was correctly interpreted. PDA only recognised the 
letters if they were written slowly and clearly. Hence, writing on data collection form using the 
traditional pen and paper would be quicker. However, the disadvantage of these forms is that the all 
data then need to be manually entered into the database at a later time. 
 
(h) Suspected adverse drug event cases 
Patients with past medication history and were admitted to the hospital due to some unwanted 
event were initially grouped as suspected ADEs. Further evaluation was conducted to ensure 
whether or not the events leading to the admissions could have been related to any of the drugs a 
patient was taking. Patients without recorded drug history were assumed as not taken any drugs. 
This aligns with the definition of ADE by WHO [45], where an undesirable event occurs while the 
patient is taking drug therapy whether or not there is a causal relationship between the medication 
and the event.  
Chapter 2 
 
 
80 
 
Out of 136 patients, 66 (49%) were suspected as having been admitted due to ADEs. There were four 
planned admissions  W when patients were admitted electively for dialysis. These patients were 
excluded as being admitted due to ADEs. All 62 remaining cases were then assessed by looking at the 
presenting complaints, symptoms, and laboratory tests. Such steps were taken in order that they can 
be classified into different categories, based on each ADE-type definition. 
However, during the pilot study it was found that classifying each case was difficult due to lack of 
information. More information was needed to identify each case into one type of ADE. All the cases 
were classified using only the available information and thus, this may not indicate the true 
percentages. 
After the assessments, 52 were classified as drug-related admissions and ten were not. These ten 
patients were admitted due to infections or newly diagnosed medical conditions. Within the drug-
related admissions, 45 (87%) of them were classified as TF, ten (19%) as ADRs, three (6%) as MEs, 
and one (2%) as DO. There were seven patients admitted with more than one type of ADE. This pilot 
study, however, did not identify any ADWS. 
(i) Inter-assessor reliability of adverse drug event classifications 
The following figures represent the ten percent of each classified group: suspected drug-related 
admissions (n= ? ? ?ĂĚŵŝƐƐŝŽŶƐŶŽƚƌĞůĂƚĞĚƚŽĂĚƌƵŐ ?ŶA? ? ?ĂŶĚƉĂƚŝĞŶƚƐ ?ǁŝƚŚŽƵƚƉĂƐƚŵĞĚŝĐĂƚŝŽŶ
history (n=7); were randomly selected and assessed by the assessor (FA). All the suspected ADR cases 
(n=10) were assessed by a pharmacist from MADRAC (SA). dŚĞĂŐƌĞĞŵĞŶƚŽŶ “ĂŶĚŶŽ ?
classifications between the assessor and researcher was excellent  W the agreement percentage being 
92. 
dŚĞĐĂƵƐĂůŝƚǇĂƐƐĞƐƐŵĞŶƚƐŽĨZĐĂƐĞƐƵƐŝŶŐƚŚĞt,K ?ƐĐĂƵƐĂůŝƚǇĂƐƐĞƐƐŵĞŶƚƐĐĂůĞ ?ƉƉendix 11) 
are shown in Table 2-1. The pharmacist from MADRAC reported the difficulty of carrying out the 
causality assessment for all suspected ADR cases due to some missing information (such as when 
exactly the drug was taken or stopped, and the name of the traditional medicine and its indication). 
For most of the reactions, a temporal association was not possible due to incomplete data. 
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Table 2-1 P^ĞĐŽŶĚĂƐƐĞƐƐŽƌ ?ƐĂĚǀĞƌƐĞĚƌƵŐƌĞĂĐƚŝŽŶĐĂƵƐĂůŝƚǇĂƐƐĞƐƐŵĞŶƚ ?ŶA? ? ? ? 
Number Suspected ADR Pharmacist's assessment
1 Hypoglycaemia secondary to insulin C5- Possible
2 Rash secondary to warfarin C5- Possible
3 Hypokalemia secondary to traditional medicine C6- Not enough information
4 Hyponatremia secondary to diuretic C6- Not enough information
5 Anemia secondary to UGIBi WĂƐƉŝƌŝŶŝŶĚƵĐĞĚ C6- Not enough information
6 Anemia secondary to UGIBi WĂƐƉŝƌŝŶŝŶĚƵĐĞĚ C6- Not enough information
7 Itchiness secondary to amlodipine C6- Not enough information
8 Renal impairment secondary to perindopril C6- Not enough information
9 Hyponatremia secondary to captopril C6- Not enough information
10 Cough secondary to perindopril C6- Not enough information
 
i
 UGIB  W upper gastrointestinal bleed 
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Amendments prior to the main study 
Based on the pilot study, the following amendments were made for the main study: 
x Prescriber appointed to assess classification 
Since the researcher and the assessor involved in the pilot study are pharmacists (FA and SA), and to 
avoid bias, it was decided appropriate to include a prescriber in the main study.  
x Research assistants for data collection 
Chart review is a time-consuming method.  Involving more personnel during data collection would 
reduce the time spent by the researcher on the wards and therefore, may increase the number of 
patients reviewed in a day. However, training of the data collectors in the use of the form would be 
required. 
x Use of trigger tool 
As discussed earlier, the trigger tool was not able to detect all types of ADE. Thus, it was realised and 
decided that its benefit of detecting ADEs would diminish if it was expanded to include all types of 
ADEs. 
x Patients screened 
As discussed in the previous section, many patients were missed because of the 48-hour time frame 
upon admission. It was already anticipated that reviewing patients admitted in the previous 24 hours 
would reduce the number of patients missed. Though such were the cases, this meant too, that 
ƉĂƚŝĞŶƚƐ ?ĚĂƚĂŶeeded to be updated the next day, had there been missing lab results or other 
ongoing tests.  
ADWS were not identified in the main chart review study due to the difficulty in recognising it using 
only the information from patient notes. Furthermore it may need further investigation on 
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associating the drugs responsible for the event: on the patient ?Ɛ medical and medication histories 
and adherence behaviour. 
x Patients interviews 
 
This pilot study found that in 70 cases, past medical and medication histories were incomplete or 
missing. Interviewing patients was considered a suitable method for collecting this information. 
x Use of Palm PDA 
 
As the use of PDA limited the charts that could be reviewed each day, to increase the efficiency, a 
paper data collection forms were used. 
An attempt was made to include research assistants for assisting in the collection of data as 
suggested upon completion of the pilot study. However, this attempt failed and led to the 
development of a classification tool as discussed in the next section (Section 2.2.2.3). 
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2.2.2.3 Development and testing of the classification tool 
Two pharmacists were appointed to help in collecting data for the main chart review study. They 
were given a briefing about what information to collect and were given the data collection forms. 
However, after a collection of 600 cases, it was found that the information collected by the 
pharmacists was insufficient in determining whether or not an ADE has occurred. Due to this, all 600 
clerked cases were discarded.  
However, during the assessment of the 600 cases by the researcher, it was found that there was a 
need for a more systematic approach in reviewing and classifying each case in the same manner. The 
researcher found that it was difficult to rely only on the ADE definitions to assess all the cases as they 
do not state what type of information is needed to suspect an event. Furthermore, the information 
collected from the patient notes were usually not complete (as reported in the pilot study). On the 
other hand, it was found out a tool could help the researcher scrutinise all the available information, 
identify any extra information as needed in classifying the cases, and gauge whether or not a patient 
interview was still needed. Upon the development of a tool to recognise and classify ADEs, all 600 
cases collected by the pharmacists were discarded and the data collection was restarted. However, 
the two pharmacists appointed to collect data were not available for re-collection due to changes in 
their work schedules. Thus, the researcher collected all the data herself for the main study. 
 
Development of the classification tool  
Although the types of information collected by studies investigating ADEs were similar, the way this 
information was assessed to identify an event differed between studies. Most studies identified or 
detected ADEs based on their definitions [9, 143, 244, 245]. Some used the criteria proposed by 
Hallas et al. [62] or Naranjo et al. [99]  that sought to associate an event with a drug and classify 
those events [134, 135, 246]. However, the criteria were used only where an ADE was already 
suspected and not on all the screened patients. In some studies, a list of triggers has been used to 
detect ADEs from charts [139, 246, 247]. However, as discussed earlier, the trigger tool was not able 
to identify all types of ADEs without substantially increasing its length, therefore, decreasing its 
usability. It also contains only specific triggers related to specific medications (for example, asthma 
exacerbation due to NSAIDs or aspirin however, this exacerbation could also be due to TF). Although 
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a trigger tool can be used as a guideline to help detect ADEs, the stringent criteria in the list may limit 
the type of ADEs detected. 
In order to be consistent in assessing all cases, a step-by-step approach to identifying ADEs was 
proposed. In each case where there is medication, history was assessed using the classification tool 
to reduce the possibility of missing an ADE. 
Based on the literature and discussions with research supervisors, a classification tool that contains 
five criteria determining whether or not an ADE was present in a case was developed (Figure 2-2).  
The said criteria are detailed on the next page. 
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Figure 2-2: The classification tool
Criteria that indicates the ADE type
Relate to the side effect of a drug (ADR)
Appear at insufficient dose (TF)
Appear due to prescribing error: wrong drug/dose/frequency etc (ME)
Appear due to drug-drug interaction (ME)
Appear at overdose of a drug (DO)
Appear due to exacerbation of a past medical condition which usually 
appear at insufficient dose (TF)
Appear due to drug-disease interaction, drug contraindicated for 
patient's medical condition or age (ME)
Addition of a new drug  (TF or ADR)
Substitution to a different drug (TF or ADR)
Abrupt cessation of a drug (ADR or DO)
Dose was increased or decreased (TF, ADR, ME or DO)
An antidote was prescribed (DO)
Abnormalities in blood test
Abnormalities in vital signs 
Abnormalities in other findings eg X-ray, CT scan, ECG etc
dŚĞĚŝĂŐŶŽƐŝƐŝƐƌĞůĂƚĞĚƚŽƚŚĞƐŝĚĞĞĨĨĞĐƚƐŽĨƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐĂƚŝŽŶ ?Z ?
dŚĞĚŝĂŐŶŽƐŝƐŝƐƌĞůĂƚĞĚƚŽŝŶƐƵĨĨŝĐŝĞŶƚĚŽƐĞŽĨƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐĂƚŝŽŶ ?d& ?
The diagnosis is related to prescribing error (ME)
dŚĞĚŝĂŐŶŽƐŝƐŝƐƌĞůĂƚĞĚƚŽŝŶƚĞƌĂĐƚŝŽŶƐŽĨƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐĂƚŝŽŶ ?D ?
dŚĞĚŝĂŐŶŽƐŝƐŝƐƌĞůĂƚĞĚƚŽŽǀĞƌĚŽƐĞŽĨƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐĂƚŝŽŶ ?K ?
The diagnosis is related to drug contraindication / drug-disease 
interactions (ME)
Review the laboratory tests 
and other findings.
4
Review the diagnoses.5
Criteria
Review patient's complaints 
and symptoms. Assess 
whether or not they may be 
related to patient's 
medication prior to 
admission.
1
Review patient's complaints 
and symptoms. Assess 
whether or not they may be 
related to past medical 
condition.
2
Review medication changes 
on admission.
3
 
Morimoto et al. [82] have discussed different methods in identifying ADEs and key factors in 
determining whether or not an event is related to a drug. The first important step was to look for any 
ƐŝŐŶƐĂŶĚƐǇŵƉƚŽŵƐŝŶƉĂƚŝĞŶƚƐƚŚĂƚĐŽƵůĚďĞƌĞůĂƚĞĚƚŽĂĚƌƵŐ ?ďǇƌĞǀŝĞǁŝŶŐƉĂƚŝĞŶƚ ?ƐĐŽŵƉůĂŝŶƚƐ ?
For example, if a patient complains of gastric pain, there could be several possible reasons  W an 
exacerbation of previous gastric disorder, an adverse effect of a drug or a new medical condition. 
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dŚĞŶĞǆƚƐƚĂŐĞŝƐĚĞƚĞƌŵŝŶŝŶŐǁŚĞƚŚĞƌŽƌŶŽƚĂŶĞǀĞŶƚŝƐĂƐƐŽĐŝĂƚĞĚǁŝƚŚƚŚĞƉĂƚŝĞŶƚ ?ƐƉĂƐƚ
medication history. Illustrating this using the same example above: If the patient was prescribed 
ĂƐƉŝƌŝŶƉƌŝŽƌƚŽĂĚŵŝƐƐŝŽŶ ?ŝƚĐŽƵůĚďĞƐƵƐƉĞĐƚĞĚĂƐƚŚĞĐĂƵƐĞŽĨƉĂƚŝĞŶƚ ?ƐŐĂƐƚƌŝĐƉĂŝŶ ?ĂŶZŵĂǇďĞ
the cause), on the other hand, if patient had a history of gastritis, and if antacid was listed in the past 
medication history, TF could be suspected after all.  ,ŽǁĞǀĞƌ ?ŝĨŶŽŶĞŽĨƚŚĞƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐĂƚŝŽŶ
ĐŽƵůĚďĞĂƐƐŽĐŝĂƚĞĚǁŝƚŚƉĂƚŝĞŶƚ ?ƐŐĂƐƚƌŝĐƉĂŝŶ ?ƚŚĞƉĂƚŝĞŶƚ ?ƐĂĚŵŝƐƐŝŽŶŵĂǇŶŽƚďĞĚƌƵŐ-related and 
the pain could have resulted from a new condition. For an ADR to be suspected, a reasonable timing 
of drug intake and the reaction need to exist. 
Following these, the first criterion in assessing a screened case was to seek for and observe  “ƉĂƚŝĞŶƚ ?Ɛ
complaints and symptoms, and consider whether or not they might bĞƌĞůĂƚĞĚƚŽƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐĂƚŝŽŶ
ƉƌŝŽƌƚŽĂĚŵŝƐƐŝŽŶ ?ĐƌŝƚĞƌŝŽŶŽŶĞ ? ?. Based on the definition of different types of ADEs that were 
ĚŝƐĐƵƐƐĞĚŝŶŚĂƉƚĞƌ ? ?ƉĂƚŝĞŶƚ ?ƐƐǇŵƉƚŽŵƐŽƌĐŽŵƉůĂŝŶƚƐƐŚŽƵůĚďĞĂƐƐĞƐƐĞĚĂƐƚŽǁŚĞƚŚĞƌor not 
they: are related to the side effects of a drug (which may indicate an ADR had occurred), appear at 
insufficient dose (which may indicate a TF had occurred), appear due to prescribing errors: wrong 
choice of drug or dose or frequency and etc. (which may indicate a ME had occurred), appear due to 
drug-drug interaction (which may indicate a ME had occurred), or appear at overdose (which may 
indicate DO had occurred). 
Using the same example above, if patient was found to have had a history of gastritis that was 
overlooked when aspirin wĂƐƉƌĞƐĐƌŝďĞĚ ?ƚŚŝƐĐŽƵůĚďĞƐƵƐƉĞĐƚĞĚĂƐĂD ?dŚŝƐƐŚŽǁƐƚŚĂƚƉĂƚŝĞŶƚ ?Ɛ
medical history is also as important. It could provide information on previous drug allergies, medical 
conditions or history of disease management. For this reason, the second criterŝŽŶǁĂƐƚŽ “assess 
ƉĂƚŝĞŶƚ ?ƐĐŽŵƉůĂŝŶƚƐĂŶĚƐǇŵƉƚŽŵƐĂŶĚĐŽŶƐŝĚĞƌǁŚĞƚŚĞƌor not ƚŚĞǇŵŝŐŚƚďĞƌĞůĂƚĞĚƚŽƉĂƚŝĞŶƚ ?Ɛ
past medical conditions (criterion two) ? ?dŚŝƐǁĂƐƚŽĨŝŶĚŽƵƚǁŚĞƚŚĞƌ or not the symptoms appear 
due to exacerbation of a past medical condition which usually appear at insufficient drug or dose 
(which may indicate a TF or ME had occurred); or appear due to drug-disease interactions or drugs 
ĐŽŶƚƌĂŝŶĚŝĐĂƚĞĚĨŽƌƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐĂůĐŽŶĚŝƚŝŽŶŽƌĂŐĞ ?ǁŚŝĐŚŵĂǇŝŶĚŝĐĂƚĞĂDŚĂĚŽĐĐƵƌƌĞĚ ? ? 
Where the two above criteria were not met, the admission was not considered as related to a drug. If 
ĂƉĂƚŝĞŶƚ ?ƐĐŽŵƉůĂŝŶƚƐŽƌƐǇŵƉƚŽŵƐĚŽŶŽƚƌĞůĂƚĞƚŽƚŚĞŝƌƉĂƐƚŵĞĚŝĐĂƚŝŽŶŽƌŵĞĚŝĐĂůŚŝƐƚŽƌǇ ?ƚŚĞƌĞ
ĐŽƵůĚďĞŽƚŚĞƌƌĞĂƐŽŶƐƚŚĂƚĐŽƵůĚŚĂǀĞĐĂƵƐĞĚƚŚĞƉĂƚŝĞŶƚ ?ƐĂĚmission, such as newly diagnosed 
medical condition or infection not related to past med
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ƐƐƵŵŝŶŐƚŚĂƚŽŶĞŽƌďŽƚŚĐƌŝƚĞƌŝĂǁĞƌĞŵĞƚ ?ƚŚĞŶĞǆƚĐƌŝƚĞƌŝŽŶƚŽĂƐƐĞƐƐǁĂƐƚŚĞĐŚĂŶŐĞƐŝŶƉĂƚŝĞŶƚ ?Ɛ
medication as derived from criterion three, (assessing medication changes on admission). The 
essential step in managing a patient presenting with an ADR is to withdraw all the suspected drugs, if 
possible and provide symptomatic treatment [59, 182]. If the effect is dose-related, dose of the 
suspected medication should be reduced or substituted with another drug [59, 182]. Usually a drug 
re-challenge is recommended if the reaction is not severe. Similarly, in case of a DO, the suspected 
drug is removed and an antidote or symptomatic treatment is given, if necessary. In contrast, if a TF 
is suspected, the usual management is to add a drug, increase the dose or substitute with a different 
drug.  Hence this criterion was aimed to look for interventions such as an addition of a new drug 
(which may indicate a TF or ADR had occurred), substitution to a different drug (which may indicate a 
TF or ADR had occurred), abrupt cessation of a drug (which may indicate an ADR or ME had 
occurred), dose were increased or decreased (which may indicate a TF, ME, or DO had occurred) or 
an anti-dote (which may indicate a DO had occurred). Referring to the example given above, if aspirin 
was withdrawn (abrupt cessation of a drug) and an antacid was given to the patient (addition of a 
new drug), this may indicate an ADR or a ME could had occurred. In contrast, if a proton pump 
inhibitor was substituted for magnesium trisilicate mixture the patient was prescribed prior to 
admission, this may indicate a TF had occurred. 
The fourth criterion (assess the laboratory tests and other findings) was based on the investigations 
carried out after admission. Results from laboratory test or other tests can confirm the symptoms 
reported by the patients. For example, a complaint of gastric pain can be confirmed through an 
endoscopy, if available. The laboratory tests may be helpful for some types of ADE, especially when it 
involves specific organs. Abnormalities in tests, such as renal profile test, liver function test, or 
complete blood count or blood sugar level may indicate a problem that is potentially related to 
medication prior to admission.  
dŚĞĨŝĨƚŚĐƌŝƚĞƌŝŽŶǁĂƐƚŽ “assess the diagnoses (criterion five) ? ?Admitted patients are sometimes 
assigned an initial diagnosis until a confirmed diagnosis can be made. Both diagnoses can assist in 
ĚĞƚĞƌŵŝŶŝŶŐǁŚĞƚŚĞƌŽƌŶŽƚĂŶŝƐƉƌĞƐĞŶƚďǇƌĞůĂƚŝŶŐŝƚƚŽƚŚĞƉĂƚŝĞŶƚ ?ƐƉĂƐƚŵĞĚŝĐĂůĂŶĚ
medication histories. Referring back to the example above, if gastritis is documented as the 
diagnosis, this could confirm the occurrence of an event. 
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After the criteria assessment, patients are categorised into each type of ADE based on the 
classification listed in Figure 2-3. 
Figure 2-3: Classification of adverse drug events 
ADE Classification
Adverse drug reaction Symptoms are related to the side effects of a drug
Overdose Symptoms appear at overdose
Therapeutic Failure
Symptoms appear at insufficient dose or due to 
exacerbation of past medical condition which usually 
appear at insufficient dose
Medication error
Symptoms appear due to wrong choice of drug and 
dose, drug-drug interaction, drug-disease interactions 
ŽƌĚƌƵŐĐŽŶƚƌĂŝŶĚŝĐĂƚĞĚĨŽƌƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐĂů
condition or age
 
 
Testing the classification tool 
The classification tool was tested to determine whether it was suitable and efficient in categorising 
ADEs. The test was conducted in cases screened during the first week of the main chart review study 
(male medical ward). The cases from the pilot study were not used because of incomplete or missing 
information in most cases. Information such as demographic data, presenting complaints, drugs on 
admission, laboratory test, and other findings and diagnoses were collected as intended for the main 
study. The criteria were used to review each patient and identify whether or not he or she was 
admitted due to an ADE.  
Of the 44 patients, 17 did not have past medication or medical histories and six were planned 
admissions for dialysis, review of renal, or blood profile; these cases were excluded from further 
assessment. Thus, using the classification tool (Table 2-2), 21 potential cases were assessed to 
determine whether or not an ADE had occurred in such. 
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Table 2-2: The assessment of cases using the classification tool (n= 21) 
1 2 3 4 5
1 A? × A? x × 2 None
2 A? A? A? × A? 4 TF, ME
3 × A? A? A? A? 4 TF
4 × × - - - NA None
5 A? × A? x × 2 None
6 A? A? A? A? A? 5 TF
7 A? A? A? A? A? 5 TF, ADR
8 A? A? A? A? A? 5 TF, ME
9 A? A? A? A? A? 5 TF, ADR
10 × × - - - NA None
11 A? A? A? A? A? 5 TF, ADR, ME
12 A? A? A? A? A? 5 TF, ADR
13 A? A? A? A? A? 5 TF
14 A? × A? A? × 4 ADR, ME
15 A? A? A? A? A? 5 TF
16 A? × A? A? A? 4 ADR
17 A? A? A? A? A? 5 TF
18 A? × A? A? A? 4 ADR
19 A? A? A? A? × 4 TF
20 A? A? A? A? A? 5 TF
21 A? × A? A? A? 4 ADR
Case 
number
Criterion Number of 
criteria met
ADE type
 
NA  W not applicable 
 
 
A total of 25 ADEs were identified using the classification tool (where one patient may have more 
than one type of ADEs). Thirteen patients were identified to have been admitted due to a TF, eight 
due to an ADR and four due to a ME. All these cases met four or more criteria. Out of 21 cases seven 
met four criteria whilst ten cases met all five criteria. Criteria one and two were not met in two cases 
(case four and ten) ?ŝŶĚŝĐĂƚŝŶŐƚŚĂƚƚŚĞƉĂƚŝĞŶƚ ?ƐĐŽŵƉůĂŝŶƚƐǁĞƌĞŶŽƚƌĞůĂƚĞĚƚŽƉĂƚŝĞŶƚƐ ?ƉĂƐƚ
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medical and medication histories. Thus these admissions were classified as not drug-related. 
Furthermore, cases one and five met criteria one and three (Figure 2-4). Fulfilling criterion one 
ŝŶĚŝĐĂƚĞĚƚŚĂƚƚŚĞƉĂƚŝĞŶƚƐ ?ĐŽŵƉůĂŝŶƚƐǁĞƌĞƌĞůĂƚĞĚƚŽƚŚĞŝƌƉĂƐƚŵĞĚŝĐĂƚŝŽŶŚŝƐƚŽƌǇ ?ĂŶĚŵĞĞƚŝŶŐ
criterion three indicated that there were some changes in their medication. However, evidence was 
not enough to be able to determine that their admission was drug-related.  
Figure 2-4: Summary of cases 1 and 5 
 
Case one: The patient was discharged one month ago and diagnosed with tuberculosis.He was 
prescribed anti-tubercular drugs. He complained of poor oral intake (anorexia) and body weakness 
for the past two days.  Poor oral intake is one of the side effects of anti-tubercular drugs but it is also 
a sign of active tuberculosis. An antibiotic wĂƐĂĚĚĞĚƚŽƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐĂƚŝŽŶ in the ward. CT scan 
showed a mid-line shift and, the patient was diagnosed with brain abscess and suspected with 
cerebral toxoplasmosis. There was no evidence to support his complaints, hence, this case was 
cůĂƐƐŝĨŝĞĚĂƐ ‘not drug-related ?. 
 
 
Case five: The patient was admitted with complaints of bed sore with pus discharge mixed with 
blood and foul smell for the past two weeks. Patient was bedridden since 2008 and was unable to 
move upper and lower limb. Patient was tolerating tube-feeding and had diabetes mellitus and 
hypertension. He was prescribed anti-diabetics and anti-hypertensive agents. Two antibiotics were 
ĂĚĚĞĚƚŽƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐĂƚŝŽŶŝŶƚŚĞǁĂƌĚ ?WĂƚŝĞŶƚǁĂƐĚŝĂŐŶŽƐĞĚǁŝƚŚgrade II bed sore secondary 
to prolonged bed-ridden. Although, poor control of diabetes mellitus can be suspected as the cause 
ŽĨƉĂƚŝĞŶƚ ?ƐďĞĚƐŽƌĞ ?ƚŚĞƌe was no evidence supporting this suspicion. Hence, this case was 
ĐůĂƐƐŝĨŝĞĚĂƐ ‘ŶŽƚĚƌƵŐ-ƌĞůĂƚĞĚ ? ? 
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All the information collected from the ward were reviewed systematically to decrease the likelihood 
of missing an ADE. All cases were reviewed in the same manner using the criteria. In using the 
criteria, it was possible to determine whether or not the information collected were sufficient to 
complete the assessment. Hence, when there was not enough collected information, the researcher 
could go back to the ward the next day to locate any missing information. 
Criterion three needs to be evaluated carefully. Although there are changes in the medication 
particularly the addition of a new drug, it may not mean that an event has occurred. Changes in 
medication could also indicate that a patient has been diagnosed with a new condition. 
Criterion four investigates whether or not there is any abnormality in the laboratory tests or other 
findings that could indicate an event may have occurred. However, this criterion is difficult to apply 
to subjective symptoms such as cough, constipation or headache. These symptoms cannot be 
measured by laboratory testing and may not be reported in the medical notes. Thus, criterion four is 
reliant on the quality of documentation in the medical notes.  
The definitions of ADE sub types overlap and it can be challenging to differentiate one from another. 
This further emphasises the need for clear definitions and system of classification is just as important 
to avoid misclassification of any ADEs. 
Seven out of 21 cases assessed using the classification tool met four criteria  W meaning there was 
only one criterion not met by these cases. Criterion 2 was not met in four of these cases. This could 
be due to missing or incomplete information. The remaining cases did not meet criterion one, four or 
five. Part of this could be because patient details were not followed-up until discharge, where more 
investigations would have been conducted and a confirmed diagnosis might have been stated.  
ZĞĨĞƌƌŝŶŐƚŽƚŚĞt,K ?ƐZĐĂƵƐĂůŝƚǇƐĐĂůĞ[98], for an event to be classified as possible, probable, or 
certain, it is important that some of the criteria are fulfilled: (a) a clinical event, (b) laboratory test 
abnormality with a reasonable time sequence, (c) clinically reasonable response on withdrawal, and 
 ?Ě ?ƐĂƚŝƐĨĂĐƚŽƌǇƌĞĂƐŽŶĂďůĞƉƌŽĐĞĚƵƌĞ ?ůƚŚŽƵŐŚ ?ƉĂƚŝĞŶƚƐ ?ĐŽŵƉůĂŝŶƚŝƐĞŶŽƵŐŚƚŽƐƵƐƉĞĐƚ an ADE, in 
order to confirm the causality of an event, it is important to get more evidence to support this. 
Similar approaches have also been used by Hallas et al. [62] and Naranjo et al. [99] where a list of 
criteria was scored to determine the causality of an event. Based on these approaches and the 
testing conducted on 21 cases using the classification tool, it was decided that cases that meet four 
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ĐƌŝƚĞƌŝĂǁŝůůďĞĐŽŶƐŝĚĞƌĞĚĂƐ ‘ĚƌƵŐ-related ?, meaning, the event may be considered as certainly or 
probably caused by a drug.  None of the 21 cases met only three criteria. However cases meeting 3 
criteria should also be ĐŽŶƐŝĚĞƌĞĚĂƐ ‘ĚƌƵŐ-ƌĞůĂƚĞĚ ?, as the remaining two criteria may not be met 
partly due to incomplete or missing information, and these cases may be considered as possibly 
caused by a drug. Cases which meet less than three criteria are considered as not drug-related, as 
there was not enough information to conclude that the event leading to the admission was related to 
a drug. TŚĞƐĞĐĂƐĞƐŵĂǇďĞĐŽŶƐŝĚĞƌĞĚĂƐƵŶůŝŬĞůǇ ?ƵŶĐůĂƐƐŝĨŝĞĚŽƌƵŶĐůĂƐƐŝĨŝĂďůĞĂĐĐŽƌĚŝŶŐƚŽt,K ?Ɛ
scale. 
 
Limitations 
The classification tool was tested only in a small number of patients due to time constraints. 
Furthermore the classification tool was developed using retrospective cases (the 600 that were 
discarded) and the tool then was tested prospectively to ensure it could be applied in practice. This 
was done using all suspected ADE cases for the first week of the main study (n=21).  The number 
cases used to test the tool was small but this test also served as an exercise for the researcher to get 
familiarised with the components in the tool. 
Not all types of MEs are identified through this chart review study. This is because only ME which 
have caused hospital admissions were investigated. Other MEs such as wrong dosage or frequency in 
the prescriptions may not be captured during the admissions because they are preventable and may 
have been intercepted before causing any harm. This chart review study will only be able to identify 
MEs that have caused harm and thus, only those MEs are included in the classification tools. 
 
Amendments made to the criteria 
The findings from testing of the classification tool in 44 patients and discussion with research 
supervisors were considered for amendments. Where a new drug is added, a further review of the 
laboratory test and diagnosis should be made to determine whether or not the new drug was added 
due to an ADE. An extra section was added to criterion four for the assessor to consider changes in 
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subjective symptoms such as cough and headache. Although the subjective symptoms should be 
reviewed in criterion one,  the progression of the symptoms (for worse or better) which may indicate 
the success or failure of the new therapy given to the patient, may be the key point to indicate that 
changes made to patient medication have improved or worsened the patient ?ƐĐŽŶĚŝƚŝŽŶ ?/ĨƚŚĞ
condition worsens, suspicion could be raised as to whether or not the suspected drug or suspected 
event was the actual reason for the admission.  
2.2.3 Sample size calculation 
The prevalence of ADE-related medical admissions in the pilot study was estimated as 38%. There 
were 374 admissions during the four-week pilot study. It was estimated that in 24 weeks, the 
number of admissions (population size) would be around 2,300 patients. The sample size was 
calculated using a formula designed by Naing et al. [248], which allows calculation of sample size of 
studies estimating prevalence. The required sample size was estimated to be 1141 at 95% confidence 
level and with 2% precision. A total of 1200 patients were included in the study. 
 
2.2.4 Ethical approval 
Ethical approval was obtained from the Malaysian Research Ethical Committee, Ministry of Health to 
conduct the pilot study (reference number: NMRR-08-260-1415) (Appendix 4) and main study 
(NMRR-08-1532-2877) (Appendix 5). Permission was also obtained from the hospital director and 
ward sisters to have ĂĐĐĞƐƐƚŽƉĂƚŝĞŶƚƐ ?ŵĞĚŝĐĂůĂŶĚŵĞĚŝĐĂƚŝŽŶĐŚĂƌƚƐ ?
 
2.2.5 Data collection 
Medication charts and medical records of patients admitted to two medical wards were reviewed 
prospectively from Nov 2009 to April 2010. Each ward was visited by the researcher on alternate 
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weeks. Data were collected for all patients admitted to the ward during the previous 24 hours, where 
their charts were available for review.  The data collected were: 
x ĞŵŽŐƌĂƉŚŝĐŝŶĨŽƌŵĂƚŝŽŶ ?ƉĂƚŝĞŶƚ ?ƐĂŐĞ ?ŐĞŶĚĞƌĂŶĚĞƚŚŶŝĐŐƌŽƵƉ ? 
x Presenting complaints (complaints recorded on the chart at admission) 
x Vital signs and other investigations since admission (results of investigation on patients since 
admission) 
x Medication since admission (medication patient was given since admission) 
x Past medical and medication history (medical and medication history recorded in the notes 
and if not satisfactory, the patient was interviewed for more information) 
x Initial and confirmed diagnoses (the initial diagnosis on admission and confirmed diagnosis 
after  investigations) 
x Laboratory results and other findings (results from the laboratory and other tests recorded in 
ƉĂƚŝĞŶƚ ?ƐŶŽƚĞƐƐŝŶĐĞĂĚŵŝƐƐŝŽŶ ? 
All data gathered were handwritten on a data collection form which was designed and modified 
following the pilot study (Appendix 6). Data was subsequently entered into a prepared Microsoft 
Office Access (2007) database.  
2.2.6 Case screening and classification 
All cases were screened by the researcher and were classified into two groups; admissions not 
related to ADE and suspected ADE-related admissions. The characteristics which distinguish these 
two groups are shown in Figure 2-5.  Patient admissions without past medication history, elective 
admissions and those due to poisoning with non-medicinal product (such as detergent or weed killer) 
ǁĞƌĞĐůĂƐƐŝĨŝĞĚĂƐ “ĂĚŵŝƐƐŝŽŶƐŶŽƚƌĞůĂƚĞĚƚŽ ? ? 
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All patients admitted with past medication history were suspected as having an ADE. These patients 
were then assessed by the researcher using the ADE classification tool and subsequently classified as 
either: 
x Suspected ADE cases if three or more criteria were met (criteria one and/ or criteria two and 
one or more of the other criteria) 
x Admissions not related to an ADE if fewer than three of the five criteria were met 
Figure 2-5: Characteristics distinguishing ADE-related admissions from admissions not related to 
ADEs 
1200 cases
No past medication history Elective admissionWith past medication history
ADE cases Admissions not 
related to ADE
Poisoning due to non-medicinal 
product
Suspected ADE-related 
admissions
Admissions not related to ADE
 
All ADE cases were then classified into four different types of ADEs: 
i) Therapeutic failure  W defined as an inadequate therapeutic response to a drug as 
evidenced by the presence of symptoms of a diagnosed disease state or condition [63] 
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ii) Adverse drug reaction   W  defined as a response to a drug that is noxious and unintended 
and occurs at doses normally used in man for prophylaxis, diagnosis or therapy of 
disease, or for modification of physiological functions [45].  
iii) Drug overdose  W defined as an exposure of an individual, by ingestion or inhalation, to an 
amount of substance associated with the significant potential to cause harm [65]. 
iv) Medication error  W defined as any preventable event that may cause or lead to 
inappropriate medication use or patient harm, while the medication is in the control of 
the health care professional, patient, or consumer[49]. 
2.2.7 Independent assessment and inter-assessor reliability 
As a process of checking the reliability of the classification tool used to identify and classify ADE 
cases, and to ensure the identification and classification of any ADE was appropriate, 10% of each 
ADE cases (n= 46) and admissions not related to ADE (n= 19) were assessed by two assessors. These 
cases were generated randomly using the Predictive Analytics SoftWare (PASW) Statistics 18.0 (© 
SPSS, Inc., 2009, Chicago, IL). The reliability could have been increased if the assessors were able to 
assess all the cases. However due to their work commitments; they were not able to look at all 1200 
cases. Thus only 10% of cases were selected. The assessors were: 
x A physician who has experience working on medical wards and  
x An academic who is a pharmacist and has experience in pharmacovigilance (FA); also a 
research supervisor. 
Both assessors were given an explanation about the study and its purposes. They were given training 
on the application of the ADE classification tool using a few sample cases. 
Each assessor was given: 
x A set of all the randomly selected cases 
x A list of ADE classification tool 
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x A British National Formulary [249] 
x A password to access online Martindale[250] ĂŶĚ^ƚŽĐŬůĞǇ ?ƐƌƵŐ/ŶƚĞƌĂĐƚŝŽŶƐ[251] 
 
Inter-assessor reliability was used to identify whether same results can be obtained by two or more 
assessors using similar method of assessment or instrument. It is a measure of the level of 
agreement between assessors. Percentage agreement and kappa statistic can be used to measure 
this level.  
 
Calculating the percentage of agreement is simple. Observed percentage agreement (Po) = total 
agreement (T) divided by total number of cases assessed (N) [252, 253]: 
Po= T/N  
However, some researchers believe this is not the best measure as it does not take into account the 
chance of agreement [253, 254]. Kappa statistic overcomes this limitation by taking into 
consideration the amount of agreement that could be expected by chance [255].  Chance agreement 
can occur for example when the assessor knows in advance that most of the cases are not related to 
ADEs and they adopt a strategy reviewing the cases as negative whenever they are in doubt [252]. 
Thus, the percentage of negative agreement will be large because of prior knowledge of the 
prevalence of ADE, not because of the information revŝĞǁĞĚŝŶƚŚĞĐĂƐĞƐ ?<ĂƉƉĂ ?ʃ ?ŝƐĐĂůĐƵůĂƚĞĚďǇ
subtracting the percentage of expected agreement (Pe), which occur by chance, from the total 
agreement (Po), then divided by  percentage agreement which is not expected to occur by chance (1- 
Pe) [252, 253, 256]:  
ʃA?Wo  W Pe / 1  W Pe 
A kappa of one indicates perfect agreement, whereas a kappa of zero indicates agreement 
equivalent to chance and kappa of <0 indicates agreement which is worse than chance. There is no 
universal standard in classifying the kappa value that reflects reliable judgement, but the commonly 
applicable ranges are by Landis and Koch [257] (Table 2-3).  
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Table 2-3: Classification of level of agreement 
Range of ʃ Description of agreement level
< 0.00 Poor agreement
0.01 - 0.20 Slight agreement
0.21 - 0.40 Fair agreement
0.41 - 0.60 Moderate agreement
0.61 - 0.80 Substantial agreement
0.81 - 1.00 Almost perfect agreement  
Source: Landis and Koch [257] 
 
Kappa has been criticised for a number of reasons. Kappa is sensitive to the distribution of 
proportion in each subject category and may not be reliable for rare observations. So caution has to 
be taken when comparing kappa between studies. Kappa treats all disagreements equally. When the 
categories are ordered, it is important to use the weighted kappa. However, this is not relevant for 
assessment of ADE and types of ADE in this study. The kappa statistic was used in this study to assess 
the level of agreement between assessors in identifying the occurrence of ADEs and classifying the 
type of ADE observed. 
It was found that percentage of agreement was slight to fair when the academic assessments were 
compared to the researcher ?Ɛ and physician ?Ɛ. Therefore, it was decided to use a second pharmacist 
to assess all the cases  W a clinical pharmacist who has experience working on medical wards. 
During the course of this study, the pharmacist (SA) from MADRAC was promoted and transferred to 
another department. Upon discussion with a new pharmacist who was appointed to replace the 
previous pharmacist, all suspected ADR cases were sent to MADRAC using the online reporting form 
[258]. Whilst sending some of the reports using the online reporting form, errors occurred on the 
webpage. The webpage could not be retrieved and it was not possible to determine whether or not 
the report had been sent.  For this reason, a hardcopy of each case was also handed personally to a 
pharmacist in MADRAC by the researcher, to ensure that the committee received all suspected cases. 
The causality of each case was assessed by the MADRAC. MADRAC conducts meetings every two 
months to review all the reports received and for causality assessments. After the causality 
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assessment, one of the pharmacists from MADRAC contacted the researcher with the outcome of 
their assessment. 
 
2.2.8 Data analysis 
Statistical analysis was performed in Predictive Analytics SoftWare (PASW) Statistics 18.0 (© SPSS, 
Inc., 2009, Chicago, IL). Descriptive statistics are shown as means, frequencies and percentages. The 
admissions identified as related to ADE, its sub-categories, and the drugs implicated are shown in 
ĨƌĞƋƵĞŶĐŝĞƐĂŶĚƉĞƌĐĞŶƚĂŐĞƐ ?dŚĞŝŶĨůƵĞŶĐĞŽĨƉĂƚŝĞŶƚƐ ?ĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐŽŶƚŚĞƉĞƌĐĞŶƚĂŐĞŽĨ
admissions due to ADE and its sub-type was assessed using Chi-square. Differences were considered 
statistically significant when the p-value was less than 0.05.  
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2.3 Results  
2.3.1 Characteristics of patients 
During the study period, 1200 patients were reviewed by the researcher. Half of the patients 
reviewed were men (n= 605, 50%) and 46% (n=551) of them were from the Malay ethnic group. The 
mean age was 50 (SD 18) ranging from 12 to 101 years. Patients aged up to 12 years are usually 
treated on paediatric wards whilst patients aged 13 years and above are treated on the adult wards. 
However depending on the availability of beds in the paediatric wards, patients aged 12 years may 
be admitted to adult wards. 
 
2.3.2 Case assessment and classification 
Of the 1200 patients, 76 (6%) were excluded due to incomplete past medication history. These 
patients could not remember the names of the drugs they took prior to admission and/ or there 
were no records detailing whether or not they had past medication. Therefore, a total of 1124 
patients were assessed for possible ADEs and the characteristics of these patients are shown in Table 
2-4.  
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Table 2-4: Characteristics of assessed patients (n=1124)
Number of patients Percentage (%)
Gender
Male 565 50.3
Female 559 49.7
Age
< 15 16 1.4
15-39 316 28.1
40-64 552 49.1
A? ? ? 240 21.3
Ethnic group
Malay 515 45.8
Indian 403 35.9
Chinese 141 12.5
Other 65 5.8
 
Of 1124 patients included in the study (Figure 2-6), 362 (32%) had no past medication history. 
Although these patients were not on any drugs prior to admission, this does not preclude them from 
having an existing medical condition. Thirteen patients were admitted due to an overdose of non-
medicinal products. These patients were admitted for intentional or unintentional household 
poisoning such as detergents or weed killers. None of these 13 patients had a past medication 
history. A total of 121 patients were admitted electively. These admissions were for planned dialysis, 
scans, surgery, or reviews on blood tests or renal profile results. These patients were on medication 
prior to admission and, although admitted electively to the admission wards, sometimes present 
with complains suspected to be related to the medication they were prescribed. Thus, they were not 
excluded from being reviewed by the researcher. However, none of their complaints turned out to 
be related to the medication they have been taking.  Thus, they were categorised as admissions not 
related to drugs. After accounting for all these patients, a total of 628 (56%) of them were suspected 
as having  ADEs. 
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Figure 2-6: Flow chart of case assessment 
1200 patients
76 patients were excluded because patients do not remember their past 
medication and there were no other records detailing whether or not they 
had past medication.
1124 patients
362 patients had no past medication history/ were not taking any medicines 
prior to admission
762 patients  had past medication history
121 patients were electively admitted
13 patients were admitted due to overdose of non-medicinal products
628 patients  were evaluated using the ADE 
classification tool
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2.3.3 Adverse drug event-related admissions 
All patients who had past medication history (after excluding elective admissions and those due to 
overdose of non-medicinal products; n= 628) were evaluated using the ADE classification tool by the 
researcher. The breakdown of cases according to the number of criteria met is shown in Figure 2-7. A 
total of 185 admissions met less than three criteria. Within this group, 167 admissions did not meet 
either of criterion one or two (the admission should meet at least one of criterion 1 or 2). Failure to 
ŵĞĞƚƚŚĞƐĞĐƌŝƚĞƌŝĂƐŚŽǁĞĚƚŚĂƚƉĂƚŝĞŶƚƐ ?ĐŽŵplaints were not related to drugs they have taken prior 
to admission. Furthermore, seven admissions met only one of the five criteria and 11 admissions met 
only two criteria, indicating that there was not enough evidence to conclude that any of these 
admissions was related to a drug. 
 A total of 443 admissions met three or more criteria and therefore, were classified as ADE-related, 
giving a prevalence of 39%.  Within these admissions, 34 (8%) met three criteria, 166 (30%) met four 
criteria, and more than 60% (n= 276, 62%) met all five criteria. 
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Figure 2-7: Breakdown of number of criteria met by potential ADE cases 
 
 
The characteristics of patients whose admissions were ADE-related are shown in Table 2-5. Of the 
443 patients, more than half were women (n= 239, 54%), almost 60% were aged between 40 to 64 
years (n= 252, 57%) and 42% (n= 187) were from Malay ethnic group. The percentage of ADE-related 
ĂĚŵŝƐƐŝŽŶƐǁĂƐƚŚĞŚŝŐŚĞƐƚŝŶƉĂƚŝĞŶƚƐĂŐĞĚďĞƚǁĞĞŶ ? ?ƚŽ ? ?ǇĞĂƌƐ ?ʖ2 = 62.03, p < 0.001). Men 
ǁĞƌĞůĞƐƐůŝŬĞůǇƚŽŚĂǀĞďĞĞŶĂĚŵŝƚƚĞĚĚƵĞƚŽĂŶ ?ʖ2 = 5.36, p = 0.02) and there was no 
relationship found between ethnic group and ADE-rĞůĂƚĞĚĂĚŵŝƐƐŝŽŶƐ ?ʖ2 = 21.7, p = 0.12). 
 
628 admissions
7 admissions met only 1 criterion
167 admissions did not met either criterion 1 or 2
11 admissions met only 2 criteria
443 admissions suspected as related to ADE
34 (8%) admissions met 3 criteria
276 (62%) admissions met 5 criteria
133 (30%) admissions met 4 criteria
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Table 2-5: Characteristics of patient admissions related and not related to ADEs (n= 1,124) 
ADE-related 
admissions
Admissions not 
related to ADE
Total
n= 443 n= 681 n= 1,124
Age (year) (n= 1,124) p <0.001
<15 - 16 (2.3) 16 (1.4)
15-39 74 (16.7) 242 (35.5) 316 (28.1)
40-64 252 (56.9) 300 (44.1) 552 (49.1)
A? ? ? 117 (26.4) 123 (18.1) 240 (21.4)
Gender (n= 1,124) p = 0.02
Male 204 (46.0) 361 (53.0) 565 (50.3)
Female 239 (54.0) 320 (47.0) 559 (49.7)
Ethnic group (n= 1,059
a
) p = 0.12
Malay 187 (43.3) 328 (52.3) 515 (48.6)
Indian 181 (41.9) 222 (35.4) 403 (38.1)
Chinese 64 (14.8) 77 (12.3) 141 (13.3)
Number (%) of patients
p-value*
a
 this group does not total 1,124, due to exclusioŶŽĨ ‘ŽƚŚĞƌ ?ĞƚŚŶŝĐŐƌŽƵƉ ?ŶA䄀  ? ? ? 
*based on chi-square tests 
 
 
 
 
There were a total of 483 ADEs identified in the 443 ADE-related admissions (patients could be 
assessed as having more than one ADE). Of the said 443 patients, 30 (7%) was admitted for TF and 
ADR, six for TF and ME, and four for ADR and ME. Almost three-quarters of ADE-related admissions 
(n= 351, 72%) were classified as resulting from TF (Table 2-6).  ADRs were the next most common 
type of ADE classified as related to one-fifth of the admissions. The most common drug groups 
causing more than 80% of the admissions were cardiovascular drugs (n= 222, 50%) followed by anti-
diabetics (n= 96, 22%), and anti-asthmatics (n= 65, 15%). 
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Table 2-6: Types of adverse drug events (n=483) 
Number of patients Percentage (%)
Therapeutic failure 351 72.1
Adverse drug reaction 96 19.7
Drug overdose 21 4.3
Medication error 15 3.1
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2.3.4 Therapeutic failure-related admissions 
Three hundred and fifty one patient admissions were assessed as related to TF, a prevalence of 31%. 
Of these, half were men (n= 178, 51%)(Table 2-7). Patients from the Malay and Indian ethnic group 
were equally distributed. The mean age was 55.6 (SD 14.4), with a minimum age of 15 years and a 
maximum of 90 years. The percentage of TF was found the highest in patients aged 40 to 64 years.  
The occurrence of TF was higher in older age- group  ?ʖ2 = 67.879, p <0.001). Those from Chinese 
ĞƚŚŶŝĐŐƌŽƵƉǁĞƌĞůĞƐƐůŝŬĞůǇƚŽďĞĂĚŵŝƚƚĞĚĚƵĞƚŽĂd& ?ʖ2 = 7.031, p= 0.03). There was no difference 
ďǇŐĞŶĚĞƌŝŶĂĚŵŝƐƐŝŽŶƐĚƵĞƚŽd& ?ʖ2 = 0.196, p =0.658).  
Table 2-7: Characteristics of patient admissions related and not related to TFs (n= 1,124) 
TF-related 
admissions
Admissions not 
related to TF
Total
n= 351 n= 773 n= 1,124
Age (year) (n= 1,124) p <0.001
<15 - 16 (2.1) 16 (1.4)
15-39 46 (13.1) 228 (34.9) 316 (28.1)
40-64 215 (61.3) 323 (43.6) 552 (49.1)
A? ? ? 90 (25.6) 149 (19.4) 240 (21.4)
Gender (n= 1,124) p= 0.658
Male 178 (50.7) 367 (50.1) 565 (50.3)
Female 173 (49.3) 349 (49.9) 559 (49.7)
Ethnic group (n= 1,059
a
) p= 0.03
Malay 150 (43.7) 365 (51.0) 515 (48.6)
Indian 150 (43.7) 253 (35.3) 403 (38.1)
Chinese 43 (12.5) 98 (13.7) 141 (13.3)
Number (%) of patients
p-value*
 a
 ƚŚŝƐŐƌŽƵƉĚŽĞƐŶŽƚƚŽƚĂů ? ? ? ? ?ĚƵĞƚŽĞǆĐůƵƐŝŽŶŽĨ ‘ŽƚŚĞƌ ?ĞƚŚŶŝĐŐƌŽƵƉ ?ŶA䄀  ? ? ?
*based on chi-square tests 
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A total of 391 uncontrolled conditions were identified in the 351 patients with TF-related admissions. 
In 16% of these patients (n= 56), poor adherence was documented in the medical notes by attending 
physicians. . From the same notes, seven patients of these had poor to fair inhaler technique. On the 
other hand, the compliance status or medication-taking behaviour of the remaining patients was not 
documented. Hence, the likely cause of the TF for the rest of the patients is undetermined.  
The drug groups most frequently associated with the four most common drug-related events are 
listed in Table 2-8. Despite being prescribed one or more antiplatelets, antianginals, and/ or statins 
prior to admission, 81 (23%) of the patients experienced chest pain resulting to their admission. This 
makes the aforementioned drugs the most common drug groups attributed to TF in this study, 
followed by corticosteroid inhaler, which was implicated in 17% of these TF-related admissions (n= 
58).  
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Table 2-8: Drug group most commonly associated with TF-related admissions (n= 351) 
Number of 
patients (%) 
(n= 351)
Antiplatelet 70 (19.9)
Antianginal 64 (18.2)
Statin 61 (17.4)
Calcium channel 
blocker
47 (13.4)
Angiotension 
converting 
enzyme inhibitor
39 (11.1)
Beta-
adrenoceptor 
blocker
35 (10.0)
Corticosteroid 
inhaler
59 (16.8)
Beta-agonist 
inhaler
50 (14.2)
Inhaler with 
combination of 
beta agonist + 
antimuscarinic 
bronchodilator
25 (7.1)
Inhaler with 
combination of 
corticosteroid + 
beta-agonist
18 (5.1)
Biguanide 28 (8.0)
Sulphonylurea 24 (6.8)
Insulin 20 (5.7)
Drug group*
Chest pain (n= 81
a
)
Hypertension         
(n= 80
a
)
Exacerbation of 
asthma (n= 65
a
)
Hyperglycemia       
(n= 55
a
)
Drug-related event 
(number of 
patients)
Individual drug (number of patients)
aspirin (42), clopidogrel (18), ticlopidine 
(18), cardiprin (8)
trimetazidime (35), glyceryl trinitrate (31), 
isosorbide dinitrate (29), isosorbide 
mononitrate (1)
simvastatin (28), lovastatin (24), 
atorvastatin (8), rosuvastatin (1)
amlodipine (33), nifedipine (10), 
felodipine (4)
budesonide + formoterol (16), fluticasone 
+ salmeterol (2), 
metformin (28)
glibenclamide (15), gliclazide (9)
intermediate to long acting insulin (29), 
short acting insulin (7)
perindopril (25), captopril (12),      
enalapril (2)
metoprolol (21), atenolol (10), bisoprolol 
(3), propranolol (1)
beclomethasone (25), budesonide (21)
salbutamol (49), formoterol (1)
ipratropium bromide + albuterol (24), 
ipratropium bromide + fenoterol (1)
a
 more than one drug group can be associated with an admission 
*only the most frequent drug groups are listed in this table 
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2.3.5 Adverse drug reaction-related admissions 
Ninety-six patient admissions were assessed as ADR-related, a prevalence of 8.5%. The breakdown of 
causality assessments following the submission of all ADR cases to MADRAC are shown in Table 2-9. 
It was found that two out of 96 cases had insufficient information for causality assessment and were 
ĐůĂƐƐŝĨŝĞĚĂƐ ‘ƵŶůŝŬĞůǇ ?ĂŶĚ ‘ƵŶĐůĂƐƐŝĨŝĞĚ ? ?dŚĞǇǁĞƌĞĞǆĐůƵĚĞĚĨƌŽŵĨƵƌƚŚĞƌĂŶĂůǇƐŝƐ ?KĨƚŚĞƌĞŵĂŝŶŝŶŐ
 ? ?ĐĂƐĞƐ ?ŽŶĞǁĂƐĐůĂƐƐŝĨŝĞĚĂƐ ‘ĐĞƌƚĂŝŶ ?ĂŶĚƚŚĞƌĞƐƚĂƐ ‘ƉŽƐƐŝďůĞ ? ?dŚĞĐĂƐĞǁŝƚŚ ‘ĐĞƌƚĂŝŶ ?ĐĂusality 
had an event with plausible time relationship (patient had an oculogyric crisis upon administration of 
metoclopromide and the drug was withdrawn immediately). In all the remaining cases, patients were 
taking two or more drugs and it was not possible to attribute the reactions to specific drugs for they 
ĐŽƵůĚďĞƌĞůĂƚĞĚƚŽĐŽŶĐƵƌƌĞŶƚĚŝƐĞĂƐĞƐ ?ŚĞŶĐĞ ?ƌĞƐƵůƚŝŶŐŝŶ ‘ƉŽƐƐŝďůĞ ?ĐĂƵƐĂůŝƚǇĂƐƐĞƐƐŵĞŶƚ ?dŚŝƐ
particular result gives an adjusted prevalence rate of 8.4%. 
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Table 2-9: Causality assessment of suspected ADR cases by MADRAC (n= 96) 
Causality Scale Description
Number of patients 
(%)
C1: Certain
A clinical event, including laboratory test abnormality, 
occurring in a plausible time relationship to drug 
administration, and which cannot be explained by 
concurrent disease or other drugs or chemicals. The 
response to withdrawal of the drug (dechallenge) should 
be clinically plausible. The event must be definitive 
pharmacologically or phenomenologically, using a 
satisfactory rechallenge procedure if necessary.
1 (1.0)
C2: Probable/            
Likely
A clinical event, including laboratory test abnormality, 
with a reasonable time sequence to administration of the 
drug, unlikely to be attributed to concurrent disease or 
other drugs or chemicals, and which follows a clinically 
reasonable response on withdrawal (dechallenge). 
Rechallenge information is not required to fulfil this 
definition.
-
C3: Possible
A clinical event, including laboratory test abnormality, 
with a reasonable time sequence to administration of the 
drug, but which could also be explained by concurrent 
disease or other drugs or chemicals. Information on drug 
withdrawal may be lacking or unclear.
93 (97.0)
C4: Unlikely
A clinical event, including laboratory test abnormality, 
with a temporal relationship to drug administration which 
makes a causal relationship improbable, and in which 
other drugs, chemicals or underlying disease provide 
plausible explanations.
1 (1.0)
C5: Conditional/ 
Unclassified
A clinical event, including laboratory test abnormality, 
reported as an adverse reaction, about which more data is 
essential for a proper assessment or the additional data 
are under examination.
1 (1.0)
C6: Unassessible/ 
Unclassifiable
A report suggesting an adverse reaction which cannot be 
judged because information is insufficient or 
contradictory, and which cannot be supplemented or 
verified.
-
 ^ŽƵƌĐĞ Pt,K ?ƐZĐĂƵƐĂůŝƚǇƐĐĂůĞ[98] 
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The characteristics of patients admitted due to ADRs are shown in Table 2-10. Of 94 patients, 60% 
were women (n= 56) and 40% were from Malay ethnic group (n= 38). About half of the patients were 
aged 40 to 64 years (n= 49, 52%). The mean age of the patients was 58.5 (SD 15.0) years, with 
minimum age of 18 years, and a maximum of 90 years. Older patients were more likely to have been 
ĂĚŵŝƚƚĞĚĚƵĞƚŽĂŶZ ?ʖ2 = 18.5, p < 0.001). Likewise, women also more likely to be admitted due 
ƚŽĂŶZĐŽŵƉĂƌĞĚƚŽŵĞŶ ?ʖ2 = 4.792, p= 0.03).  Patient admissions related to ADR was higher in 
the Malay ethnic group than those ĨƌŽŵŚŝŶĞƐĞĂŶĚ/ŶĚŝĂŶĞƚŚŶŝĐŐƌŽƵƉ ?ʖ2 = 13.3, p= 0.001). 
Table 2-10 Characteristics of patient admissions related and not related to ADRs (n= 94) 
ADR-related 
admissions
Admissions not 
related to ADR
Total
n= 94 n= 1030 n= 1124
Age (year) (n= 1124) p < 0.001
<15 - 16 (1.6) 16 (1.4)
15-39 10 (10.6) 306 (29.7) 316 (28.1)
40-64 49 (52.1) 503 (48.8) 552 (49.1)
A? ? ? 35 (37.2) 205 (19.9) 240 (21.4)
Gender (n= 1124) p = 0.03
Male 38 (40.4) 527 (51.2) 565 (50.3)
Female 56 (59.6) 503 (48.8) 559 (49.7)
Ethnic group (n= 1059
a
) p= 0.001
Malay 38 (41.3) 477 (49.3) 515 (48.6)
Indian 30 (32.6) 373 (38.6) 403 (38.1)
Chinese 24 (26.1) 117 (12.1) 141 (13.3)
Number (%) of patients
p-value*
 a
 ƚŚŝƐŐƌŽƵƉĚŽĞƐŶŽƚƚŽƚĂů ? ? ? ? ?ĚƵĞƚŽĞǆĐůƵƐŝŽŶŽĨ ‘ŽƚŚĞƌ ?ĞƚŚŶŝĐŐƌŽƵƉ ?ŶA䄀  ? ? ?
*based on chi-square tests 
 
The drug group most frequently responsible for ADR-related admissions was anti-diabetics (n= 36, 
38%) (Table 2-11). Reactions affecting the endocrinology or metabolic system (n= 51, 54%) were 
responsible for more than half of the said admissions (Table 2-12).  Among these, hypoglycaemia was 
found the most common adverse reaction (n= 34, 36%). The most common causative drugs 
associated with hypoglycaemia-related admissions were combination of glibenclamide and 
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metformin (n= 12). However, almost 80% (n= 26, 77%) of patients admitted due to hypoglycaemic 
ƌĞĂĐƚŝŽŶŚĂĚƉŽŽƌŽƌĂůŝŶƚĂŬĞƉƌŝŽƌƚŽĂĚŵŝƐƐŝŽŶ ?dŚŝƐŝŶĨŽƌŵĂƚŝŽŶǁĂƐĚŽĐƵŵĞŶƚĞĚŝŶƉĂƚŝĞŶƚƐ ?
medical notes. In addition, one of the patients developed prolonged hypoglycaemic reaction (which 
was not immediately recognised by a family member) due to insulin. Subsequently, patient was 
hospitalised and diagnosed with neuroglycopenia coma. 
Table 2-11: Drugs involved in admissions related to adverse drug reactions (n= 94) 
Number of patients (%)
(n= 94
a
)
Antidiabetic 36 (38.3)
metformin (21), glibenclamide (14), 
gliclazide (13), insulin (13), acarbose (1)
Antiplatelet 10 (10.6) aspirin (9), ticlopidine (1)
Thiazide diuretic 10 (10.6) chlorothiazide (10)
Angiotensin converting enzyme 
inhibitor
10 (10.6) perindopril (7), captopril (2), enalapril (1)
Calcium channel blocker 10 (10.6) amlodipine (4), nifedipine (4), felodipine (2)
Beta-adrenoceptor blocker 5 (5.3) atenolol (3), metoprolol (2)
Analgesic 4 (4.3)
diclofenac (2), mefenamic acid (1), 
naproxen (1)
Other* 18 (19.1) -
Drug group Individual drug (number of patients)
a
 more than one drug group can be associated with an admission 
 踃?ŽƚŚĞƌ ?ĚƌƵŐŐƌŽƵƉƐŚĂǀĞĨƌĞƋƵĞŶĐŝĞƐŽĨƚǁŽŽƌůĞƐƐ 
 
Electrolyte imbalance was found the second most common reaction related to endocrinology or 
metabolic system (n= 11, 12%). Electrolyte imbalance means the serum electrolyte level is higher or 
lower than the normal level. The most common causative drug associated with electrolyte imbalance 
was hydrochlorothiazide (n= 5). Gastritis and peptic ulcer diseases were found to be the next 
common reaction related to admission (n= 6). Gastritis is inflammation of gastric lining and peptic 
ulcer disease is an ulcer of the gastric lining or duodenum. The most common causative drug 
associated with gastritis or peptic ulcer disease was aspirin (n= 5).  
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Table 2-12: The frequency of the types of adverse drug reactions (n= 94) 
Number of patients (%)
(n= 94)
Endocrinology or metabolic system 51 (54.3)
Hypoglycaemia 34 (36.2)
Electrolyte imbalances 11 (11.7)
Hyperglycaemia 3 (3.2)
Renal impairment 2 (2.1)
Neuroglycopenia 1 (1.1)
Central nervous system 16 (17.0)
Giddiness 5 (5.3)
Headache 4 (4.3)
Seizure 2 (2.1)
Dizziness 2 (2.1)
Vertigo 1 (1.1)
Fever 1 (1.1)
Oculogyric crisis 1 (1.1)
Cardiovascular system 13 (13.8)
Palpitation 4 (4.3)
Bradycardia 3 (3.2)
Hypotension 2 (2.1)
Exacerbation of angina 1 (1.1)
Tachycardia 1 (1.1)
Leg oedema 1 (1.1)
Gastrointestinal system 11 (11.7)
Gastritis or peptic ulcer disease 6 (6.4)
Nausea or vomiting 2 (2.1)
Diarrhoea 1 (1.1)
Constipation 1 (1.1)
Upper gastrointestinal bleed 1 (1.1)
Type of adverse reaction
  
table continued.. 
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Table 2-12 continued: The frequency of the types of adverse drug reactions (n= 94) 
Number of patients (%)
(n= 94)
Dermatology 10 (10.6)
Rashes 4 (4.3)
Facial swell or oedema 3 (3.2)
Itchiness 2 (2.1)
Stevens-Johnson Syndrome 1 (1.1)
Haematology 6 (6.4)
Anaemia 2 (2.1)
Menorrhagia 1 (1.1)
Neutropenia 1 (1.1)
Jaundice 1 (1.1)
Respiratory system 5 (5.3)
Exacerbation of asthma 3 (3.2)
Shortness of breath 1 (1.1)
Cough 1 (1.1)
Type of adverse reaction
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2.3.6 Drug overdose-related admissions 
Twenty-one admissions were related to DO, a prevalence of 1.9%.  The characteristics of patients 
admitted due to DO are shown in Table 2-13. Four-fifths of patients with overdose were women (n= 
17, 81%) and all but one, were aged under 65 years (n= 20, 95%). The number of patients admitted 
for overdose was too small to be able to determine whether or not there were any relationships 
between patient characteristics and DO. 
Table 2-13: Characteristics of patients admitted due to drug overdoses (n= 21) 
Number of patients Percentage (%)
Gender
Male 4 19.0
Female 17 81.0
Age (year)
40-64 20 95.2
A? ? ? 1 4.8
Ethnic group
Malay 9 42.9
Indian 9 42.9
Chinese 1 4.8
Other 2 9.5
 
 
The drugs associated with patients admitted due to overdose are shown in Table 2-14. Single drugs 
caused the admissions of 10 patients suspected for overdose whilst multiple drugs were responsible 
for the remaining admissions. The drug group most frequently responsible for overdose-related 
admissions was analgesics either as a single drug (n= 5) or in combination with another analgesic or 
other drugs (n= 10). The most common analgesic responsible for overdose was paracetamol (n= 12), 
either alone or in combination with other drugs. All but one has intentionally ingested an overdose of 
drug. 
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 Table 2-14: Drugs involved in admissions related to drug overdoses (n= 21) 
Number of patients (%)
(n= 21)
paracetamol (4)
aspirin (1)
paracetamol + mefenamic acid (1)
paracetamol + mefenamic acid + diclofenac (1)
paracetamol + bromhexine + naproxen + diclofenac  
+ norethisterone + mefenamic acid (1)
paracetamol + methyl salicylate (1)
paracetamol + oftalein (1)
paracetamol + antidiarrhoea* (1)
paracetamol + diclofenac + calcium lactate (1)
cough mixture* + tablets for runny nose* (1)
salbutamol inhaler + prednisolone + 
chlorpheniramine + cough mixture*, salbutamol + 
pain killer* (1)
paracetamol + prednisolone + hyoscine 
butylbromide + pseudoephedrine/tripolidine +  
mefenamic acid + multi-vitamin* + frusemide (1)
glibenclamide (1)
metformin (2)
Antidepressants 1 (4.8) lorazepam + mirtazapine (1)
Beta-adrenoceptor blocker 1 (4.8) metoprolol (1)
Calcium supplement 1 (4.8) calcium carbonate (1)
Drug group Drugs (number of patients)
Antidiabetic agent
Multiple drugs 7 (33.3)
3 (14.2)
Analgesic 8 (38.1)
*patient could not remember the drug name or did not bring the drug to the hospital 
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2.3.7 Medication error-related admissions 
Fifteen patients were admitted due to MEs. The characteristics of these patients are shown in Table 
2-15. More than half of the patients were women (n= 9, 60%), two thirds were aged 40 to 64 years 
(n= 10, 67%), and around half were from Indian ethnic group (n= 8, 53%). However, the number of 
patients admitted for ME was too small to determine whether or not there were any relationships 
between patient characteristics and ME. The drug groups associated with ME are shown in Table 2-
16. It was found that antiplatelets were the most common drug group which caused ME-related 
admissions. Three out of 15 patients were prescribed an antiplatelet without a prophylactic drug 
despite having history of gastritis or peptic ulcer disease. 
 Table 2-15: Characteristics of patients admitted due to drug medication errors (n= 15) 
Number of patients Percentage (%)
Gender
Male 6 40.0
Female 9 60.0
Age (year)
15-39 1 6.7
40-64 10 66.7
A? ? ? 4 26.7
Race
Malay 4 26.7
Indian 8 53.3
Chinese 3 20.0
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Table 2-16: Drug group most commonly associated with medication errors (n= 15) 
Drug group
Drug-related event           
(number of patients)
Problem
Gastric pain (3)
Prescription in patients with history of gastritis 
without gastrointestinal protection
Uraemic symptoms (2)
Prescription in patients with history of severe 
renal impairment
Gout episode (1)
Prescription in patient with history of gouty 
arthritis
Electrolyte imbalance (1)
Prescription in patient with history of 
hyponatremic and hypokalemic episodes
Dizziness due to 
hypotension (2)
Unnecessary polypharmacy*
Prescription in patient who is a chronic 
alcoholic
Failure to reduce the dose of gliclazide in elderly 
patient with known renal failure
Hypoglycaemic attack (1)
Prescription in patient with frequent 
hypoglycaemic attacks (drug may mask the 
symptoms)
Dizziness due to 
hypotension (1)
Unnecessary polypharmacy*
Statin Chest pain (2)
Failure to prescribe in patient needing 
secondary prevention
Calcium channel blocker
Dizziness due to 
hypotension (1)
Unnecessary polypharmacy*
Alpha-adrenergic 
agonist
Worsening of systemic 
lupus erythematosus (1)
Prescription in patient with history of systemic 
lupus erythematosus
Beta-blockers
Hypoglycaemic agent Hypoglycaemic attack (2)
Anti-platelet
Angiotension converting 
enzyme inhibitor
*more than one drug group associated with an admission 
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2.3.8 Inter-assessor reliability 
dŽĂƐƐĞƐƐƚŚĞƌĞůŝĂďŝůŝƚǇŽĨƚŚĞƌĞƐĞĂƌĐŚĞƌ ?ƐĐĂƚĞŐŽƌŝƐĂƚŝŽŶ ?ƚǁŽĂĚĚŝƚŝŽŶĂůŚĞĂůƚŚĐĂƌĞƉƌŽĨĞƐƐŝŽŶĂůƐ
and a research supervisor classified a sample 10% of all potential ADEs. The results are shown in 
Table 2-17 and Table 2-18. Each assessor reviewed 65 cases and from these 75 types of ADEs were 
identified. 
dŚĞŽǀĞƌĂůůĂŐƌĞĞŵĞŶƚĨŽƌƉƌĞƐĞŶĐĞŽĨĂŶďĞƚǁĞĞŶĂůůĂƐƐĞƐƐŽƌƐƌĂŶŐĞĚĨƌŽŵ ‘ƐůŝŐŚƚĂŐƌĞĞŵĞŶƚ ?
ƚŽ ‘ŵŽĚĞƌĂƚĞĂŐƌĞĞŵĞŶƚ ? ?dŚĞĂŐƌĞĞŵĞŶƚďĞƚǁĞĞŶĂůůĨŽƵƌĂƐƐĞƐƐŽƌƐƌĞŐĂƌĚŝŶŐĐůĂƐƐŝĨŝĐĂƚŝŽŶŽĨ
types ƌĂŶŐĞĚĨƌŽŵ ‘ĨĂŝƌĂŐƌĞĞŵĞŶƚ ?ƚŽ ‘ƐƵďƐƚĂŶƚŝĂůĂŐƌĞĞŵĞŶƚ ? ? 
The agreement for classification of TF between the researcher and the physician indicated 
 ‘ƐƵďƐƚĂŶƚŝĂůĂŐƌĞĞŵĞŶƚ ? ?>ŝŬĞǁŝƐĞ ?ƚŚĞĂŐƌĞĞŵĞŶƚĨŽƌĐůĂƐƐŝĨŝĐĂƚŝŽŶŽĨZďĞƚǁĞĞŶƚŚĞƌĞƐĞĂƌĐŚĞƌ
ĂŶĚƚŚĞƉŚĂƌŵĂĐŝƐƚƐŝŶĚŝĐĂƚĞĚ ‘ƐƵďƐƚĂŶƚŝĂůĂŐƌĞĞŵĞŶƚ ? ?dŚĞƉĞƌĐĞŶƚĂŐĞĂŶĚŬĂƉƉĂĂŐƌĞĞŵĞŶƚĨŽƌ
classification of ME and DO were not conducted due to a small number of cases. There was only one 
ME and two DO cases assessed in 65 cases. 
The percentage of ADE-related admissions identified by the researcher from the 10% of random 
cases was the highest (n= 46, 71%). The percentage was also higher for TF (n= 37, 57%) and ADR (n= 
14, 22%) compared with other assessors. This showed that clinical judgement is based on individual 
interpretation and may vary between individuals. The pharmacists have identified few cases of TF (n= 
17, 26%). However, no changes were made to the classification of ADEs by researcher but given the 
ƌĞƐĞĂƌĐŚĞƌ ?ƐŚŝŐŚĞƌŶƵŵďĞƌŽĨĐĂƐĞƐ ?ŝƚŵĂy be that the prevalence rates were overestimated. 
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Table 2-17: The agreement for ADEs classification (n= 75) 
TF ADR ADE or not
researcher * academic 0.46 (73.3) 0.47 (86.7) 0.33 (58.7)
researcher * physician 0.71 (85.3) 0.55 (89.3) 0.47 (72.0)
researcher * pharmacist 0.36 (68.0) 0.75 (93.3) 0.34 (60.0)
academic * physician 0.31 (66.7) 0.21 (86.7) 0.05 (50.7)
academic * pharmacist 0.28 (70.7) 0.40 (88.0) 0.17 (0.25)
pharmacist * physician 0.30 (66.7) 0.63 (93.3) 0.13 (57.3)
Kappa value
a 
(percentage agreement)
 
a
kappa value; <0 indicates poor agreement, 0.01-0.20 indicates slight agreement, 0.21-0.40 indicates fair 
agreement, 0.41-0.60 indicates moderate agreement, 0.61- 0.80 indicates substantial agreement and 0.81-1.00 
indicates perfect agreement 
 
Table 2-18: Classification of random cases by all four assessors (n= 65) 
TF ADR ADE
Researcher 37 (56.9) 14 (21.5) 46 (70.8)
Academic 25 (38.5) 8 (12.3) 32 (49.2)
Physician 34 (52.3) 6 (9.2) 43 (66.2)
Pharmacist 17 (26.2) 9 (13.8) 27 (41.5)
Number of cases (% )
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2.4 Discussion 
2.4.1 Key findings and comparison with other studies 
2.4.1.1 Prevalence of adverse drug event-related admissions 
Two-fifths (39%) of admissions to two medical wards in a government hospital in Malaysia were 
considered related to ADEs with almost 80% of it being due to TF. This was followed by ADR which 
accounted for 22% of ADE-related admissions. In other words, of 628 patients who were on 
medication prior to admissions, 70.5% admissions were related to ADE. 
The prevalence of ADE-related admissions in this study is higher than previous studies, 0.5% to 30.4% 
[1, 8-11, 83, 119, 142]. The results from these published studies cannot, however, be directly 
ĐŽŵƉĂƌĂďůĞĂƐƚŚĞůŝŵŝƚĂƚŝŽŶƐŝŶƚŚĞĐƵƌƌĞŶƚƐƚƵĚǇ ?ƐŵĞƚŚŽĚŽůŽŐǇĐŽƵůĚŚĂǀĞŝŶĨůƵĞŶĐĞĚƚŚĞ
differences in the findings. Furthermore, the study design, population, and criteria used in each study 
are different from one another and they make comparisons between the published studies and 
current study difficult. The latter was conducted only in two wards in one hospital compared with 
that by Bhalla et al., Ahmed et al., and Hallas et al., which were conducted in all medical wards of the 
study site (giving a prevalence of 10.1 to 11.4%), whilst Chan et al. conducted theirs (the highest 
prevalence of 30.4%) in acute medical units for elderly patients more than 75 years old. Despite 
these differences, the prevalence of ADE-related admissions found in the current study is alarming.   
In common with previous studies [63, 143, 146], the present study found that admissions related to 
TF were highest compared to other types of ADE. Previous studies reported that TF accounted for 
45% to 81% of ADE-related admissions.  However, some studies have found ADRs the highest 
contributor to ADE-related admissions, accounting for 53% to 90% of it in these studies [9, 83, 140, 
142]. This may be explained by a number of factors: First, the comprehensive assessment method 
using a classification tool may have increased the likelihood of all drug-related admissions as being 
identified. Second, a single assessor evaluated all the cases and the result heavily relied on individual 
interpretation. Individual interpretation may tend to have caused overestimation of the rate of ADE-
related admissions as supported too, by the higher percentage in identified ADEs by the researcher 
herself compared with the other assessors. Third, the unavailability of patient medication adherence 
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information may have led to misclassification of some ADE cases and may have caused 
overestimation of the percentage of therapeutic failure. Finally, the types of ADEs investigated in the 
present study were comprehensive, whilst other studies have only investigated particular types such 
as ADR and TF [62], ADR and overdose [1, 11, 142] or ADR, TF, and overdose [9, 83, 143]. Thus, the 
differences in definitions resulted in a wide range of prevalences, making comparisons between and 
among studies difficult.  
As previous studies have investigated different types of ADE (making comparisons difficult), the 
characteristics of each type are discussed individually and compared among ADE-related studies. 
 
2.4.1.2 Prevalence of therapeutic failure-related admissions 
The prevalence of TF-related admission was 31% and was higher than previous studies, where the 
prevalence ranged from 1.1% to 9.3% [8, 10, 62, 83, 143, 146, 147, 152].  The differences in the 
prevalence may be the result of differences in the criteria used to assess TF. Hallas et al. [62] 
proposed a classification tool (the symptoms are known to reappear at insufficient dosages, the 
symptoms were not likely to have been caused by progression of the disease, a reasonable temporal 
relationship exists between the start of inadequate or excessive dosage and the appearance of the 
symptoms, symptoms improved by dose adjustment, no other conditions could explain the 
symptoms and drug level below therapeutic range) to assess suspected TF and evaluate the causal 
relationship. This assessment method was also used in other studies [9, 63, 146, 147, 152]. The 
stringency of these criteria could have affected the evaluation and categorisation of suspected TFs. 
The criteria used in the present study, however, did include some of these criteria but they were less 
stringent (symptoms appear at insufficient doses, exacerbation of a medical condition, medication 
changes, lab and other findings associated with the symptoms, and diagnosis associated with 
symptoms) ?/ƚĚŝĚŶŽƚŝŶĐůƵĚĞƚŚĞĐƌŝƚĞƌŝĂ “ƚĞŵƉŽƌĂůĂƐƐŽĐŝĂƚŝŽŶ ?ĂŶĚ “ƐǇŵƉƚŽŵƐŶŽƚĐĂƵƐĞĚďǇ
ƉƌŽŐƌĞƐƐŝŽŶŽĨƚŚĞĚŝƐĞĂƐĞ ?ĂƐŝŶƚŚĞĐƌŝƚĞƌŝĂďǇ,ĂůůĂƐĞƚĂů ?This is because establishing and 
identifying these criteria are difficult for patients usually seek medical attention after the symptoms 
have already worsened and not in the early stages of such. Therefore, in this study, the use of less 
stringent criteria in identifying and classifying TF, is likely contributed to the detection of higher TF 
frequency. 
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Another possible reason for the higher prevalence in this study could be that there was no follow up 
or review on patients until they were discharged. In the study by Howard et al. [147], patients were 
followed up until their discharge. This gives the advantage of confirming the actual reasons for 
ƉĂƚŝĞŶƚƐ ?ĂĚŵŝƐƐŝŽŶƐĨŽůůŽǁŝŶŐĨƵƌƚŚĞƌŝŶǀĞƐƚŝŐĂƚŝŽŶ ?/Ŷ ƚŚĞŝƌƐƚƵĚǇ ? ? ?A?ŽĨĂĚŵŝƐƐŝŽŶƐǁŚŝĐŚǁĞƌĞ
initially classified as possible drug-related were excluded after further follow-up. Failure of this study 
to have done the same could have resulted in its probable overestimation of prevalence.  
dŚĞƚŚŝƌĚƌĞĂƐŽŶĨŽƌŚŝŐŚĞƌƉƌĞǀĂůĞŶĐĞŝŶƚŚŝƐƐƚƵĚǇĐŽƵůĚďĞƚŚĂƚĂƉĂƚŝĞŶƚ ?ƐĂĚŚĞƌĞŶĐĞƐƚĂƚƵƐǁĂƐ
not assessed in this study. Patients complaining of chest pain, for example, although could be a result 
from the progression of their disease was classified under TF due to the lack of this crucial 
information. Thus, a number of limitations in the methodology could have overestimated the true 
prevalence of TF in this study. 
 
2.4.1.3 Prevalence of adverse drug reaction-related admissions 
The prevalence of ADR-related admissions was estimated to be 8.4%. Despite the differences in study 
methodology and population, the prevalence of ADR-related admissions found in this study was in 
common range with that of the previous studies, which was 7.5% to 8.5% [62, 83, 84, 134].  
One of the strengths of the current study is that all suspected ADR cases were assessed for causality 
by MADRAC, a committee whose one routine among others, is to assess the causality of all the 
reports it receives. This is in contrast with other studies [62, 83, 84, 134] where two or more 
assessors were trained to evaluate all cases for causality, their judgment were then compared, and 
majority decision took into account in classifying cases as drug-related. There could be a potential 
weakness in their assessment method for they were subjected to individual clinical judgment of 
which may vary from person to person. 
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2.4.1.4 Prevalence of drug overdose-related admissions 
DO was found to have caused 2% of medical admissions in this study, with an estimated prevalence 
higher than previous studies in Malaysia [164, 165]. However, it was within the range of prevalence 
reported in other countries  W 0.1% to 17% [1, 9, 11, 63, 122, 143]. The higher prevalence in this study 
compared to the previous ones in Malaysia may be explained by the study design. The prospective 
design of the current research allowed collection of complete medical and medication histories and 
ensured that all information needed to correctly classify the events were gathered. Furthermore, 
chart review has been reported an effective method in identifying higher number of drug-related 
admissions [96, 117, 119, 120]. The previous studies conducted in Malaysia were retrospective, using 
computer records or discharge diagnoses [164, 165] to determine the rate of overdose. This method 
relies on the quality and accuracy of documentation, which, if not met, may result in 
underestimation of the actual rate. However, it should be criticised that the current study was 
conducted only in two medical wards in one hospital, compared with the previous studies in 
Malaysia, which have retrospectively examined the entire admissions in a specific hospital for more 
than two years.  Thus, this current study in contrast, may have overestimated the true prevalence of 
DO-related admissions in the study site 
 
2.4.1.5 Prevalence of medication error-related admissions 
ME was responsible for 1.4% of admissions in this study. Although the prevalence was low it was still 
within the range of other studies, 1.2% to 10.6% [134, 139, 146-148]. Among these, only a small 
number of studies have investigated admissions related to ME per se [139, 148]. These studies 
reported a prevalence range of 1.2% to 4.3%. Other studies investigated drug related admissions and 
assessed the preventability of the event [134, 139, 146, 147]. The preventable event may include TF 
[8, 63, 83, 146], DO, [146, 147] and, in some studies, ADR [71, 134]. The prevalence reported by 
these studies was from 1.2% to 10.6%. Due to the differences in the definitions, comparisons of the 
prevalence rates among these studies are difficult.  
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2.4.2 Drug causes of ADE-related admissions 
The most common drug groups, resulting in more than 80% of the ADE-related admissions were 
cardiovascular drugs, antidiabetics, and antiasthmatics. Within these groups, antiplatelets were the 
most frequently implicated. Similarly in other studies, cardiovascular drugs were reported as the 
most common drug group associated with ADE-related admissions in other studies [8-10, 63, 146].  
Likewise, the highest proportion of admissions related to TF was seen in cardiovascular diseases 
(chest pain and hypertension), followed by respiratory diseases (exacerbation of asthma), and 
endocrinology and metabolic disorders (hyperglycaemia). TF was most frequently related to 
therapies with cardiovascular drugs (antiplatelets, antianginals, statins and antihypertensives), 
antiasthmatics and antidiabetics.  TF in 16% of these patients was known to be related to poor 
adherence to medication whilst of 65 patients admitted for asthma 11% had poor to fair inhaler 
technique. In common with previous studies of drug-related admissions, TF was most frequently 
implicated with cardiovascular drugs [8, 83, 143, 146, 147, 152-154, 259], antiasthmatics [83, 147, 
153], and antidiabetics [8, 83, 152], probably due to their widespread use in the medical practice. 
The Malaysian National Health and Morbidity Survey III which was conducted in 2006 reported that 
hypertension, diabetes mellitus, asthma and heart disease were the most prevalent conditions 
among the Malaysian population [260]. Thus, it is not suprising that TF in this study was frequently 
related to the same medical conditions. The prevalence of these medical conditions is reported to be 
increasing in Malaysia [33-36]  W the reasons being poor dietary control and sedentary lifestyle [36]. In 
addition these studies reported that more than 70% of patients on drug therapy had poor control of 
their medical conditions [33, 34]. This shows that Malaysia has a serious problem with poor control 
of chronic medical conditions which may in part account for the higher TF prevalence found in this 
study. Non-adherence to medication was found the main cause of TF-related admissions in previous 
studies [62, 83, 143, 146, 152]. Although, patient medication adherence was not assessed in the 
present study, 16% of TF-related, admitted patients had a record of non-adherence in their notes.  
The drugs which most commonly resulted in ADR-related admissions were antidiabetics.  Hence, 
hypoglycaemic reaction was the most common event in these patients.  This was in contrast with 
other studies Hallas et al. [83], Green et al. [134], and Rivkin et al. [84], which reported that 
gastrointestinal events due to NSAIDs and aspirin as most common ADR found in their studies.  
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Green et al. [134] in their study, reflected the possible for this: these drugs are most commonly 
prescribed drugs in the UK, thus, accounting for high incidence of ADRs relating to them. The study 
made by Rivkin et al. [84], on the other hand, used a population different from that of the current 
study: patients in an intensive care unit with severe ADRs such as bleeding.  
The combination of glibenclamide and metformin was most frequently associated with 
hypoglycaemic reactions. However, almost 80% of patients admitted due to hypoglycaemia had poor 
oral intake prior to admission.  A study and government statistics have shown metformin and 
glibenclamide to be the most utilised drugs in Malaysia [260, 261]. Furthermore, diabetes mellitus is 
one of the most prevalent medical conditions in Malaysia. In light of this, high utilisation of 
antidiabetics is expected. As indicated in the Malaysian Clinical Practice Guideline for the 
Management of Type 2 Diabetes Mellitus [262], metformin is the preferred choice of first line 
treatment. Patients who do not reach Hb1Ac (hemoglobin A1c) target of less than 6.5% after three to 
six months of metformin monotherapy or newly diagnosed patients who have Hb1Ac of 8-10% and 
fasting glucose level of 6-10 mmol/L, a combination is indicated [262]. In the guideline, metformin 
and glibenclamide are the suggested choice of combination therapy, probably due to  cheaper price 
compared with other antidiabetics [263]. Thus, higher prevalence of hypoglycaemia in this study 
could also reflect high utilisation of these drugs. 
Overdoses occurred due to ingestion of multiple drugs in one-thirds of the patients whilst 
paracetamol was most often, the drug ingested by more than half of the patients. All but one has 
ingested an overdose of drugs intentionally. The ingestion of multiple drugs as overdoses found in 
this study has also been reported in a study by Oguzturk et al.  [166] in their research in Turkey. In 
common with previous studies [9, 122, 165], paracetamol was the most common drug associated 
with overdose-related admissions. Paracetamol is widely prescribed and available over-the-counter 
in Malaysia, and their predominance in overdose admissions could reflect their easy availability. 
Paracetamol is the second most commonly used substance in Malaysia in deliberate self- poisoning, 
the first being pesticides [165]. 
Antiplatelets (aspirin) were responsible for six out of 15 admissions related to ME, and three of the 
patients were prescribed aspirin without a gastro-protective drug (despite having history of gastritis 
or peptic ulcer). Similar with a previous study in the Netherlands, aspirin were found to have been 
prescribed to patients, who had high risk of developing GI bleeding without a prophylactic drug 
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[139]. However studies from Switzerland [148], the UK [134, 147] and Denmark [83] reported that 
NSAIDs were the most common drug group associated with MEs  W resulting in GI bleeding. 
 
2.4.3 Factors influencing the percentage of ADE-related admissions 
2.4.3.1 Age 
Seventy percent of 1200 screened patients were aged 40 years and above, with 21% aged over 64 
years.  The latter group of patients accounted for 26% of the ADE-related admissions. Older patients 
were more likely to be admitted due to an ADE. This has also been reported by previous studies [83, 
146]. Similar results were found in admissions related to TF and ADR. The findings that older patients 
were more likely to be admitted for an ADR are similar with the results in previous studies of ADR-
related admissions [11, 71, 83, 135, 264, 265]. It is possibly because elderly patients are likely to have 
a higher number of morbidities requiring prescription and are more sensitive to the adverse effects 
of drugs. Great care is essential when prescribing for this age group to avoid long-term adverse 
effects and TF.  
 
2.4.3.2 Ethnic groups 
Patients from Chinese ethnic group were less likely to be admitted for TF compared with patients 
from Malay and Indian ethnic groups. There is no study that allows comparisons of TF-related 
occurrences among different ethnic groups of Malaysia. However, a review of trends in 
cardiovascular diseases and risk factors in Malaysia revealed that Indians and Malay women were at 
higher risks of cardiovascular diseases due to high prevalence of high blood pressure, high blood 
cholesterol, glucose intolerance and being overweight [259]. Moreover, two studies have reported 
that the prevalence of diabetes was highest in the Indian ethnic group [33, 36]. Like Malaysia, 
Singapore is a multi-ethnic group with a majority of Chinese ethnic group (80%). A Singaporean study 
of multi-ethnic differences in diabetes found that Indians had higher prevalence of diabetes and 
poorer control of their condition [266]. Diabetes increases the risk of cardiovascular diseases, 
therefore, the high prevalence of cardiovascular diseases in Indians could be attributed to their said 
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high prevalence of diabetes [267]. Hence, this explains the higher proportion of TF-related, admitted 
patients from the Indian ethnic group. 
Patients from Chinese ethnic group were more likely to be admitted due to ADRs. No studies have 
compared the occurences of ADR between Malaysian ethnic groups. However, pharmacogenetic 
differences between ethnic groups have been assumed the reason for susceptibility to different 
reactions [268, 269]. 
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2.4.4 Methodological considerations 
2.4.4.1 Patient screening method 
This study was conducted prospectively (a major strength of this study), allowing the collection of 
complete and accurate information in evaluating and classifying ADEs. In the case of incomplete 
information on past medication, patients were interviewed for further information. Chart review 
method is known as a good method in identifying ADEs because it allows complete review of patient 
medical notes and charts [93, 94]. The most complete data, however, is collected through the use of 
multiple methodologies, such as computerised surveillance, incident reporting, intervention 
documentation, and patient and practitioner interviews. Since the study site did not have a 
computerised patient database, computerised surveillance or monitoring was not possible. However, 
if necessary, patients were interviewed to gain more information on their past medication history. 
The prospective chart review method was piloted with the aim to ensure the highest possible 
number of patients screened in a day. The piloting meant that percentage of admissions screened in 
a day increased from less than half of the admissions to nearly all admissions, as patients were more 
likely available for review within 24 hours of admission, whilst the researcher was collecting data on 
that ward. However, half of the patients were still missed in both wards because the researcher 
visited the wards on alternate weeks. The basic information, such as, reason for admission, past 
medication and medical histories of these patients were not available.  This would be necessary to  
ascertain in order to be confident that the patients screened by the researcher were indeed 
representative of all admissions to these two wards. Similarly, patients were missed when patient 
charts were not available for screening, for example when patients were attending to procedures 
such as scans and X-rays. 
An attempt was made to include two pharmacists in screening all the cases in one ward while the 
researcher did the same in the other ward. However, although they were trained by the latter, the 
information collected by the two pharmacists were found insufficient to assess whether or not a 
patient was admitted due to an ADE.  Thus, all the cases screened by the pharmacists were 
discarded. The data collection was restarted without the help of the two pharmacists because of 
changes in their work schedules, thus, making them no longer available to participate in the study.  
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Left single-handed with limited time, the researcher collected data from each ward on alternate 
weeks.  As discussed in chapter 1 (section 1.5.1), chart review is labour intensive and a time- 
consuming method. A comprehensive study of all admissions would have required more researchers 
to collect data from the seven medical wards in the hospital.  
Despite these criticisms, it seemed likely that the screening of ADE-related patients in this study was 
thorough.  Data was collected systematically from two wards on alternate weeks, and a classification 
tool was used to systematically review all the cases in the same manner. Thus, the reported 
prevalence of admissions related to ADE is likely an accurate reflection of the true prevalence.  
 
2.4.4.2 Case assessment and classification 
The assessment of the admissions using a classification tool relied on the clinical experience and 
judgement of the researcher to classify ADE-related admissions. The reliability of the criteria 
assessed in 65 (10%) admissions showed Ă ‘ĨĂŝƌƚŽŵŽĚĞƌĂƚĞ ?ĂŐƌĞĞŵĞŶƚĂŵŽŶŐƚŚĞĂƐƐĞƐƐŽƌƐ. 
Furthermore, the percentage of ADE and types of ADE identified by the researcher was higher than 
the other assessors. This showed that different assessors have different clinical judgement which 
could be influenced by their different experiences. However, the enthusiasm and high interest of the 
researcher towards the study could have resulted in her identifying more ADEs compared with other 
assessors. Thus, the number of ADEs identified in this study may be an overestimate. Additionally, 
the information documented in the patient notes by attending physicians were assumed as accurate, 
thus, the assessments conducted were based on this information. Howard et al. [147]  have included 
three assessors in their study to independently classify all the cases. After the independent 
classification, the three assessors met and majority decision was used to classify the cases where 
there were disagreements. The present study was not able to gather all the assessors to discuss and 
decide on the classification of the cases due to their different work schedules. Furthermore, the 
assessors were only able to assess 10% of the cases unlike the study by Howard et al. [147].  A lack of 
external validation may have caused an overestimate of the prevalence. 
The main challenge in this study was to classify the ADEs into sub-types. As discussed in Chapter 1, all 
types of ADEs overlap and it can be difficult to distinguish one from another. Failure to appropriately 
classify cases may result in overestimation or underestimation of a sub-type. This problem is made 
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worse by a lack of standardisation in the terminologies. The pharmacist (assessor from the hospital) 
expressed that it was difficult to assess whether an admission was caused by TF without knowing the 
ƉĂƚŝĞŶƚ ?ƐĂĚŚĞƌĞŶĐĞďĞŚĂǀŝour. Furthermore, the same pharmacist suggested that the assessment 
should be conducted whilst the patients were still on the ward so that further evaluation of an event 
could be done. 
This study detected a high prevalence of TF-related admissions and highlights the areas for possible 
intervention. However, only a single assessor was responsible for detecting, assessing, and classifying 
all ADE-related cases. Thus, systematic misclassification of cases could have influenced the 
prevalence; in this case, the researcher identified a higher number of TF cases compared to other 
three assessors.  Furthermore, patient adherence to medication was not assessed for all patients. 
Although likely to be a cause of TF, non-adherence was recorded in only 16% of the patients and the 
adherence status in the remaining patients is unknown. Due to this insufficient information, it was 
also challenging to differentiate whether or not an admission was due to therapeutic failure or 
progression of a disease. For example, the complaints of chest pain by patients classified under TF 
could be due to the progression of their disease. However, since the adherence status of each 
patient is not known, and whilst the patient complaints and medical interventions were suggestive of 
therapeutic failures, these cases were classified as TF. This highlights the importance of obtaining 
history of patient medication-taking behaviour to understand the underlying cause of uncontrolled 
diseases. Hence, the frequency of admissions due to TF is likely an overestimate. 
The study was able to identify types of ADR and the drugs implicated in ADR-related admissions.  
Furthermore, all the ADR cases were sent to MADRAC for causality assessment and thus, have had an 
external validation. However, a lack of informĂƚŝŽŶŽĨƚĞŵƉŽƌĂůƌĞůĂƚŝŽŶƐŚŝƉŚĂƐƌĞƐƵůƚĞĚŝŶ ‘ƉŽƐƐŝďůĞ ?
categorisation by MADRAC in almost all the cases.  
ůƚŚŽƵŐŚ ? ? ?A?ĂĚŵŝƐƐŝŽŶƐǁĞƌĞĐůĂƐƐŝĨŝĞĚĂƐD ?ŝƚŝƐƵŶĚĞŶŝĂďůĞƚŚĂƚĂƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐĂƚŝŽŶ
behaviour could have influenced the occurrence of an error. For example, three patients were 
admitted due to GI bleeds but were not taking any prophylactic gastroprotective drug. However, it is 
unknown whether or not these patients have been prescribed a gastroprotective drug, as this was 
not reported by the patients and review of their medical and medication histories did not reveal such 
a prescription. Therefore, the prevalence of ME-related admissions is likely to be an overestimate or 
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2.4.4.3 Choice of study setting 
The overall aim of the study was to identify ADE-related admissions to a tertiary care hospital in 
Malaysia. The setting chosen was a typical government hospital suitable for identifying admissions 
associated with a broad range of medical conditions, and is likely to be representative of medical 
admissions to most government hospitals in Malaysia. However, the data from this study may not be 
representative of admissions to private hospitals because the characteristics of patients visiting these 
hospitals may be significantly different from those visiting the government hospitals. A study in 
Malaysia reported that a higher percentage of patients from Chinese ethnic group obtained 
treatment from private sectors compared to Indian and Malay ethnic groups [33]. This could explain 
the lower percentage of patients from Chinese ethnic group in this study. The generalisability of data 
from this study is further discussed in the next section. 
Only two medical wards were selected for this study out of six. This selection was made by the head 
of medical department. These two medical wards serve as admissions wards (third class wards) and 
after further review and evaluation the patients may be transferred to a higher class ward (second 
class or first class wards) as explained in Chapter 1. Thus, the admissions to all medical wards are 
likely similar. 
 
2.4.4.4 Generalisability of data  
It is not known whether or not the admissions screened for this study are comparable with those not 
screened by the researcher and one of the major limitations was undersampling of cases each week 
(cases were missed alternately for one week in each ward as the researcher collected data in the 
other ward). Information on these cases such as age and reason for admissions are incomplete due 
to lack of documentation at the wards. Thus, a comparison cannot be made between the screened 
and unscreened admissions. However, since both wards were wards for general admission  W one for 
males, the other, for females, the patients admitted to both wards are likely to be representative of 
the seven medical wards in the hospital. The results from this study, however, will not be 
generalisable to other types of departments such as intensive care unit, orthopaedic, or surgical 
because these population of patients in such will be very different to medical admissions. 
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The results of this study broadly reflect the health care practice in tertiary care. Therefore, the 
important factor in wider generalisability of this study is how representative this sample population 
is to the rest of Malaysia. Malaysia is represented by multiple ethnic groups. Malay ethnic group 
makes up 54% of the population, followed by Chinese (25%), and Indian (7%) ethnic groups [24]. In 
this study, 47% of patients were from Malay ethnic group followed by Indian (36%), and Chinese 
(13%).  The population in this study does not reflect the ethnic group distribution of the Malaysian 
because patient attendance at the public hospitals differs by ethnic groups [33]. However, it is likely 
to be representative of the Malaysian patient-population attending government hospitals as 
compared to private hospitals. 
 
2.4.4.5 Ways in which this chart review study could have been strengthened 
The study would have been strengthened if all admissions to the medical wards had been 
prospectively screened and followed up throughout their admission. The medical wards in the study 
site received 10 to 20 admissions each day. Therefore it was not feasible to screen all these 
admissions with only one researcher collecting the data. Appointing a research assistant to collect 
data on one of the wards could have solved this problem. Although two pharmacists were recruited 
to assist with data collection, initial problems and changes in their professional work patterns 
hindered this from happening through the study. A thorough training of at least one month would 
need to be given to a research assistant so that he or she becomes familiar with the patient record 
system and data collection form. Additionally, an inter-rater test would need to be conducted to 
ensure data has been collected and assessed in the same manner. 
Each patient was screened on admission and data were checked so that the next day any queries 
could be followed-up. However, charts for each patient were not checked daily for their entire 
hospital stay. It was not feasible to do this because, ĨŽƌŝŶƐƚĂŶĐĞ ?ŝĨĂƉĂƚŝĞŶƚ ?ƐĚƵƌĂƚŝŽŶŽĨŚŽƐƉŝƚĂů
stay was for three days, it would have meant screening as many as 40 to 60 charts in a day.  
The study would have been also strengthened if all patients were interviewed to determine their 
adherence status. However it was not feasible to interview 10 to 20 patients a day, in addition to 
screening 10 to 20 charts with only one researcher. It was likely that not all patients would be well 
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enough for an interview, particularly on the first day of admission.  However, gaining data on each 
ƉĂƚŝĞŶƚ ?ƐĂĚŚĞƌĞŶĐĞƐƚĂƚƵƐǁŽƵůĚŚĂǀĞĂůůŽǁĞĚĞĂƐŝĞƌĐůĂƐŝĨŝĐĂƚŝŽŶŽĨĞǀĞŶƚƐ ? 
Therefore, the methodology used in this study was the most appropriate given the available 
resources.  
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2.4.5 Implications 
Health care system and health care professionals  
This study revealed that 70.5% of patients on medication were admitted due to ADEs and based on 
the results from the current and previous studies, ADEs continues to be a considerable burden on 
health care systems. This warrants for a continuous monitoring of patients on medication. It is 
important that prescribers determine the need for a particular drug in patients and whether or not it 
is appropriate for them. Additionally, prescribers should continuously monitor or follow-up on 
patients and the progress in their medical conditions, to ensure that the therapy given is adequate or 
appropriate.  
 One of the important issues observed in this study was the lack of information on patŝĞŶƚƐ ?ƉĂƐƚ
medical and medication histories which could result in inadequate monitoring of progress of the 
patients. If a patient followed-ƵƉǁŝƚŚƉŚǇƐŝĐŝĂŶƐŝŶŐŽǀĞƌŶŵĞŶƚŚŽƐƉŝƚĂůƐ ?ƚŚĞǇǁĞƌĞŐŝǀĞŶĂ ‘ƐŵĂůů
ďŽŽŬ ?ǁŚĞƌĞƚŚĞĚĞƚĂŝůƐŽĨƚŚĞŝƌƉĂƐƚŵĞĚŝĐĂůĂnd medication were documented. Patients are to carry 
the book every time they visit the hospital. However, some patients in this study were found to have 
lost the book or forgotten it, giving limited information about their past treatment. Furthermore, 
medŝĐĂůƚƌĞĂƚŵĞŶƚƐƌĞĐĞŝǀĞĚŝŶƉƌŝǀĂƚĞŝŶƐƚŝƚƵƚŝŽŶƐĂƌĞƵƐƵĂůůǇŶŽƚĚŽĐƵŵĞŶƚĞĚŝŶĂ ‘ƐŵĂůůďŽŽŬ ? ?
Perhaps, there is a need for a better system for recording patient medical and medication histories, 
as well as, information linkage between the government and private institutions to ensure that 
progress of patients are monitored continuously. 
Cardiovascular diseases are the principal cause of admissions and death in Malaysian public hospitals 
[25]. Poor control of these medical conditions could worsen the situation. Furthermore, hypertension 
and diabetes mellitus are the major predisposing risk factors for many cardiac complications. Poor 
control of these medical conditions could increase the risk of cardiovascular events. Thus, it is 
important to recognise patients with established cardiovascular disease or those at high risk of it to 
prevent the recurrence of the event, and provide advice to patients regarding the importance of 
adherence, the impact and risk of an uncontrolled medical condition. With the current situation in 
public hospitals in Malaysia which are always crowded, it is not possible for physicians to provide a 
one-to-one care for patients, let alone a counselling service. These provide opportunities for 
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pharmacists to play their role, and their involvement in educating patients with regular, follow-up 
check-ups have been shown to improve disease management and medication adherence of patients 
[270, 271]. The implementation of MTAC services in certain public hospitals in Malaysia is one of the 
strategies provided by pharmacists to improve patient medication adherence behaviour. This service 
has been reported to increase the medication adherence and better disease control in patients who 
have attended eight counselling sessions with a pharmacist [211]. More MTAC services should be 
encouraged in all hospitals  W public and private sectors, and at community level  W community 
pharmacy. In educating patients on adherence to medication, pharmacists should be trained to 
recognise patients at high risk of disease complications to ensure they are referred to such services 
or reminded about adherence regularly. Patients who were admitted for recurrent or poor control of 
their medical conditions should be enrolled to the MTAC service and regularly monitored. To 
guarantee the quality of the services provided in the clinic, it is important to have a protocol or 
guideline to ensure minimum standards of all hospitals. 
Malhotra et al. [153] reported in their study that a greater number of physicians regularly consulted 
by patients was one of the factors associated with increased risk of hospitalisation related to non-
adherence. In view of the current health care system in Malaysia, this poses a great danger to 
patients. A lack of coordination in the primary care level may have contributed to poor control of 
ŵĞĚŝĐĂůĐŽŶĚŝƚŝŽŶƐ ?^ƚĞƉƐŶĞĞĚƚŽďĞƚĂŬĞŶƚŽŵŝŶŝŵŝƐĞƚŚĞ ‘ƉŚǇƐŝĐŝĂŶ-ŚŽƉƉŝŶŐ ?ŚĂďŝƚƐŽĨDĂůĂǇƐŝĂŶ
people so that the care they receive is consistent and adequately monitored. The mixed treatment in 
the private and public sectors could create confusion to patients and thus increase the risk of ADEs. 
There should be a system that allows practitioners to have access to complete patient information  W 
past medical and medication histories, drug allergies, and OTC drugs, and this should be made 
available to all the practitioners a patient consults with. Primary care practitioners also play crucial 
role in educating patients about the safe and effective use of prescription and non-prescription 
drugs. Thus, providers must allow sufficient time for consultations with patients about medication 
management. Primary care practitioners, particularly in the private sector should work closely with 
MOH to ensure that their disease management practice is according to the guideline and protocols 
developed by MOH.  
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Although, MOH has taken steps to increase the number of public clinics and hospitals in Malaysia, 
the overcrowding of patients is still a problem. This may have forced the public to seek treatment 
from the private sector. However, some patients without the insurance coverage may find the costs 
too high and thus may not receive a comprehensive care. It would be a good strategy to introduce a 
national insurance scheme available for all Malaysians so that patients can receive treatment in any 
health institutes without the concern about costs and waiting in long queues. 
In this study, most ADRs were predictable from the known pharmacology of the drugs and therefore, 
likely to be preventable (especially hypoglycaemic reactions found in most patients). The main 
reason for admission related to hypoglycaemic reaction was poor oral intake prior to admission. This 
indicates lack of knowledge about disease management and drug therapy among patients. Since the 
physicians and pharmacists are responsible for providing adequate information about drug effects, 
the blame falls on the health care system.  As hypoglycaemia is a prominent problem in diabetic 
patients, prescribers should be vigilant when prescribing antidiabetics and ensure that patients have 
adequate knowledge about their medicines. It is important that primary care practitioners provide 
information about side effects, contraindications, and how to recognise and handle adverse 
reactions, as well as where to obtain high quality information.   
 Many countries such as the UK and France have restricted the sale of paracetamol [168]. Other than 
the habit of selling paracetamol in individual blister rather than tablets, there is no sale restriction on 
its amount that can be sold in Malaysia. Furthermore, other than obtaining paracetamol from a 
pharmacy, paracetamol-contained products can also be purchased from convenience stores. This 
explains the popularity of this pharmaceutical agent in intentional self-poisoning. Restricting the 
amount of paracetamol or paracetamol-contained products sold at one time may be a good strategy 
to reduce the rate of overdose related to it. Studies in some countries show reduction in the rates of 
overdose since the introduction of such restriction [272, 273].  
Although the product packaging of OTC drugs always comes with an overdose warning, OTC drugs 
sold in blister strips do not include information about the appropriate dose or warning about the 
dangers of overdose. This places the health care professionals in the best position to warn patients, 
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or counsel them about OTC drugs, to reduce the potential risk of misusing them, especially, taking 
more than the required dose. 
The fact that Malaysians are able to get treatment from any GP or pharmacist could be detrimental 
ƚŽƚŚĞŝƌŚĞĂůƚŚ ?dŚŝƐ ?ŶŽƚŽŶůǇĞŶĐŽƵƌĂŐĞƐ ‘ĚŽĐƚŽƌ- or pharmacy-ŚŽƉƉŝŶŐ ?ďǇƉĂƚŝĞŶƚƐ ?ŝƚĐŽƵůĚĂůƐŽ
pose danger of possessing multiple drugs obtained from visits to different practitioners, which may 
be ingested by anyone with suicidal intention. dŚĞ ‘ĨƌĞĞĚŽŵ ?ŽĨŽďƚĂŝŶŝŶŐƚƌĞĂƚŵĞŶƚĨƌŽŵĚŝĨĨĞƌĞŶƚ
practitioners is in part, due to primary care being a private transaction and without system of 
registration with doctors. The current system needs improvement especially in sharing of patient 
information among hospitals, general practitioners (GPs), and pharmacies. 
It is reported that previous ulcer history, aspirin, NSAID and Helicobacter pylori are the risk factors for 
GI bleed [274, 275]. The strategies to reduce the risk of drug-induced GI bleed should, therefore, 
include minimising the use of aspirin in patients with known history of GI bleed, or who are at high 
risk of such (for example, one who was already prescribed a drug which can cause it). Thus, it is the 
responsibility of health care professionals to obtain accurate and thorough medical and medication 
histories of patients before prescribing a drug. When use of aspirin is unavoidable, patients should be 
prescribed a gastroprotection drug (such as proton pump inhibitor or misoprostol) to reduce the risk 
of GI bleed [276]. The risk factors for GI bleed have been published in a local guideline [274] and 
practitioners should be encouraged to adhere to it during the prescribing process. 
 
Patients and society 
The drugs implicated with TF-related admissions (cardiovascular drugs, anti-asthmatics, and anti-
diabetics) confirm their key role in TF. Treatment with such drugs may have a high risk of poor 
adherence due to being used for long-term therapies. Patients with cardiovascular diseases were 
found at higher risk for TF-related admissions. Cardiovascular disease itself is a complex medical 
condition, therefore, patient should be educated about the disease, complications, and 
consequences of poor control of their condition.  While emphasising the importance of disease 
control, it is important to also identify the risk factors and causes of poor control to implement 
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preventative strategies. Many studies have identified poor adherence to medication as the most 
common cause of TF [9, 83, 146, 152]. However, poor adherence does not only relate to medication- 
taking behaviour but also to lifestyle changes, such as dietary control. Thus, educational programs for 
patients should emphasise the importance of adherence, dietary control and other lifestyle changes. 
Hypoglycaemic reactions are a known side effect of anti-diabetic drugs. WĂƚŝĞŶƚƐ ?ůĂĐŬŽĨĂǁĂƌĞŶĞƐƐŽĨ
their condition and poor oral intake after these drugs could precipitate a hypoglycaemic reaction. In 
this study, a female patient developed prolonged hypoglycaemic reaction and this was not 
recognised by her family members. She was hospitalised and diagnosed with neuroglycopenia coma. 
Neuroglycopenia is caused by deprivation of glucose in the brain resulting from chronic 
hypoglycaemia [277]. The early symptoms which develop in response to a low blood glucose level 
such as, sweating, tachycardia, and tremor could alert patients and their families to take necessary 
actions (ingestion of sugar by the patient) [278, 279]. However, failure to recognise these symptoms 
can lead to development of neuroglycopenia, and ultimately, death. This illustrates the importance 
of recognising hypoglycaemic symptoms, and how lack of information can be detrimental to patients. 
Therefore, it is vital for patients and their family members to be well informed about the effects, 
monitoring steps, and management of any side effects at an early stage. 
One of the strategies of preventing hypoglycaemia as suggested by NHS is regular self-blood glucose 
monitoring for early identification [280]. Self-monitoring of blood glucose provides the possibility of 
collecting information on blood glucose level at different time points, which could allow adjustment 
of therapy in response to blood glucose level [281]. This has been associated with improved 
outcomes [282, 283]. Thus, blood glucose self-monitoring should be recommended to all patients 
with diabetes. However, the self-monitoring program should be individualised and the program 
should take into account the ƉĂƚŝĞŶƚ ?ƐĚŝƐĞĂƐĞĐŽŶƚƌŽůůĞǀĞůĂŶĚƚǇƉĞŽĨƚŚĞƌĂƉǇ[284]. 
Educational interventions for the public should be provided to increase their awareness about the 
impact and risks of DOs. They should also be advised on the proper storage of their drugs.  Patients 
should be encouraged to return their unused medication either to nearby hospitals, clinics or 
pharmacies. This may help in preventing intentional drug overdoses using multiple drugs. Women 
ƉĂƌƚŝĐƵůĂƌůǇ ?ƐŚŽƵůĚďĞĞŶĐŽƵƌĂŐĞĚƚŽƌĞĂĐŚŽƵƚĨŽƌŚĞůƉ ?ƐƵĐŚĂƐĨƌŽŵ ‘ĞĨƌŝĞŶĚĞƌƐ ?[285] a non-
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profit organisation run by volunteers that provide emotional support and telephone counselling to its 
caller, or family, and friends in case of emotional distress.  
It is important that patients are advised on the importance of adhering to medication that reduces 
the risk of GI bleed. Furthermore, patients should be made aware that concomitant use of OTC drugs 
ƐƵĐŚĂƐE^/ ?ƚŽŐĞƚŚĞƌǁŝƚŚĂƐƉŝƌŝŶ ?ŝŶĐƌĞĂƐĞƚŚĞƌŝƐŬŽĨ'/ďůĞĞĚ ?ƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐĂůĂŶĚ
medication histories are important in evaluating his or her suitability for the drug.   Thus, patients 
should be encouraged to disclose their medication-taking behaviour to the health care professionals, 
so that an appropriate therapy is planned for him or her. 
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Future research 
x The prevalence of ADEs identified through this study is high compared to other published 
studies. This figure is rather alarming and creates speculation on ADEs being supposedly, a 
really big problem in Malaysia. Since this study was conducted only in two wards of only one 
hospital, it may not be able to give a bigger and clearer picture of the actual burden of ADEs 
in Malaysia, thus, a larger study involving more than one hospital is needed. Additional to 
this, due to differences in the characteristics of the population visiting the government and 
private healthcare institutions, it would be practical to involve the private institutions as well 
in the proposed future study. This large study should involve more manpower to collect data 
to avoid missing cases and data, and inter-rater reliability test should be conducted to 
ascertain the reliability of the data collected.  
x  The present study showed that TF was major cause of admission but was not able to identify 
the causes or risk factors of TF. This should be investigated to provide an insight into the 
problem and highlight areas for intervention.  As patient adherence behaviour is an 
important determinant for TF, further investigation on this should highlight the factors 
associated with non-adherence and suggest ways to improve the opposite. This can be done 
through patient interviews. 
x  Similarly, patient interviews can be conducted to understand the underlying reasons for 
ĂĚŵŝƐƐŝŽŶƐƌĞůĂƚĞĚƚŽŚǇƉŽŐůǇĐĂĞŵŝĂ ?WĂƚŝĞŶƚƐ ?ƵŶĚĞƌƐƚĂŶĚŝŶŐĂďŽƵƚĚŝƐĞĂƐĞŵĂŶĂŐĞŵĞŶƚ
and drug therapy should be evaluated to identify the root cause of hypoglycaemia-related 
admissions. This would provide information whether a better patient education is needed to 
overcome this problem. 
x This research revealed that the rate of admissions due to overdose is actually higher than the 
reported results in previous studies [164, 165]. However, a larger, prospective, multi-centred 
study is needed to provide an insight of the demographic profiles of DO-related admissions 
and therefore, determine the area for interventions. A number of studies have already been 
conducted in public hospitals, therefore, overdose cases should also be investigated in the 
private sector. Furthermore, research on the type of drugs used in these cases and where 
they are obtained could as well suggest areas for prevention strategies. 
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x The restriction of the amount of paracetamol sale was found to have reduced overdose cases 
in a few countries [272, 273]. Perhaps, this approach should be proposed and a study could 
be designed to evaluate whether or not similar outcomes can be achieved in Malaysia. 
x Antiplatelet has been found to be the main cause of admissions related to ME. However, it is 
not known whether or not errors resulting from this drug group are attributable to lack of 
knowledge about patients or poor prescribing by doctors. Thus, further investigation is 
needed in this area to understand the underlying cause resulting in ME-related admissions. 
This will suggest ways to minimise or prevent future errors.  
 
2.5 Summary 
This study found that 39% of admissions in two medical wards were related to drugs. TF was the 
highest contributor to these admissions with poor control of cardiovascular conditions being the 
most frequent reason for such admissions. The prevalence of ADRs was 8.4% and hypoglycaemia 
associated with the use of anti-diabetics was the most common symptom that led to these 
admissions. The prevalence of admissions due to overdoses and MEs were small (2.0% and 1.4% 
respectively) but comparable with other studies. 
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3 CHAPTER 3: SURVEY STUDY 
CHAPTER 3 
 
SURVEY STUDY 
 
A questionnaire was designed using new questions and previously published questions to explore the 
experiences of health care professional of ADEs. The questionnaire was tested by piloting during a 
pharmacy seminar. A population survey was conducted using the piloted questionnaire to investigate 
the experiences of pharmacists about ADE  W its types, the drugs involved, and actions taken in 
response to ADEs. In addition, the experiences of hospital and clinic pharmacists were compared 
with those of the community pharmacists ? ? 
 
3.1 Objectives 
The objectives of this survey were: 
i) To investigate whether or not pharmacists were able to observe occurrences of ADEs 
during their daily work activities 
ii) To identify the strategies taken by pharmacists to solve the ADEs observed 
iii) To evaluate whether or not the pharmacists are aware of the role of MADRAC and ADR 
reporting system 
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3.2 Method 
3.2.1 Development of the questionnaire 
A questionnaire was designed following a literature search and discussions with supervisors 
(Appendix 7). It included previously validated questions [216, 219, 232] and alongside, new questions 
to determine the experiences of Malaysian health care professionals of adverse drug events. 
The questionnaire contained 52 items with six sections: (i) awareness of ADR, (ii) attitudes towards 
ADR reporting, (iii) awareness of TF, (iv) awareness of other ADEs, (v) demographic information, and 
(vi) feedback about the questionnaire. Majority of the questions were closed questions with 
categorical answers, and 10 to 15 minutes were given to complete the questionnaire. Respondents 
were requested to recall the ADEs they had observed in the last six months and answer the questions 
based on that. A summary of the questionnaire contents follows. 
 
Experience of observing ADRs 
3.2.1.1 Percentages of ADRs occurring in Malaysia- all respondents 
Respondents were asked to estimate the percentage of suspected ADRs and severe ADRs that occur 
in Malaysia. Respondents were expected to answer these questions based on their experiences, 
rather than based on the previously reported levels. 
3.2.1.2  Experience of observing ADRs and actions taken- respondents who have observed ADRs 
Respondents were asked if they have observed ADRs in their daily activities in the last six months and 
if so, were asked for descriptions of such in terms of frequency and its type they have encountered 
most recently. Additionally, they were asked to report the specific actions they took upon 
encountering one.  
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3.2.1.3  Experiences of patients reporting ADRs and actions taken- all respondents 
Respondents were asked whether or not they have received any ADR-related reports from patients 
and if so, were asked for descriptions of the group of patients who reported ADRs most frequently, 
and the type of ADRs most frequently and recently reported. Additionally, they were asked to 
recount the specific actions they took after receiving a report.  
3.2.1.4 Attitudes or awareness on spontaneous reporting- all respondents 
Respondents were asked to select from a list the factors that encourage and discourage them from 
reporting a suspected ADR. They were also asked about their awareness of the following: reporting 
system in Malaysia, the existence of a reporting system, availability of report forms, places or areas 
where to obtain them, and purpose of collating the reports from across Malaysia. Furthermore, 
respondents were asked their manner of preference in reporting ADRs (online, fax, phone, email, or 
post) and type of ADRs they think should be reported. 
 
Experiences of observing therapeutic failures  
3.2.1.5 Percentages of TF occurring in Malaysia- all respondents 
Respondents were asked to estimate the percentage of TFs that occur in Malaysia. They were 
expected to answer based on their experiences rather than their knowledge of its prevalence based 
on previous studies. 
3.2.1.6  Experiences of observing TFs and actions taken- respondents who have observed TFs 
Respondents were asked whether or not they have observed TFs in their daily activities and if so, 
were asked for descriptions of the observed TFs in terms of frequency, the disease or therapy 
associated with the observed TFs, and the type of TFs they have encountered most commonly and 
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recently. Additionally, they were asked to report the actions they took in response to an observed TF 
and describe the group of patients they usually encounter with TFs. 
 
Experiences of observing medication errors, adverse drug withdrawal syndromes and drug 
overdoses  W respondents who observed medication errors, adverse drug withdrawal 
syndromes and drug overdoses 
Respondents were asked whether or not they have observed MEs, ADWS, and DOs during their daily 
activities and if so, were asked to describe the frequency of encounter with them. Respondents were 
also asked about the type of DOs they experienced and the drug involved in the most recent case. 
 
Demographics  W all respondents 
All respondents were asked to answer this section which includes gender, state of residence, highest 
level of education, work area, and number of years of practice as a pharmacist. Additionally, 
respondents were asked their educational and professional specialisations.  
 
Comments about the questionnaire- all respondents 
Respondents were asked whether or not all the questions were clear and easy to understand and if 
not, state which questions were unclear and answer why. They were also asked of the time span it 
took them to completely answer the questionnaire and the manner they prefer to answer a similar 
questionnaire in the future. Respondent were also given space to write their comments about the 
questionnaire. 
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3.2.2 Piloting and testing the questionnaire 
Ethical approval was obtained from the Division of Social Research in Medicines and Health, School 
of Pharmacy, University of Nottingham, and UK and permission for conducting the survey, from the 
President of MPS. 
 The questionnaires were handed out to pharmacists attending a three-day pharmacy seminar 
organised by MPS. The seminar was held in conjunction with the MPS annual general meeting and 
was targeted at pharmacists from all sectors of the profession. 
Pharmacists were approached during the seminar registration, tea or meal break by the researcher 
and details of the survey were briefly explained. An information sheet (Appendix 8), together with 
the questionnaire (Appendix 7) was provided to prospective participants. The questionnaires were 
distributed to the pharmacists over all three days of the seminar which was attended by around 400 
pharmacists. Announcements between the talks were made by the organiser to encourage 
pharmacists to complete the questionnaire. Respondents were asked to drop off the completed 
questionnaire in a box placed at the registration counter. 
The testing of the questionnaire addressed the following: 
i) Response rate 
- The proportion of completed questionnaire returned out of the quantities 
distributed [286] 
ii) Internal consistency 
- Refer to different items which aim to measure the same or similar things  
iii)  Completion rate 
- Percentage of respondents responding to all questions 
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3.2.2.1  Results from piloting and testing the questionnaire 
3.2.3 Response rate 
Two hundred and nine (n= 209) questionnaires were distributed and 122 completed questionnaires 
were returned giving a response rate of 58%. Demographic details of pharmacists are shown in Table 
3-1. Most of the respondents were female (n=97, 80%), while almost 80% of them have been 
practicing pharmacy for five or less years (n= 92, 76%). Furthermore, almost four-fifths (n= 95, 78%) 
of the respondents worked in the hospital setting. 
 
Table 3-1: Characteristics of the respondents (n= 122) 
Hospital Community              Other
a            
(n= 95) (n= 12) (n= 14)
Gender (n= 121
b
)
Male (n= 24) 17 (17.9) 5 (41.7) 2 (14.3)
Female (n= 97) 78 (82.1) 7 (58.3) 12 (85.7)
Years of work experience (n= 121
b
)
More than 5years (n= 29) 24 (82.8) 5 (17.2) -
5years or less (n= 92) 71 (74.7) 7 (58.3) 14 (100.0)
Level of education (n= 121
b
)
Bachelor's degree (n= 114) 88 (92.6) 12 (100.0) 14 (100.0)
Master's degree (n= 7) 7 (7.4) - -
Number of respondents (%)
 
a
 other includes respondents working at a pharmacy enforcement (n= 8), government health clinic (n= 4), state 
health department (n= 1) and industrial sector (n= 1). 
b
 these groupings do not total 122 due to missing data 
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3.2.4 Completion rate 
Completion rate for the 52 items in the questionnaire ranged from 1 to 100% (Table 3-2). Majority of 
the items had completion rates of 90% or more. High completion rates were seen in sections on 
ADRs, where all items had more than 90% completion rates. Questions related to ADWS had 
completion rates of 80 to 86%, and a question about drug groups associated with DO had completion 
rate of 81%. Furthermore, questions related to the type of patients associated with TF and its most 
common type had completion rate of less than 90%. The lowest completion rates were obtained 
ĨƌŽŵŽƉĞŶƋƵĞƐƚŝŽŶƐƚŚĂƚĂƐŬƌĞƐƉŽŶĚĞŶƚƐƚŽƐƚĂƚĞƚŚĞŝƌ ‘ĞĚƵĐĂƚŝŽŶƐƉĞĐŝĂůŝƐĂƚŝŽŶ ? ? ‘ƉƌŽĨĞƐƐŝŽŶ
speĐŝĂůŝƐĂƚŝŽŶ ? ?ĂŶĚ ‘ĐŽŵŵĞŶƚƐĂďŽƵƚƚŚĞƋƵĞƐƚŝŽŶŶĂŝƌĞ ? ?ĐŽŵƉůĞƚŝŽŶƌĂƚĞ ?ůĞƐƐƚŚĂŶ ? ?A? ? ? 
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Table 3-2: Completion rates of the 52 items in the questionnaire (n= 122 respondents) 
Question (question number)
Number of 
respondents 
expected to answer
Number of 
respondents 
answered
Completion 
rate
Percentage of ADRs in Malaysia (Q1a & Q1b) 122 121 99.2%
Observed a suspected ADR (Q2) 122 122 100.0%
Frequency of ADR (Q3) 107 107 100.0%
Frequency of recent ADR (Q4) 107 106 99.1%
Symptoms of recent ADR (Q5) - multiple 
choice
107 107 100.0%
Actions taken in response to observed ADR 
(Q6) - multiple choice
107 107 100.0%
Patient reported ADR (Q7) 122 122 100.0%
Group of patient who report (Q8) 104 100 96.2%
Most frequent patient-reported ADR (Q9) 104 90 86.5%
Most recent patient-reported ADR (Q10) - 
multiple choice
104 103 99.0%
Actions taken in response to patient-reported 
ADR (Q11) - multiple choice
104 104 100.0%
Factor encouraging ADR reporting (Q12)- 
multiple response
122 120 98.4%
Factor discouraging ADR reporting (Q13)- 
multiple response
122 113 92.6%
Preference to report ADR (Q14)- multiple 
choice
122 120 98.4%
Aware of a form to report ADR (Q15) 122 120 98.4%
Aware of where to obtain the form to report 
ADR (Q16)
117 117 100.0%
Where to obtain the form (Q17)- multiple 
choice
117 115 98.3%
           
table continued......... 
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Table 3-2 continued: Completion rates of the 52 items in the questionnaire (n= 122 respondents) 
Question (question number)
Number of 
respondents 
expected to answer
Number of 
respondents 
answered
Completion 
rate
Aims of monitoring ADR reports (Q18)- 
multiple choice
122 122 100.0%
Which ADR should be reported (Q19)- 
multiple choice
122 122 100.0%
Percentage of therapeutic failures in Malaysia 
(Q20)
122 121 99.2%
Observed a therapeutic failure (Q21) 122 120 98.4%
Types of therapeutic failure encountered 
(Q22)- multiple choice
84 84 100.0%
Most common therapeutic failure (Q23) 84 73 86.9%
Frequency of observed therapeutic failure 
(Q24)
84 84 100.0%
Frequency of recent therapeutic failure (Q25) 84 77 91.7%
Actions taken in response to observed 
therapeutic failre (Q26) - multiple choice
84 84 100.0%
Types of disease/ therapy associated with 
therapeutic failure (Q27)- multiple choice
84 84 100.0%
Group of patient therapeutic failure observed 
- age (Q29)
84 84 100.0%
Group of patient therapeutic failure observed 
- gender (Q29)
84 75 89.3%
Group of patient therapeutic failure observed 
- race (Q29)
84 74 88.1%
Observed a medication error (Q30a) 122 119 97.5%
Observed a adverse drug withdrawal 
syndrome (Q30b)
122 105 86.1%
Observed a drug overdose (Q30c) 122 110 90.2%
                                                                                                                                                       table continued... 
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 Table 3-2 continued: Completion rates of the 52 items in the questionnaire (n= 122 respondents) 
Question (question number)
Number of 
respondents 
expected to answer
Number of 
respondents 
answered
Completion 
rate
Frequency of observed medication error 
(Q31a)
122 113 92.6%
Frequency of observed adverse drug 
withdrawal syndrome (Q31b)
122 98 80.3%
Frequency of observed drug overdose (Q31c) 122 102 83.6%
Cause of drug overdose (Q32) 122 114 93.4%
Drug group associated with drug overdose 
(Q33)
84 68 81.0%
Gender (Q34) 122 122 100.0%
State of residence (Q35) 122 112 91.8%
Highest level of education (Q36) 122 121 99.2%
Specialization in education (Q36a)- open 
question
122 1 0.8%
Profession (Q37) 122 121 99.2%
Specialisation within profession (Q37a)- open 
question
122 7 5.7%
Number of years working as pharmacist 
(Q38)
122 122 100.0%
Questionnaire clear and easy (Q39) 122 116 95.1%
Comments on the clarity and level of 
difficulty of the questions (Q39a)- open 
question
9 9 100.0%
Time taken to answer all questions (Q40) 122 116 95.1%
Preference to answer future questionnaire 
(Q41)
122 112 91.8%
Other comments (Q42)- open question 122 18 14.8%
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3.2.5 Internal consistency 
Consistency was expected between responses of two pairs of items in the questionnaire. These items 
were compared. The consistency was 95% and 100% (Table 3-3). 
 
Table 3-3: Test of internal consistency of questionnaire responses 
First-question response
Number of 
respondents
Second-question 
response
Number of 
respondents
Consistency
Involvement of a new 
drug encourage reporting
84
Reactions to new drug 
should be reported
80 95.2%
Unusual/ unexpected 
reactions encourage 
reporting
74
Unusual/ unexpected 
reactions should be 
reported
74 100.0%
 
 
3.2.6 Comments of respondents about the questionnaire 
Almost all respondents (n= 112, 92%) reported that the questionnaire was clear and easy to 
understand. The comments given by the respondents who disagreed are summarised in few points 
(Figure 3-1). ZĞƐƉŽŶĚĞŶƚƐƌĞƉŽƌƚĞĚƚŚĂƚƐŽŵĞŽĨƚŚĞƋƵĞƐƚŝŽŶƐƵƐŝŶŐƚŚĞƉŚƌĂƐĞ ‘ŵŽƐƚĐŽŵŵŽŶ ? ?
 ‘ŵŽƐƚƌĞĐĞŶƚ ? ? ‘ŵŽƐƚĨƌĞƋƵĞŶƚ ? ?ĂŶĚ ‘ĞǀĞƌ ?ǁĞƌĞĐŽŶĨƵƐŝŶŐ ?dŚĞǇŚĂǀĞĂůƐŽƐƚĂƚĞĚƚŚĂƚƐŽŵĞƋƵĞƐƚŝŽŶƐ
were not clear (question about the cause of DO  W question number 32), repetitive (questions about 
factors encouraging and discouraging ADR-reporting  W question numbers 12 and 13), and too general 
(questions about the percentage of ADR and TF occurring in Malaysia) and lengthy. 
The respondents reported that the average time taken to answer the questionnaire was 16 minutes 
(SD 8.7), a minimum of 5 minutes, and a maximum of 60 minutes. When asked about the preferred 
mode of answering similar questionnaire in the future, almost 60% (n= 68, 56%) preferred email over 
post (n= 25, 20%).  Second preference is face-to-face (n= 20, 16%), and third is telephone (n= 1, 1%). 
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 Figure 3-1: Comments of respondents about the questionnaire 
1) Confusing
a) the use of "most common", "most recent" and "most frequent"
b) the phrase sub-optimal dosage and inadequate dosage
c) the use of "ever"
2) Not clear
a) question regarding the cause of drug overdoses
b) some questions were ambiguous
3) Repetitive questions
a) questions regarding factors encouraging and discouraging ADR reporting were overlapping
4) Questionnaire is too lengthy
5) Too simple and general
a) questions regarding the percentage of occurrence of events were too general
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3.2.7 Discussion of results from piloting and testing of the questionnaire 
 
The completion rates for questions were generally good with majority being more than 90%. A few 
questions generated a completion rate less than 90%. Questions about ADWS fell into this group. The 
reasons could be that the respondents may be unfamiliar with the term ADWS, or have poor 
knowledge of ADWS and therefore, are more likely to find the questions hard to answer. Open 
questions had the lowest completion rates, especially about the educational specialisation and 
ƉƌŽĨĞƐƐŝŽŶĂůƐƉĞĐŝĂůŝƐĂƚŝŽŶ ?dŚĞƌĞĂƐŽŶĐŽƵůĚďĞƚŚĂƚƉŚĂƌŵĂĐŝƐƚƐ ?ƐƉĞĐŝĂůŝƐĂƚŝŽŶƐĂƌĞǇĞƚƚŽďĞ
established in Malaysia. In connection, only a small number of respondents reported having achieved 
a higher degree and would be more likely to specialise in certain fields. Thus, pharmacists with 
ďĂĐŚĞůŽƌ ?ƐĚĞŐƌĞĞ ?ǁŚŽǁĞƌĞƚŚĞŵĂũŽƌŝƚǇŽĨƚŚĞƌĞƐƉŽŶĚĞŶƚƐ ?ŵĂǇďĞŐĞŶĞƌĂůŝƐƚƐƌĂƚŚĞƌƚŚĂŶ
specialists.  
As about internal consistency, very few respondents were found with inconsistent answers. However 
this was only done for four questions.  Four respondents who have reported that reaction involving 
new drug encouraged them to report ADR (question number 12), but in another question (question 
number 19), did not state that reactions involving such should be reported.. Possible reason could be 
that respondents were not sure what type of reactions should be reported. 
 
3.2.8 Strengths and limitations 
The mode of distributing the questionnaire allowed the researcher to personally explain the purpose 
of the survey to the respondents. It also allowed the respondents to interact with the researcher 
when they had questions. This is likely to increase the response rate. 
In this survey, respondents were asked to report their preferred mode of answering future 
questionnaire, allowing planning for the main study. 
However, there is no gold standard to identify or detect an ADE, and observing one is subject to 
individual interpretation and clinical judgement. The ADE definitions given in the questionnaire may 
not be the same as the ones known and used by the pharmacists. Furthermore, the questions did not 
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mention about time frames of an observed ADE (e.g., six months ago or three months ago).  Hence, 
the observed ADE reported by the pharmacists could be, for example, of one observed one year ago 
 W a time frame obsolete enough to make the reported event significantly irrelevant to the research. 
Therefore, in the main study, a time frame will be asked in the questions. 
 
3.2.9 Review of pilot questionnaire and amendments prior to the main survey 
The questions with low completion rate were reviewed for changes prior to the main study. Some 
new questions were added to have a common pattern of questions in all the sections. The following 
amendments were made to the questionnaire: 
1) Percentages of ADR and TF occurring in Malaysia 
Questions that asked about the percentage of ADR and TF occurrences (question numbers 
1a, 1b, and 20) were deleted. There is no data on the occurrences of ADR and TF in Malaysia, 
and these questions will be answered by the respondents based only on their experiences. 
Furthermore, the researcher was not able to compare the answers given with any data. 
These questions were added based on a study conducted in Italy [216], and may not be 
suitable for one that is conducted in Malaysia due to lack of available data for comparison. 
2)  Symptoms of the most recent observed ADR 
Initially, the symptoms of ADRs in question 5 (section A) were derived from the literature 
[216, 232]. Following the pilot study, a longer list was created based on the answers given by 
respondents and the common ADR symptoms listed by MADRAC [287]. 
3) Drug associated with recently observed ADR 
In the pilot study, pharmacists were asked whether or not they have observed any ADR and 
to list down the types of reactions they have observed. However, the drug(s) that were 
associated with the reaction(s) were not asked. It would be useful to know what types of 
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drugs are associated with the reactions observed by the respondents, and whether or not 
respondents working in different settings observe reactions to different types of drugs. Thus 
a new question was added to identify the type of drug(s) associated with the ADR observed 
by respondents. The list of drugs was obtained from MADRAC annual report which has listed 
the type of drugs most commonly reported to them [287]. 
4) Patients reporting ADRs 
Questions about patients reporting ADRs were deleted (question number 7 to 11). Upon 
discussion with supervisors, it was decided so because it was found that they may overlap 
with questions aboƵƚƚŚĞƉŚĂƌŵĂĐŝƐƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐŽĨŽďƐĞƌǀŝŶŐZƐ ?
5)  Therapeutic failure 
Questions that asked about the types of observed TF (question number 22, 23 and 26) were 
deleted.  All three questions had similar answers and in order to identify the reason or cause 
of TF, further investigation need to be done. It is not known whether or not the respondents 
would have been able to conduct further investigations and correctly classify the TF observed 
according to the list. Furthermore, the completion rate for question 23 was less than 90%, 
and this may indicate that respondents were unsure how to answer. Thus, based on 
discussions with supervisors, these questions were deleted. 
The question about the patient group most commonly associated with TF was deleted 
(question number 29). This question was found to be too general as reported by some of the 
respondents. The group of patients most commonly encountered with TF cannot after all, be 
ŐĞŶĞƌĂůŝƐĞĚďĂƐĞĚŽŶƚŚĞƌĞƐƉŽŶĚĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐŽƌŽďƐĞƌǀĂƚŝŽŶ ? 
6) Medication error 
As discussed in chapter 1, ME overlaps with other types of ADEs. The question on whether or 
not respondents have recently observed ME will not be able to provide details on what the 
respondents have actually observed  W it could be a TF or an ADR. For this reason, a list of 
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types of ME was added. This means that not only the different types of MEs observed by 
them may be identified, but this also allows comparisons of types of MEs observed by 
hospital and community pharmacists.  Additional questions about the actions taken in 
response to the observed ME were incorporated to be consistent with other sections. Since 
the questionnaire is designed for both hospital and community pharmacists, all types of ME 
were included in questions about types of MEs observed in the last six months. Thus, the 
types of MEs identified during the chart review study (Chapter 2) are only a small part of this 
list. 
7)  Adverse drug withdrawal syndrome 
Questions asking about ADWS were deleted (question number 30b and 31b). The chart 
review discussed in Chapter 2 did not identify any ADWS and studies found that it is difficult 
to identify and are rare [175, 178]. In addition, the completion rates for these questions in 
the pilot study were less than 90%. Considering all these factors, these questions were 
deleted. 
8)  Drug overdose 
Additional questions about the actions taken as responses to the observed DO were 
incorporated. This is to ensure consistent and similar questions in all sections. 
9)  Time frame 
A time frame was indicated in some questions (question numbers 2, 21 and 30), thus, 
questions about the time frame of recently observed ADEs were deleted (question numbers 
4 and 25). 
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10)  Demographic 
Questions about educational and professional specialisations were deleted (question 
numbers 36a and 37a). Pharmacist specialisation is still new in Malaysia and this was evident 
in the completion rates for these questions which were less than 10%. 
Additional questions were numbered 4, 6, 21, 22, and 26 in the revised questionnaire (Appendix 9). 
The deleted questions were numbered 1a, 1b, 7 to 11, 20 to 25, 29, 36a, and 37a in the pilot 
questionnaire (Appendix 7). 
 
3.2.9.1 Methodological issues 
The content of survey for other health care professionals was also validated by a few doctors, nurses, 
and research supervisors after the pilot study (Appendix 10). Approval was obtained from National 
Institutes of Health, Malaysia to distribute the questionnaire to all health care professionals working 
in the medical wards of the study site where the chart review study took place (Appendix 11). The 
survey was planned to be distributed during a few internal hospital meetings. However, due to lack 
of willingness from the head of department on the day of distribution, it could not be conducted 
(before this day he had given his support for the survey and approved of the said distribution during 
meetings). Approaching health care professionals individually was suggested by the head of 
department, but this was not possible due to time constraints. Thus, the survey was only conducted 
among Malaysian pharmacists. 
 
3.2.10 Main survey population sample 
There are more than 6,000 pharmacists in Malaysia. There are about 2,000 pharmacists registered as 
members of Malaysian Pharmaceutical Society (MPS). MPS stores the contact details of all its 
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members. They consist of 750 (38%) hospital and health clinic pharmacists, 727 (36%) community 
pharmacists, and 523 (26%) working in other sectors such as industrial and education institutions.  
Since this study aims to explore their experiences of ADEs during their daily work activities, 
pharmacists needed to have patient contact to be able to identify or detect it. Industrial pharmacists 
and academics do not usually have direct patient contact in their daily work activities. These 
categories of pharmacists were not included in this study. Thus, all 1477 (74%) hospital, health clinic, 
and community pharmacists were included in the main survey study. 
Based on the findings from the pilot survey, most of the respondents preferred email over post as a 
method of receiving and responding to questionnaires. However, confidentiality constraint meant 
the MPS was not able to provide the researcher with email addresses of all its members. After 
further discussion, the MPS agreed to post the questionnaires on behalf of the researcher. The home 
or office addresses of its members were not given to the researcher but the researcher prepared 
envelopes containing all the documents for the survey. Thereafter, MPS addressed the envelopes 
and posted the survey. 
 
3.2.11 Mailing method 
The questionnaires were given serial numbers ŵĂƚĐŚŝŶŐƚŚŽƐĞŽĨƚŚĞƉŚĂƌŵĂĐŝƐƚƐ ?ƌĞĐŽƌĚƐĂƚDW^
database. The survey packs contained a cover letter explaining the survey (Appendix 12), the 
questionnaire (Appendix 9), and a post-paid return envelope.  
On return of the completed questionnaires, the serial numbers of the questionnaires were entered in 
a mailing database. The serial numbers of non-respondents were then given to the staff at MPS, 
together with a second survey pack which contained the same questionnaire, an edited cover letter, 
(Appendix 13) and a post-paid return envelope. 
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3.3 Data analysis 
Statistical analysis was performed in Predictive Analytics SoftWare (PASW) Statistics 18.0 (© SPSS, 
Inc., 2009, Chicago, IL). 
 
3.3.1 Data cleaning and checking 
The survey questions were coded and all data were entered in PASW. In order to ensure the data 
were entered accurately and completely, frequencies of variables were computed and checked for 
values outside possible ranges. A random five percent of cases (n= 24) were selected and data entry 
for these cases was compared with the data in the questionnaires. Data entry errors were found in 
four questionnaires and cleaned. 
 
3.3.2 Descriptive analysis 
Frequency and percentage tables were used to describe the demographic data of respondents, their 
experiences of ADEs, types of ADEs or drugs, and their ADR-reporting attitudes, and the experiences 
were compared across work setting. Drugs were classified into therapeutic classes and ADR 
symptoms, according to organ systems. The frequency of observing ADEs was categorised into two 
groups: i) observation of one or more ADEs per month (which included ADE-observation of at least 
one per day, per week, or per month) and ii) observation of less than one ADE per month or its 
absence.  
3.3.3 Difference between groups 
The chi-square was used to assess whether or not there was a difference in the response rates of 
pharmacists according to years of work experience and work setting, where appropriate. Differences 
were considered statistically significant when p-value was less than 0.05. 
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3.4 Results - Survey response 
A total of 1477 questionnaires were mailed. Of these, 271 completed questionnaires were returned 
after the first mailing and an additional 202 after the second, giving a total of 472 (32% response) 
returned questionnaires.  Response rate was higher in hospital/ clinic pharmacists compared with 
community pharmacists with 35% and 25% returning the completed questionnaires respectively 
(Table 3-4). No other details about the non-respondents were available. 
Table 3-4 : Response rate according to work settings (n= 1,477) 
Respondents Non-respondents Total 
n = 472 n = 1,036 n = 1,477
Hospital/ clinic pharmacists 259 (34.5) 491 (65.5) 750
Community pharmacists 182 (25.0) 545 (75.0) 727
Number of respondents (%)
 
 
The characteristics of the respondents are shown in Table 3-5. Most respondents (74%, n= 208) were 
women. Most of the hospital or clinic pharmacists (n= 186, 72%) had been in practice for five years or 
less compared with the community pharmacists where majority (n= 162, 89%) had been in practice 
for more than five years  ?ʖ2 = 12.384, p <0.001).  This is attributed to the implementation of a three-
year compulsory service in the public sector for newly graduated pharmacists in 2005. Due to 
shortage of pharmacists at the public sector, freshly graduated pharmacists are placed in public 
hospitals or clinics and must serve the government for three years upon completing a one-year pre-
registration. This approach has led to an influx of young pharmacists to the government hospitals or 
clinics. 
All community pharmacists (n= 180, 100%) reported direct contact with patients compared to 
hospital or clinic pharmacists where 12% (n= 32) reported no direct patient contact  ?ʖ2 = 24.829, p 
<0.001). The nature of work of hospital or clinic pharmacists is diversified. Unlike the community 
pharmacists, not all of them have direct contact with patients. Some are located in departments 
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where little patient contact is possible, for example, the pharmacy stores and department of 
ĞǆƚĞŵƉŽƌĂŶĞŽƵƐƉƌĞƉĂƌĂƚŝŽŶ ?dŚĞƐĞƉŚĂƌŵĂĐŝƐƚƐ ?ũŽďƐĐŚĞĚƵůĞƐĐŚĂŶŐĞƌĞŐƵůĂƌůǇ ?ǁŝƚŚŝŶƚŚƌĞĞƚŽƐŝǆ
months), and although the current department is restricted from direct patient contact, they would 
have had patient contacts in their previous department  W thus, these pharmacists were included in 
the analysis. For the purpose of this study, views of only pharmacists who currently have direct 
ƉĂƚŝĞŶƚĐŽŶƚĂĐƚǁĞƌĞĚĞĞŵĞĚŶĞĞĚĞĚĂŶĚƚŚĞƌĞĨŽƌĞ ?ƚŚĞ ‘ŽƚŚĞƌ ?ŐƌŽƵƉǁĂƐ excluded from further 
analysis. 
Table 3-5: Characteristics of the respondents (n= 472) 
Hospital/ clinic Community Other Total
n= 259 n= 182 n= 29 n= 472
Gender (n= 468
a
)
Male 50 (19.4) 62 (34.3) 9 (31.0) 121 (25.9)
Female 208 (80.6) 119 (65.7) 20 (69.0) 347 (74.1)
Years of work experience (n= 468
a
)
5 years or less 186 (72.1) 19 (10.5) 9 (31.0) 214 (45.7)
More than 5 years 72 (27.9) 162 (89.5) 20 (69.0) 254 (54.3)
Level of education (n= 468
a
)
Bachelor's degree 218 (84.5) 163 (90.1) 28 (96.6) 409 (87.4)
Master's degree 38 (14.7) 17 (9.4) 1 (3.4) 56 (12.0)
Doctorate degree 2 (0.8) 1 (0.6) - 3 (0.6)
Have direct patient contact (n= 438
b
)
Yes 226 (87.3) 180c (100.0) - 406 (92.7)
No 32 (12.4) - - 32 (7.3)
Characteristics
Number of respondents (%)
a 
these groupings do not total 472 due to missing data 
b
 ƌĞƐƉŽŶĚĞŶƚƐĨƌŽŵ ‘ŽƚŚĞƌ ?ŐƌŽƵƉƐŬŝƉƉĞĚ this question, however, this group does not total 439 due to missing 
data  
c 
this group does not total 181 due to missing data 
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3.5 Results - Experiences about adverse drug reactions 
3.5.1 The pharmacists experiences of observing an adverse drug reactions 
Pharmacists were asked to state their experiences of observing ADRs in the last six months (Table 3-
6). About 70% of respondents reported observing ADRs in the said time frame (n= 293, 68%). Seven 
out of ten combined hospital and clinic pharmacists (n= 186, 73%), and six out of ten community 
pharmacists (n= 107, 60%) reported they had observed ADRs in the last six months. Additionally, 
more than 50% of all pharmacists reported to have observed one or more ADR cases per month (n= 
152, 53%) (Table 3-7). 
Table 3-6: Experiences of pharmacists observing ADRs in the last 6 months (n = 439) 
Observed Did not observe any
n= 293 n= 141
Work setting (n= 434
a
)
Hospital/clinic (n= 255) 186 (72.9) 69 (27.1)
Community (n= 179) 107 (59.8) 72 (40.2)
Years of work experience (n= 431
a
)
5 years or less (n= 204) 154 (75.5) 50 (24.5)
More than 5 years (n= 227) 136 (59.9) 91 (40.1)
Level of education (n= 432
a
)
Bachelor's degree (n= 375) 250 (66.7) 125 (33.3)
Postgraduate degree (n= 57) 41 (71.9) 16 (28.1)
Number of respondents (%)
 
a 
these groups do not total 439 due to missing data 
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Table 3-7: Frequency of observing ADRs (n = 293) 
One or more ADR(s) Less than one ADR
n= 152 n= 135
Work setting (n= 287
a
)
Hospital/clinic (n= 183) 102 (55.7) 81 (44.3)
Community (n= 104) 50 (48.1) 54 (51.9)
Years of work experience (n= 285
a
)
5 years or less (n= 153) 81 (52.9) 72 (47.1)
More than 5 years (n= 132) 69 (52.3) 63 (47.7)
Level of education (n= 285
a
)
Bachelor's degree (n= 246) 130 (52.8) 132 (53.7)
Postgraduate degree (n= 39) 24 (61.5) 15 (38.5)
Number of respondents (%)
 
a 
these groups do not total 293 due to missing data 
 
 
3.5.2 Characteristics of adverse drug reactions observed by the pharmacists 
The types of ADRs observed by pharmacists are listed in Table 3-8. The characteristics of the most 
common ADRs they have observed involved dermatology (rash and itchiness), gastrointestinal 
(gastritis and diarrhoea), and central nervous systems (dizziness, headache and giddiness). ADRs 
related to gastrointestinal systems were reported most often by community pharmacists. The 
specific symptoms all responding pharmacists reported observing most often was rash (n= 160, 55%), 
followed by itchiness (n= 138, 47%).  
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Table 3-8: Most recent ADRs observed by the pharmacists (n = 293) 
Hospital/ clinic Community Total
 (n = 186) (n = 107) (n= 293
a
)
Dermatology
Rash 96 (51.6) 64 (59.8) 160 (54.6)
Itchiness 80 (43.0) 58 (54.2) 138 (47.1)
Oedema periorbital 16 (8.6) 18 (16.8) 34 (11.6)
Erythema 13 (7.0) 12 (11.2) 25 (8.5)
Steven Johnson Syndrome 18 (9.7) 6 (5.6) 24 (8.2)
Pemphigus 1 (0.5) - 1 (0.3)
Gastrointestinal system
Gastritis 30 (16.1) 40 (37.4) 70 (23.9)
Diarrhoea 30 (16.1) 31 (29.0) 61 (20.8)
Nausea 24 (12.9) 26 (24.3) 50 (17.1)
Heartburn 12 (6.5) 34 (31.8) 46 (15.7)
Flatulence 16 (8.6) 27 (25.2) 43 (14.7)
Vomiting 22 (11.8) 14 (13.1) 36 (12.3)
Constipation 11 (5.9) 19 (17.8) 30 (10.2)
Other 2 (1.1) - 2 (0.7)
Central nervous system
Dizziness 59 (31.7) 37 (34.6) 96 (32.8)
Headache 58 (31.2) 26 (24.3) 84 (28.7)
Giddiness 55 (29.6) 25 (23.4) 80 (27.3)
Other 7 (3.8) 4 (3.7) 11 (3.8)
Respiratory system
Dry cough 57 (30.6) 49 (45.8) 106 (36.2)
Cough 16 (8.6) 20 (18.7) 36 (12.3)
Other 2 (1.1) 1 (0.3) 3 (1.0)
Cardiovascular system
Oedema 31 (16.7) 25 (23.4) 56 (19.1)
Palpitation 12 (6.5) 22 (20.6) 34 (11.6)
Other 6 (3.2) 1 (0.9) 7 (2.3)
Number of respondents (%)
Symptoms or complications    
according to organ systems*
 
 a 
the total is based on the number of pharmacists who have reported observing an ADRs in the last six months 
(n=293) 
*respondents had the choice to select more than one answer  W as an ADR may present with more than one 
symptom 
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table continued....... 
Table 3-8 continued: Most recent ADRs observed by the pharmacists (n= 293) 
 
Hospital/ clinic Community Total
 (n = 186) (n = 107) (n= 293
a
)
Bones, joints and muscles
Myalgia 19 (10.2) 20 (18.7) 39 (13.3)
Muscle cramps/ rigidity/ weakness 2 (1.1) 1 (0.3) 3 (1.0)
Haematology
Thrombocytopenia 18 (9.7) - 18 (6.1)
Jaundice 8 (4.3) 1 (0.9) 9 (3.1)
Other 2 (1.1) - 2 (0.6)
Endocrinology or metabolic system
Renal failure 15 (8.1) 1 (0.9) 16 (5.5)
Other 5 (2.7) - 5 (1.7)
Liver
Acute hepatitis 13 (7.0) - 13 (4.4)
Elevated liver enzymes 4 (2.2) - 4 (1.4)
Other 6 - 6
Symptoms or complications    
according to organ systems*
Number of respondents (%)
 
a 
the total is based on the number of pharmacists who have reported observing an ADRs in the last six months 
(n=293) 
*respondents had the choice to select more than one answer W as an ADR may present with more than one 
symptom 
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3.5.3 Drugs associated with the observed adverse drug reaction 
Pharmacists were asked to state the drug(s) associated with the most recent ADR they have observed 
and these drugs are listed in Table 3-9. Overall, cardiovascular drugs were the most often reported 
drug group followed by NSAIDs. More than half of the community pharmacists (n= 58, 54%) reported 
perindopril as one of the drugs associated with most recent ADRs whilst less than half of the hospital 
or clinic pharmacists (n= 68, 37%) reported so. Furthermore, four out of ten community pharmacists 
reported observing ADRs associated with diclofenac (n= 46, 43%). A correlation between the drugs 
with suspected ADRs could not be done because both questions were multiple choice questions. 
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Table 3-9: Drugs associated with the most recent suspected ADRs (n = 293) 
Hospital/ clinic Community Total
   (n= 186) (n =107) (n= 293
a
)
Angiotensin-converting 
ezyme inhibitor (ACEI)
Perindopril 68 (36.6) 58 (54.2) 126 (43.0)
Captopril 10 (5.4) 11 (10.3) 21 (7.2)
Otherb 1 (0.5) 3 (2.8) 4 (1.4)
Nonsteroidal Anti-
inflammatory Drug 
(NSAID)
Diclofenac 22 (11.8) 46 (43.0) 68 (23.2)
Mefenamic acid 13 (7.0) 30 (28.0) 43 (14.7)
Paracetamol 8 (4.3) 7 (6.5) 15 (5.1)
Otherb 6 (3.2) 10 (9.3) 16 (5.5)
Antibiotics
Co-trimoxazole 15 (8.1) 10 (9.3) 25 (8.5)
Erythromycin 7 (3.8) 15 (14.0) 22 (7.5)
Amoxicillin 7 (3.8) 13 (12.1) 20 (6.8)
Cloxacillin 8 (4.3) 7 (6.5) 15 (5.1)
Otherb 36 (19.4) 5 (4.7) 41 (14.0)
Calcium channel blocker
Amlodipine 38 (20.4) 38 (35.5) 76 (25.9)
Nifedipine 15 (8.1) 11 (10.3) 26 (8.9)
Felodipine 1 (0.5) - 1 (0.3)
Antiplatelet
Aspirin 31 (16.7) 38 (35.5) 69 (23.5)
Ticlopidine 12 (6.5) 7 (6.5) 19 (6.5)
Number of respondents (%)
Drugs associated with 
the most recent ADRs*
 
a 
the total is based on the number of pharmacists who have reported observing ADRs in the last six months 
(n=293) 
b
 ƚŚĞŶƵŵďĞƌŽĨƌĞƐƉŽŶĚĞŶƚƐǁĂƐůĞƐƐƚŚĂŶƚĞŶĨŽƌĞĂĐŚ ‘ŽƚŚĞƌ ?ĚƌƵŐƐ 
*respondents had the choice to select more than one answer     
table continued........ 
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Table 3-9 continued: Drugs associated with the most recent suspected ADRs (n = 293) 
Hospital/ clinic Community Total
   (n= 186) (n =107) (n= 293
a
)
Hypoglycaemic agent
Metformin 30 (16.1) 34 (31.8) 64 (21.8)
Otherb 6 (3.2) - 6 (2.0)
Traditional medicine
Traditional medicine 25 (13.4) 16 (15.0) 41 (14.0)
Statin
Lovastatin 17 (9.1) 11 (10.3) 28 (9.6)
Otherb 3 (1.6) 5 (4.7) 8 (2.7)
Antigout
Colchicine - 1 (0.9)
Allopurinol 18 (9.7) 13 (12.1) 31 (10.6)
Nitrate
Isosorbide dinitrate 15 (8.1) 5 (4.7) 20 (6.8)
Beta-adrenergic blocker
Atenolol 4 (2.2) 10 (9.3) 14 (4.8)
Metoprolol 1 (0.5) - 1 (0.3)
Biphosphonate
Alendronate 4 (2.2) 10 (9.3) 14 (4.8)
Thiazide
Chlorothiazide 8 (4.3) 3 (2.8) 11 (3.8)
Vaccine
H1N1i vaccine 9 (4.8) - 9 (3.1)
Vaccinec 1 (0.5) - 1 (0.3)
Other
b 66 28 94
Drugs associated with 
the most recent ADRs*
Number of respondents (%)
 
a 
the total is based on the number of pharmacists who have reported observing an ADR during the last six 
months (n=293) 
b
 ƚŚĞŶƵŵďĞƌŽĨƌĞƐƉŽŶĚĞŶƚƐǁĂƐůĞƐƐƚŚĂŶƚĞŶĨŽƌĞĂĐŚ ‘ŽƚŚĞƌ ?ĚƌƵŐƐ 
c
 respondent did not specify the name of the vaccine 
*respondents had the choice to select more than one answer 
i
H1N1- influenza A virus 
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3.5.4 Actions taken in response to observed adverse drug reactions 
While more than 50% (n= 96, 52%) of combined hospital and clinic pharmacists reported sending 
ADR reports to MADRAC in response to most recently observed ADRs, only 3% (n= 3) of community 
pharmacists reported doing so (Table 3-10). Furthermore, more than 40% of the first mentioned 
group of pharmacists (n= 81, 44%) reported sending ADR reporting forms to drug information centres 
of hospitals. Almost half of the same group (n= 89, 48%) have also reported taking the initiative to 
explain to patients about the reactions. However, about eight out of ten community pharmacists (n= 
88, 82%) claimed referring the patients back to their doctors, or explaining to the patients about the 
reactions (n= 83, 78%). They have also reported suggesting to patients to stop taking the drug (n= 59, 
55%), introduced another to relieve the reaction (n= 49, 46%), or suggesting an alternative drug (n= 
41, 38%). In contrast, only a small number of combined hospital and clinic pharmacists have reported 
taking these actions.   
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Table 3-10: Actions taken in response to observed ADRs (n = 293) 
Number of respondents (%)
n =293
a
Explained to patient about the reaction 172 (58.7)
Suggested patient to inform doctor 170 (58.0)
Sent ADR form to MADRAC 99 (33.8)
Suggested patient to stop the medicine 96 (32.8)
EŽƚĞĚŝŶƉĂƚŝĞŶƚ ?ƐĐŚĂƌƚ ?ƌĞĐŽƌĚ 94 (32.1)
Did further evaluation 88 (30.0)
Sent ADR form to hospital DICb 81 (27.6)
Informed the physician in-charge 77 (26.3)
Suggested patient a medicine to relieve the reaction 66 (22.5)
Suggested patient a different medicine 54 (18.4)
Informed the pharmacist in hospital DICb 27 (9.2)
Informed the associated pharmaceutical company 11 (3.8)
Issued an allergy card to patient 13 (4.4)
No action 4 (1.4)
Other action 3 (1.0)
Actions taken*
 
a 
the total is based on the number of pharmacists who have reported observing ADRs in the last six months 
(n=293) 
b
 DIC  W drug information centre 
*respondents had the choice to select more than one answer 
 
The actions taken by pharmacists were further evaluated according to work setting and years of 
experience and are shown in Table 3-11 (only the actions with more than 20% response were 
evaluated). The education level was not cross-tabulated in this evaluation because the number of 
pharmacists under the postgraduate group is small and therefore comparison would not be 
meaningful.  
About 80% of community pharmacists reported suggesting patients to inform their doctors (n=88, 
82%) and/or explained to patient about the reaction (n= 83, 78%), but less than 50% of combined 
hospital and clinic pharmacists reported taking these actions.  Additionally, about 50% of community 
pharmacists suggested patient to stop taking the medicine (n= 59, 55%) and/or suggested another 
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drug to relieve the reaction (n= 49, 46%), whilst less than 30% of the other group of pharmacists did 
so. About half of the hospital and clinic pharmacists reported to have sent an ADR form to MADRAC 
(n=96, 52%) but only three community pharmacists (3%) had done the same.  
More than 50% (n= 79, 51%) of pharmacists who have been in practice for 5 years or less claimed to 
have submitted an ADR form to MADRAC but only 14% (n= 19) of pharmacists who have been in 
practice for more than 5 years reported to have done the same task. Around two-thirds of 
pharmacists who have been in practice for more than 5 years  reported explaining to patient about 
the reaction (n= 92, 68%) and/or suggesting patients to inform their doctors about the ADRs (n= 90, 
66%) compared with around half of those who have been qualified for less time.  
 Table 3-11: Actions taken in response to observed ADRs according to work setting and years of 
experience (n= 293) 
Hospital/clinic Community 5 years or less More than 5 years
(n= 186) (n= 107) (n= 155) (n= 136)
Explained to patient about the reaction 89 (47.8) 83 (77.6) 79 (51.0) 92 (67.6)
Suggested patients to inform their 
doctors 
82 (44.1) 88 (82.2) 78 (50.3) 90 (66.2)
Sent ADR form to MADRAC 96 (51.6) 3 (2.8) 79 (51.0) 19 (14.0)
Suggested patient to stop the medicine 37 (19.9) 59 (55.1) 33 (21.3) 62 (45.6)
EŽƚĞĚŝŶƉĂƚŝĞŶƚ ?ƐĐŚĂƌƚ ?ƌĞĐŽƌĚ 60 (32.3) 34 (31.8) 45 (29.0) 47 (34.6)
Did further evaluation 61 (32.8) 27 (25.2) 49 (31.6) 37 (27.2)
Sent ADR form to hospital DIC 81 (43.5) - 63 (40.6) 17 (12.5)
Suggested patient a medicine to relieve 
the reaction
17 (9.1) 49 (45.8) 18 (11.6) 48 (35.3)
Number of respondents (%)
Actions
Work setting Years of experience
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3.6 Results  W Spontaneous adverse drug reaction reporting 
3.6.1 The pŚĂƌŵĂĐŝƐƚƐ ?ĂǁĂƌĞŶĞƐƐĂďŽƵƚƚŚĞĂĚǀĞƌƐĞĚƌƵŐƌĞĂĐƚŝŽŶƌĞƉŽƌƚing system 
Pharmacists were asked about their experiences of reporting ADRs. More than 80% (n= 220, 86%) of 
combined hospital and clinic pharmacists claimed reporting ADRs but only 14% (n= 36) of community 
pharmacists have ever reported one (Table 3-12). In terms of work experience, more than 80% of 
pharmacists with 5 years or less of this have claimed reporting ADRs, whilst about 70% of 
pharmacists with more than 5 years of experience have claimed to have done otherwise. 
Reporting online was the preferred method for almost 70% of combined hospital and clinic 
pharmacists (n=170, 66%) and 60% of community pharmacists (n= 103, 57%). 
 
Table 3-12: The pharmacists experiences about reporting ADRs (n = 439) 
Reported Never reported
Working setting (n= 437
a
)
Hospital/ clinic (n = 256) 220 (85.9) 36 (14.1)
Community (n = 181) 25 (13.8) 156 (86.2)
Years of work experience  (n= 434
a
)
5 years or less (n = 202) 169 (83.7) 33 (16.3)
More than 5 years (n= 232) 74 (31.9) 158 (68.1)
Level of education (n= 435
a
)
Bachelor's degree (n = 378) 205 (54.2) 173 (45.8)
Postgraduate degree (n =57) 39 (68.5) 18 (31.5)
Number of respondents (%)
Characteristics
 
a  
these groupings do not total 439 due to missing data 
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Almost all the combined hospital and clinic pharmacists (n= 250, 97%) were aware of ADR report 
forms and of these, only 5% (n= 12) were not aware of where to obtain them. Majority obtained the 
forms from a drug information centre at hospitals (n=192, 81%).  
Seven out of ten community pharmacists (n= 131, 72%) were aware of the existence of the said 
report forms, although 36% (n= 46) of these did not know where to obtain them. The remaining said 
population reported to have obtained such from drug information books (n=59, 73%). 
 
3.6.2 Factors that encourage and discourage pharmacists to report an ADR 
Almost all the pharmacists claimed that they are more likely to report ADRs if the reactions are 
severe (n= 418, 95%) (Table 3-13). Moreover, they are more likely to report one if the reaction is 
related to a new drug (n= 345, 79%), unusual or unexpected (n= 331, 75%), not widely known (n= 
320, 73%), or they are certain that the drug had caused the reaction (n= 301, 69%). Similar traits 
were found in factors that discourage ADR reporting: if the reaction is widely known (n= 265, 60%), if 
pharmacists are unsure if the drug indeed had caused the reaction (n= 273, 62%), or if they are 
unsure of the types of reactions that need to be reported (n= 265, 60%). However, almost 80% stated 
that the most common factor discouraging them from reporting an event was the lack of information 
from patients (n= 333, 76%). Additionally, the following reasons were found to discourage four out of 
ten community pharmacists in reporting ADRs: lack of information regarding the regulations and 
procedure for such action (n= 79, 43%), finding it difficult to obtain report forms (n= 77, 42%), and 
that the form was complex to accomplish (n= 83, 46%).  However, only two out of ten combined 
hospital and clinic pharmacists reported facing these difficulties. 
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Table 3-13: Factors that encourage or discourage ADR reporting (n= 439) 
Hospital/ clinic Community Total
(n= 258) (n =181) (n= 439)
Factors encouraging ADR reporting (n= 439)
The high degree of severity of a clinical reaction 249 (96.5) 169 (93.4) 418 (95.2)
The involvement of a newly licensed drug 221 (85.7) 124 (68.5) 345 (78.6)
The specific typology of the reaction (unusual/ 
unexpected)
216 (83.7) 115 (63.5) 331 (75.4)
The reaction is not widely known 211 (81.8) 109 (60.2) 320 (72.9)
An obvious causal relationship with the administration of 
the drug
197 (76.4) 104 (57.5) 301 (68.6)
The explicit request of a pharmaceutical company 65 (25.2) 78 (43.1) 143 (32.6)
Factors discouraging ADR reporting (n= 439)
A lack of information from the affected patient 194 (74.9) 139 (76.4) 333 (75.9)
The uncertainty of a causal relationship with the 
administration of the drug 
150 (57.9) 123 (67.6) 273 (62.2)
Uncertainty regarding the type of reactions to be 
reported 
147 (56.8) 118 (64.8) 265 (60.4)
The reaction is widely known 141 (54.4) 124 (68.1) 265 (60.4)
The low degree of severity of a clinical reaction 121 (46.7) 115 (63.2) 236 (53.8)
A lack of time due to heavy responsibilities 94 (36.3) 67 (36.8) 161 (36.7)
The complexity of the form 69 (26.6) 83 (45.6) 152 (34.6)
A lack of knowledge regarding the regulations and 
procedure for reporting 
57 (22.0) 79 (43.4) 136 (31.0)
The difficulty in obtaining a form 52 (20.1) 77 (42.3) 129 (29.4)
Reporting does not seem worthwhile 55 (21.2) 62 (34.1) 117 (26.7)
The fear of medical legal consequences 43 (16.6) 66 (36.3) 109 (24.8)
A lack of support from organisation/ head of 
department/ colleagues 
61 (23.6) 47 (25.8) 108 (24.6)
Number of respondents (%)
Factors*
*respondents had the choice to select more than one answer 
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3.6.3 Types of adverse drug reactions the pharmacists believe should be reported 
/ŶĨƵůůĂŐƌĞĞŵĞŶƚǁŝƚŚDZ ?ƐƌĞƋƵŝƌĞŵĞŶƚ ?ǁŚŝĐŚƐƚĂ ĞƚŚĂƚĂůůƐƵƐƉĞĐƚĞĚZƐƐŚŽƵůĚďĞ
reported), almost 80% of combined hospital and clinic pharmacists (n= 203, 79%) believe that 
suspected reactions should be reported. However, only half of the community pharmacists believe so 
(n= 90, 50%) (Table 3-14).  Similar to the factors that encourage ADR reporting, more than 80% of the 
pharmacists stated that severe reactions (n= 425, 97%), reactions to new drugs (n= 393, 90%), and 
unexpected or unusual reactions (n= 389, 89%) should be reported.  
 
Table 3-14: The types of ADRs that the pharmacists believe should be reported (n= 439) 
Hospital/ clinic Community Total
(n= 258) (n =181) (n= 439)
Severe reactions 252 (97.7) 173 (95.6) 425 (96.8)
Reactions to new drugs 244 (94.6) 149 (82.3) 393 (89.5)
Unexpected/ unusual reactions 240 (93.0) 149 (82.3) 389 (88.6)
Certain reactions 218 (84.5) 131 (72.4) 349 (79.5)
Teratogenicity phenomena 218 (84.5) 128 (70.7) 346 (78.8)
Reactions to vaccinations 220 (85.3) 103 (56.9) 323 (73.6)
Suspected reactions 203 (78.7) 90 (49.7) 293 (66.7)
Interactions between drugs 144 (55.8) 106 (58.6) 250 (56.9)
Reactions to drugs that have 
been in use for a long time
131 (50.8) 83 (45.9) 214 (48.7)
Mild reactions 139 (53.9) 32 (17.7) 171 (39.0)
Known reactions 111 (43.0) 42 (23.2) 153 (34.9)
Lack of efficacy of a drug due to 
development of newly resistant 
strain
83 (32.2) 62 (34.3) 145 (33.0)
Type of ADRs*
Number of respondents (%) 
 
*respondents had the choice to select more than one answer 
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3.6.4 The pŚĂƌŵĂĐŝƐƚƐ ?ƉĞƌĐĞƉƚŝŽŶĂďŽƵƚƚŚĞĂŝŵƐŽĨŵŽŶŝƚŽƌŝŶŐZƌĞƉŽƌƚƐ 
Almost all pharmacists believe that the purpose of ADR spontaneous reporting system is to measure 
incidence of ADRs (n= 412, 94%) and identify uncommon ADRs (n= 412, 94%) (Table 3-15). 
Furthermore, 80% of them believe that the system is able to identify predisposing factors to ADRs 
(n= 350). More than 30% of the pharmacists believe that the reporting system is able to identify the 
indication for which the drugs are prescribed, which is not an aim of monitoring ADR reports. 
 
Table 3-15: The pharmacists opinion about the aims of monitoring ADRs (n = 439) 
Hospital/ clinic Community Total
(n= 258) (n =181) (n= 439)
To measure the incidence of ADR 242 (93.8) 170 (93.9) 412 (93.8)
To identify uncommon ADR (allergic, 
idiosyncratic, etc)
252 (97.7) 160 (88.4) 412 (93.8)
To identify previously unknown ADR 241 (93.4) 156 (86.2) 397 (90.4)
To maintain a database of ADR 227 (88.0) 152 (84.0) 379 (86.3)
To identify factors predisposing patients to 
ADR
210 (81.4) 140 (77.3) 350 (79.7)
To identify safe drugs 194 (75.2) 130 (71.8) 324 (73.8)
To identify the indication for which the drugs 
are prescribed
78 (30.2) 61 (33.7) 139 (31.7)
Aims*
Number of respondents (%)
 
*respondents had the choice to select more than one answer 
 
 
 
 
Chapter 3 
 
 
181 
 
3.7 Results  W Experiences about therapeutic failure 
3.7.1 The pharmacists experiences of observing therapeutic failures 
When asked about their experiences of observing TFs, about half of the pharmacists from hospitals 
or clinics (n= 132, 52%) and community (n= 101, 56%) reported observing TF-related patients in the 
last six months (Table 3-16). The same is to be said for more than 50% of pharmacists with five years 
or less of work experience, as well as those in practice for more than five years. Similar results were 
ĂůƐŽĨŽƵŶĚŝŶƚŚĞŐƌŽƵƉƐŽĨĚŝĨĨĞƌĞŶƚĞĚƵĐĂƚŝŽŶůĞǀĞůƐ ?ƚŚŽƐĞǁŝƚŚďĂĐŚĞůŽƌ ?ƐĚĞŐƌĞĞĂŶĚ
postgraduate degree).  
Table 3-16: Experiences of pharmacists observing TFs in the last 6 months (n = 439) 
Observed Did not observe any
n= 233 n= 202
Work setting (n= 435
a
)
Hospital/ clinic (n= 256) 132 (51.6) 124 (48.4)
Community (n= 179) 101 (56.4) 78 (43.6)
Years of work experience (n= 429
a
)
5 years or less (n= 202) 108 (53.5) 94 (46.5)
More than 5 years (n= 227) 120 (52.9) 107 (47.1)
Level of education (n= 433
a
)
Bachelor's degree (n= 376) 198 (52.7) 178 (47.3)
Postgraduate degree (n= 57) 34 (59.6) 23 (40.4)
Number of respondents (%)
 
a  
these groups do not total 439 due to missing data 
 
 
More than 70% of pharmacists who observed TF reported observing one or more TF-related patients 
each month (combined hospital and clinic pharmacists, n=94, 74%, community pharmacists, n=73, 
74%).  
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Table 3-17: Frequency of observing TF cases (n= 233) 
One or more case(s) Less than one case
n= 161 n= 66
Work setting (n= 226
a
)
Hospital/ clinic (n= 132) 96 (72.7) 36 (27.3)
Community (n= 105) 75 (71.4) 30 (28.6)
Years of work experience (n= 231
a
)
5 years or less (n= 107) 78 (72.9) 29 (27.1)
More than 5 years (n= 129) 92 (71.3) 37 (28.7)
Level of education (n= 233)
Bachelor's degree (n= 203) 146 (71.9) 57 (28.1)
Postgraduate degree (n= 33) 24 (72.7) 9 (27.3)
Number of respondents (%)
 
 
a  
these groups do not total 233 due to missing data 
 
 
 
 
3.7.2 Characteristics of therapeutic failures as observed by pharmacists 
Seven out of ten pharmacists from hospitals or clinics and community setting reported observing 
cases of TF in patients with diabetes mellitus (n= 180, 77%) and hypertension (n= 159, 68%). Almost 
90% (n= 90, 89%) of the community pharmacists reported observing TFs in patients with diabetes 
mellitus (Table 3-18). The same group have observed TF in pain management (n=63, 62%) more often 
than pharmacists from either hospitals or clinics. 
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Table 3-18: Most recent therapeutic failures observed by pharmacists (n = 233) 
Hospital/ clinic Community         Total
(n= 132) (n= 101) (n= 233
a
)
Diabetes mellitus 90 (68.2) 90 (89.1) 180 (77.3)
Hypertension 82 (62.1) 77 (76.2) 159 (68.2)
Asthma 66 (50.0) 42 (41.6) 108 (46.4)
Antibiotic therapy 50 (37.9) 46 (45.5) 96 (41.2)
Pain management 29 (22.0) 63 (62.4) 92 (39.5)
Other cardiovascular disease 36 (27.3) 17 (16.8) 53 (22.7)
Epilepsy 20 (15.2) 5 (5.0) 25 (10.7)
Renal failure 17 (12.9) 2 (2.0) 19 (8.2)
Cancer 11 (8.3) 4 (4.0) 15 (6.4)
HIVi/ AIDSii therapy 11 (8.3) - 11 (4.7)
Tuberculosis 8 (6.1) - 8 (3.4)
Weight management - 2 (2.0) 2 (0.9)
Antiplatelet/ anticoagulant therapy 2 (1.5) - 2 (0.9)
Psychiatric disorder 2 (1.5) - 2 (0.9)
Cough and cold management 1 (0.8) 1 (1.0) 2 (0.9)
Antifungal therapy - 1 (1.0) 1 (0.4)
Gastritis 1 (0.8) - 1 (0.4)
Hormone replacement therapy 1 (0.8) - 1 (0.4)
Migraine - 1 (1.0) 1 (0.4)
Ear, nose and throat disorder - 1 (1.0) 1 (0.4)
Skin disease - 1 (1.0) 1 (0.4)
Disease-modifying antirheumatic drug therapy 1 (0.8) - 1 (0.4)
Number of respondents (%)
Medical condition or therapy*
a 
the total is based on the number of pharmacists who have observed a patient with therapeutic failures in the 
last six months (n= 233) 
*respondents had the choice to select more than one answer 
i
HIV- Human Immunodeficiency Virus; AIDS- Acquired Immunodeficiency Syndrome 
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3.7.3 Actions taken in response to observed therapeutic failures 
Counselling patients on how to consume or use their drugs (n= 199, 85%) and/or the importance of 
adherence (n= 180, 77%) were the actions reported taken by more than 70% of the pharmacists in 
response to observed cases of TF (Table 3-19).  
 
Table 3-19: Actions taken by pharmacists in response therapeutic failures (n = 233) 
Number of respondents
(n= 233
a
)
Counsel the patient the right way to use/ 
consume their medicines
199 (85.4)
Explained to patient/ family member about the 
importance of adherence to medicines
180 (77.3)
Did further evaluation 136 (58.4)
Suggested patients to inform their physicians 133 (57.1)
Informed the physician in-charge 87 (37.3)
EŽƚĞĚŝŶƉĂƚŝĞŶƚ ?ƐĐŚĂƌƚ ?ƌĞĐŽƌĚ 79 (33.9)
Suggested patient a different medicine 46 (19.7)
No action 2 (0.9)
Counsel the patient about diet and lifesytle 
modification
1 (0.4)
Follow-up patient through medicines 
reconcilation
1 (0.4)
Actions taken*
  
a 
the total is based on the number of pharmacists who have observed a patient with therapeutic failures in the 
last six months (n= 233) 
*respondents had the choice to select more than one answer 
 
 
Further evaluation was conducted according on the questions which gathered more than 20% 
response, according to work setting and years of experience. Cross-tabulation of level of education 
with the actions taken was not conducted because of small number of respondents in the 
postgraduate group (Table 3-20).  The table shows that more than 70% of the pharmacists, 
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regardless of their number of years of practice or work setting have counselled their patients on the 
right way to use or consume their medicines and/or explained to them and their family members the 
importance of adherence. Meanwhile, nine out of ten community pharmacists reported referring the 
patients back to their physicians (n= 87, 86%), whilst 60% of the combined pharmacists from either 
clinic or hospital reported communicating to the physicians-in-charge about the patient (n= 79, 60%). 
Of pharmacist who have been in practice for 5 year or more 76% reported suggesting to patients that 
they inform their physicians about the ADE compared with 38% of those with less experience. More 
than half of the latter group of pharmacists reported informing the physicians-in-charge of the 
observed TF cases while only 23% of those with more than 5 years of practice reported taking the 
same action. 
Table 3-20: Actions taken in response to observed TFs according to years of work experience and 
work setting (n= 233) 
Hospital/ clinic Community 5 years or less More than 5 
years
(n= 127) (n= 101) (n= 108) (n= 120)
Counsel the patient the right way to 
use/ consume their medicines
109 (82.6) 90 (89.1) 94 (87.0) 105 (87.5)
Explained to patient/ family member 
about the importance of adherence to 
medicines
98 (74.2) 82 (81.2) 87 (80.6) 93 (77.5)
Did further evaluation 82 (62.1) 54 (53.5) 62 (57.4) 71 (59.2)
Suggested patients to inform their 
physicians
46 (34.8) 87 (86.1) 41 (38.0) 91 (75.8)
Informed the physician in-charge 79 (59.8) 8 (7.9) 60 (55.6) 27 (22.5)
Noted in patient's chart/record 52 (39.4) 27 (26.7) 38 (35.2) 40 (33.3)
Number of respondents (%)
Work setting Years of experience
Actions taken
 a  
this group does not total 199 due to missing data 
b 
this group does not total 136 due to missing data 
c  
this group does not total 133 due to missing data 
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3.8 Results  W Experiences about medication errors 
3.8.1 The pharmacists experiences of observing medication errors 
More than 60% of pharmacists reported having observed medication errors in the last six months 
(Table 3-21). Of these, eight out of ten were hospital or clinic pharmacists (n= 204, 71%). Whilst 75% 
(n= 152) of the hospital or clinic pharmacists reported observing more than one ME in a month, only 
36% (n= 30) of community pharmacists reported the same (Table 3-22).  
 
Table 3-21: Experiences of pharmacists observing ME cases in the last six months (n = 439) 
Observed Did not observe any
n= 289 n= 147
Work setting (n= 435
a
)
Hospital/ clinic (n= 258) 204 (79.1) 54 (20.9)
Community (n= 178) 85 (47.8) 93 (52.2)
Years of work experience (n= 433
a
)
5 years or less (n= 230) 132 (57.4) 98 (42.6)
More than 5 years (n= 203) 155 (76.4) 48 (23.6)
Level of education (n= 434
a
)
Bachelor's degree (n= 377) 246 (65.3) 131 (34.7)
Postgraduate degree (n= 57) 42 (73.7) 15 (26.3)
Number of respondents (%)
 
a  
these groups do not total 439 due to missing data 
 
 
About 80% of pharmacists with more than 5 years of experience reported observing MEs in the last 
six months (n= 155, 76%), with more than half of these pharmacists observing less than one ME in a 
month (n= 71, 54%). Conversely, 78% of 132 pharmacists with 5 years or less experience (who 
reported to have observed MEs in the last 6 months), observed more than one ME in each month.  
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Table 3-22: Frequency of observing MEs (n= 289) 
One or more ME(s) Less than one ME
n= 183 n= 106
Work setting (n= 286
a
)
Hospital/ clinic (n= 202) 152 (75.2) 50 (24.8)
Community (n= 84) 30 (35.7) 54 (64.3)
Years of work experience (n= 287
a
)
5 years or less (n= 155) 121 (78.1) 34 (21.9)
More than 5 years (n= 132) 61 (46.2) 71 (53.8)
Level of education (n= 288
a
)
Bachelor's degree (n= 246) 151 (61.4) 95 (38.6)
Postgraduate degree (n= 42) 31 (73.8) 11 (26.2)
Number of respondents (%)
 
a  
these groups do not total 289 due to missing data 
 
3.8.2 Characteristics of medication errors observed by the pharmacists 
Prescribing errors (n= 241, 83%) was reported as being the most recent error observed by more than 
80% of pharmacists followed by dosage error (n= 183, 63%) (Table 3-23). A higher percentage of 
hospital or clinic pharmacists than community pharmacists reported observing errors related to 
dosage form (n= 48, 24%), administration technique (n= 44, 22%), drug preparation (n= 36, 18%), and 
route of administration (n= 27, 13%). 
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Table 3-23: Most recent types of errors observed by the pharmacists (n = 289) 
Hospital/ clinic Community Total
(n = 204) (n = 85) (n = 289
a
)
Prescribing error 185 (90.7) 56 (65.9) 241 (83.4)
Dosage error 136 (66.7) 47 (55.3) 183 (63.3)
Omission error 94 (46.1) 14 (16.5) 108 (37.4)
Wrong time error 68 (33.3) 31 (36.5) 99 (34.3)
Monitoring error 60 (29.4) 23 (27.1) 83 (28.7)
Unauthorised drug error 50 (24.5) 16 (18.8) 66 (22.8)
Dosage form error 48 (23.5) 14 (16.5) 62 (21.5)
Administration technique 
error
44 (21.6) 15 (17.6) 59 (20.4)
Drug preparation error 36 (17.6) 4 (4.7) 40 (13.8)
Route of administration error 27 (13.2) 8 (9.4) 35 (12.1)
Deteriorated drug error 19 (9.3) 12 (14.1) 31 (10.7)
Compliance error 1 (0.5) - 1 (0.3)
Labelling error 1 (0.5) - 1 (0.3)
Storage error 1 (0.5) - 1 (0.3)
Types of error*
Number of respondents (%)
 
a 
the total is based on the number of pharmacists reported observing MEs in the last six months (n =289) 
*respondents had the choice to select more than one answer 
 
 
 
3.8.3 Actions taken in response to observed medication errors 
The most common actions taken by pharmacists in response to MEs were correcting the error (n= 
190, 66%) and/or informing the physicians-in-charge (n= 189, 65%) (Table 3-24). Only 30% of the 
pharmacists made incident reports or records of observed MEs (n= 88, 30%). 
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Table 3-24: Actions taken by the pharmacists in response to observed medication errors (n = 289) 
Number of respondents (%)
(n =289
a
)
Corrected the error 190 (65.7)
Informed the physician in-charge 189 (65.4)
Explained to patient about the error 124 (42.9)
Suggested ways to minimise the error 115 (39.8)
Suggested patient to inform their doctors 105 (36.3)
Made an incident report/ record 88 (30.4)
Informed the nurse in-charge 77 (26.6)
EŽƚĞĚŝŶƉĂƚŝĞŶƚ ?ƐĐŚĂƌƚ ?ƌĞĐŽƌĚ 72( 24.9)
No action 3 (1.0)
Inform all staff involved 1 (0.3)
Further evaluation 1 (0.3)
Change to a different drug 1 (0.3)
Actions taken*
 
a 
the total is based on the number of pharmacists who reported observing MEs in the last six months (n= 289) 
*respondents had the choice to select more than one answer 
 
 
 
While most of the hospital and clinic pharmacists reported communicating with physicians-in-charge 
about the error (n= 170, 83%) and/or correcting the error (n= 137, 67%), most of the community 
pharmacists reported explaining to patients about the error (n= 70, 82%) and/or suggesting that 
patients inform their doctor (n= 61, 72%) (Table 3-25). Only 27% (n= 54) of hospital and clinic 
pharmacists reported explaining to patients about the error. Meanwhile, more than 40% (n= 86, 
42%) of hospital and clinic pharmacist reported making incident reports or recording the observed 
MEs compared with only 2% (n=2) of community pharmacists who did the same. 
 Most of the pharmacists with 5 years or less work experience reported communicating with 
physicians-in-charge about the error (n= 130, 84%), compared with only 43% of those with more than 
5 years of work experience. Conversely, 60% of pharmacists with more than 5 years of experience 
claimed explaining to patients about the error (n= 79, 60%), while only 29% of those with 5 years or 
less work experience reported so (n= 45, 29). 
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Table 3-25: Actions taken in response to observed MEs according to work setting and years of work 
experiences (n= 289) 
Hospital/ clinic Community 5 years or less More than 5 
years
(n= 204) (n= 85) (n= 155) (n= 132)
Corrected the error 137 (67.2) 53 (62.4) 103 (66.5) 87 (65.9)
Informed the physician in-charge 170 (83.3) 19 (22.4) 130 (83.9) 57 (43.2)
Explained to patient about the error 54 (26.5) 70 (82.4) 45 (29.0) 79 (59.8)
Suggested ways to minimise the 
error
82 (40.2) 33 (38.8) 56 (36.1) 57 (43.2)
Suggested patient to inform their 
doctors
44 (21.6) 61 (71.8) 43 (27.7) 61 (46.2)
Made an incident report/ record 86 (42.2) 2 (2.4) 51 (32.9) 34 (25.8)
Informed the nurse in-charge 75 (36.8) 2 (2.4) 54 (34.8) 24 (18.2)
Noted in patient's chart/record 61 (29.9) 11 (12.9) 43 (27.7) 28 (21.2)
Actions taken
Number of respondents (%)
Years of experienceWork setting
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3.9 Results  W Experiences about drug overdoses 
3.9.1 The pharmacists ? experiences of observing drug overdoses 
Of 439 pharmacists who responded to the survey, only 32% (n= 138, 31.4%) reported having 
observed patients with drug overdose in the last six months (Table 3-26). This was lower than the 
percentages of pharmacists who reported having observed ADRs, TFs or MEs.  
 
Table 3-26: Experiences of pharmacists observing DOs in the last six months (n = 439) 
Observed Did not observe any
n= 139 n= 295
Work setting (n= 434
a
)
Hospital/ clinic (n= 254) 87 (34.3) 167 (65.7)
Community (n= 180) 52 (28.9) 128 (71.1)
Years of work experience (n= 433
a
)
5 years or less (n= 200) 67 (33.5) 133 (66.5)
More than 5 years (n= 231) 71 (30.7) 160 (69.3)
Level of education (n= 434
a
)
Bachelor's degree (n= 376) 122 (32.4) 254 (67.6)
Postgraduate degree (n= 56) 17 (30.4) 39 (69.6)
Number of respondents (%)
 
a  
these groups do not total 439 due to missing data 
 
 
About 60% of the hospital and clinic pharmacists (n= 52, 61%) and almost 60% of community 
pharmacists (n= 30, 58%), who reported having observed DOs reported encountering less than one 
patient with DO in a month (Table 3-27). Whilst more than 50% of pharmacists with 5 years or less 
work experience reported observing one or more patient with DO in a month (n= 44, 54.3%), 53% of 
pharmacists with more than 5 years of work experience reported observing less than one patient 
with DO in a month (n= 30, 52.6%). 
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Table 3-27: Frequency of observing DO cases 
One or more case(s) Less than one case
n= 57 n= 82
Work setting (n= 138
a
)
Hospital/ clinic (n= 86) 34( 39.5) 52 (60.5)
Community (n= 52) 22 (42.3) 30 (57.7)
Years of work experience (n= 138
a
)
5 years or less (n= 81) 44 (54.3) 37 (45.7)
More than 5 years (n= 57) 27 (47.4) 30 (52.6)
Level of education (n= 139)
Bachelor's degree (n= 122) 51 (41.8) 71 (58.2)
Postgraduate degree (n= 17) 6 (35.3) 11 (64.7)
Number of respondents (%)
 
a  
these groups do not total 139 due to missing data 
 
 
3.9.2 Drugs associated with observed drug overdoses 
Almost 70% of community pharmacists reported having observed cases of DO associated with 
analgesics (n= 36, 69%) (Table 3-28). This was followed by cough and cold drugs (n= 52, 37%) and 
vitamin, mineral, or food supplement (n= 38, 27%). In contrast, only 36% (n= 31) of hospital or clinic 
pharmacists reported having observed events of DO associated with analgesics, followed by cough 
and cold drugs (n= 23, 26%), and anti-infectives (n= 23, 26%).  
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Table 3-28: Types of drugs associated with DOs as observed by the pharmacists (n = 139) 
Hospital/ clinic Community Total
(n= 87) (n =52) (n= 139
a
)
Analgesic 31 (35.6) 36 (69.2) 67 (48.2)
Cough and cold medication 23 (26.4) 29 (55.8) 52 (37.4)
Anti-infective 23 (26.4) 15 (28.8) 38 (27.3)
Cardiovascular drug 20 (23.0) 4 (7.7) 24 (17.3)
Vitamin/ mineral/ food supplement 7 (8.0) 17 (32.7) 24 (17.3)
Respiratory drug 13 (14.9) 8 (15.4) 21 (15.1)
Psychiatric drug 14 (16.1) 3 (5.8) 17 (12.2)
Topical agent 1 (1.1) 14 (26.9) 15 (10.8)
Gastrointestinal drug 5 (5.7) 10 (19.2) 15 (10.8)
Anti-epileptics 13 (14.9) - 13 (9.4)
Mixed drugsi 9 (10.3) 2 (3.8) 11 (7.9)
Herbal remedies 2 (2.3) 4 (7.7) 6 (4.3)
Hormones - 3 (5.8) 3 (2.2)
Anti-diabetic 2 (2.3) 1 (1.9) 3 (2.2)
Central nervous system drug 2 (2.3) - 2 (1.4)
Vaccines 2 (2.3) - 2 (1.4)
Cytotoxic drugs 1 (1.1) - 1 (0.7)
Recreational drugs 1 (1.1) - 1 (0.7)
Bisphosphonate 1 (1.1) - 1 (0.7)
Steroid 1 (1.1) - 1 (0.7)
Number of respondents (%)
Drug group*
 
a
 the total is based on the number of pharmacists who reported observing patients with drug overdose in the 
last six months (n= 139) 
*respondents had the choice to select more than one answer 
i
mixed drugs  W a combination of more than one drug from different drug classes 
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3.9.3 Actions taken in response to observed DOs 
The most common action taken by pharmacists in response to the observed DOs was informing the 
physicians- in-charge (n= 79, 56.8%) (Table 3-29). In terms of work setting, most of the hospital or 
clinic pharmacists (n= 70, 80%) reported informing the physicians-in-charge regarding the DO, whilst 
40% (n= 21) of community pharmacists reported referring the patients to hospitals. While 30% (n= 
24, 28%) of hospital or clinic pharmacists claimed making incident reports or records, only two (4%) 
community pharmacists reported making such. However, only a small number of pharmacists 
reported counselling the patient on the correct dose and proper use of drug (n= 12, 9%), or 
contacting the national poison centre for clarification (n= 6, 4%). Comparisons between levels of 
education and years of work experience were not done because of small number of respondents in 
each group. 
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Table 3-29: Actions taken by pharmacists in response to observed DOs (n = 139) 
Hospital/ clinic Community Total
(n= 87) (n =52) (n= 139
a
)
Informed the physician in-charge 70 (80.5) 9 (17.3) 79 (56.8)
EŽƚĞĚŝŶƉĂƚŝĞŶƚ ?ƐĐŚĂƌƚ ?ƌĞĐŽƌĚ 22 (25.3) 16 (30.8) 38 (27.3)
Referred patient to a hospital 7 (8.0) 21 (40.4) 28 (20.1)
Made an incident report/ record 24 (27.6) 2 (3.8) 26 (18.7)
Suggested an antidote 17 (19.5) 2 (3.8) 19 (13.7)
Counselled patient on the correct dose/ proper use 
of  a drug
3 (3.4) 9 (17.3) 12 (8.6)
No action 4 (4.6) 8 (15.4) 12 (8.6)
Call national poison centre to clarify about the effects 
of drug overdoses
5 (5.7) 1 (1.9) 6 (4.3)
Suggest patient to inform doctor - 4 (7.7) 4 (2.9)
Monitor patient through therapeutic drug 
monitoring
2 (2.3) - 2 (1.4)
Suggest patient to stop medication - 2 (3.8) 2 (1.4)
Suggest to doctor to reduce the dose 1 (1.1) - 1 (0.7)
Treat symptoms - 1 (1.9) 1 (0.7)
Actions taken*
Number of respondents (%)
a 
the total is based on the number of pharmacists who reported having observed DOs in the last six months (n= 
139) 
*respondents had the choice to select more than one answer 
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3.10 Discussion 
3.10.1 Key findings and comparisons with other studies 
At least half of the pharmacists reported having observed ADRs, MEs, and/or TFs in the last 6 months 
but less than half reported having observed DOs. Further evaluation showed that different groups of 
pharmacists (depending on work setting and/ or years of practice) reported having observed 
different types of ADEs. These are discussed in the following paragraphs. 
More than 70% of hospital and clinic pharmacists reported having observed ADRs and MEs in the last 
6 months where, 80% of those who observed ADRs and 73% of those who observed MEs, have 
practised for 5 years or fewer. Thus, a logical explanation for the high percentage of pharmacists 
from this group could be due to the implementation of the three-year compulsory service in the 
public sector for newly graduated pharmacists (where they work in either a hospital or a clinic). This 
has increased the number of pharmacists in the public sector, and one of the requirements for their 
training during these three years is to identify and report at least 10 ADR cases each year. Parallel to 
these findings, the number of reports received by MADRAC has also increased since the 
implementation of this three-year compulsory service  W an almost 200% increase in reports between 
2006 to 2011 [20]. Discussion with a pharmacist from MADRAC revealed this compulsory service as 
one of the main reasons for the increase in reports and this was evident in this survey, where almost 
90% of the pharmacists who have practised for five years or less, claimed to have reported ADRs to 
MADRAC.  A high percentage of hospital and clinic pharmacists observing MEs is expected, as it is 
one of their routines to receive and screen prescriptions before dispensing medication to patients. 
While screening, it is their responsibility to identify and rectify the prescribing and legal errors. 
Out of 182 community pharmacists who have responded to this survey, 60% reported having 
observed ADRs whilst 56% reported observing TFs in the last 6 months. Additionally, almost 50% 
reported having observed MEs. It is an interesting finding as community pharmacists do not receive 
as many prescriptions as pharmacists in other countries. A study in Malaysia found that community 
pharmacists fill an average of 1.8 prescriptions per day [288]. This is because community pharmacists 
in Malaysia do not have dispensing rights  W ƚŚĞƚƌĂĚŝƚŝŽŶĂů ‘ĚŝƐƉĞŶƐŝŶŐƉƌĞƐĐƌŝďĞƌƐ ?ĂƌĞƐƚŝůůŝŶƉƌĂĐƚŝĐĞ
and community pharmacists have little involvement with dispensing of prescription medicines.  The 
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events claimed seen by these pharmacists could have bĞĞŶƉĂƚŝĞŶƚƐ ?ĐŽŵƉůĂŝŶƚƐĂďŽƵƚƚŚĞŝƌ
medication, or perhaps the small numbers of prescriptions that they receive do come with errors. 
Furthermore the errors could also been due to OTC medicines. It is a limitation of this survey that the 
number of prescriptions received by the pharmacists responding to this survey was not identified to 
justify this finding. However, 54% of these pharmacists reported that the ADRs observed were 
associated with perindopril and 43%, with diclofenac. These indicate that ADRs seen by community 
pharmacists not only were associated with prescribed medicines but also over-the-counter (OTC) 
medicines which could explain the high percentage of them observing ADRs. Unlike other countries, 
most community pharmacists in Malaysia provide disease monitoring services such as screening 
ƉĂƚŝĞŶƚƐ ?ďůŽŽĚƉƌĞƐƐƵƌĞ ?ďůŽŽĚŐůƵĐŽƐĞĂŶĚďůŽŽĚĐŚŽůĞƐƚĞƌŽůůĞǀĞůƐ ?tŚŝůƐƚƉƌŽǀŝĚŝŶŐƚŚĞƐĞƐĞƌǀŝĐĞƐ
to patients, it is likely that they encounter patients with poor control of their medical conditions and 
thus, report on observing TF cases. 
At least 30% of the pharmacists reported having observed cases of DO in the last 6 months. It is 
acceptable that hospital and clinic pharmacists are able to observe events of DO since these cases 
are regularly admitted to hospitals for medical attention. It was anticipated that community 
pharmacists would observe less DO compared with those working in the hospital setting, however a 
similar percentage of community pharmacists reported observing DOs. These DOs are likely to be less 
severe that those seen in the hospital. Perhaps, one limitation of the survey was that it did not ask 
about the severity of cases the respondents have witnessed. Although DO was defined in the 
questionnaire, it was still subject to individual interpretation of the pharmacists, thereby, affecting 
the way they classify the cases.  
The following sections discuss experiences of pharmacists with different types of ADEs and the 
actions taken in response to these observed events. 
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3.10.1.1 Adverse drug reaction 
More than half of the pharmacists who imparted having had observed ADRs in the last six months did 
so one or more times in each one month. This finding is similar with that of Vessal et al. [215] in a 
study of knowledge, attitude, and perceptions of pharmacists to ADRs in Iran. In this study, 73% of 
pharmacists reported that they have noticed an ADR during their daily work routines. However, 
majority of the pharmacists (90%) were community pharmacists. Similarly, another study by Irujo et 
al., [220] in Spain reported almost all pharmacists in their study have detected ADRs at least once in 
their professional life. These two studies did not state how frequently they noticed ADRs, however, 
the findings do suggest that pharmacists are capable of recognising and identifying ADRs in their 
work setting. 
 In response to the observed ADRs, most hospital or clinic pharmacist in this study claimed they made 
ADR reports.  Community pharmacists, on the other hand, tend to refer the patients to their 
physicians which was also reported in a Spanish study of factors influencing ADR-reporting among 
community pharmacists [220]. The number of prescriptions received by community pharmacists in 
Malaysia is small [288] However, when patients report symptoms that the pharmacists attribute to 
potential ADRs and they think the patients need to take action, referring them to their physician is a 
reasonable course of action if there is no immediate need for medical intervention. It is reassuring 
that the results show that more than 70% of community pharmacists discussed the reaction with 
their patients.  Similarly, a German survey of drug-related problems identified by community 
pharmacists cited that 37% of the community pharmacists solve these problems by consulting with 
patients [194].  
In common with the report from MADRAC, it was found that reactions involving dermatological, 
gastrointestinal, and central nervous systems were the most often reported ADRs [241]. 
Furthermore, in both 2007 and 2008, perindopril was the drug with the highest number of ADR 
reports sent to MADRAC [287]. Incidentally, this was the drug most often reported by pharmacists in 
this survey as associated with ADRs. Furthermore, in common with other studies, cardiovascular 
drugs [72, 135, 136] and NSAIDs [71, 85, 124, 135, 140] were also frequently associated with ADRs. 
This is in contrast with the finding from the chart review study (Chapter 5) where antidiabetics were 
found instead, to be the most common drug associated with ADRs. However, the chart review study 
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had only identified ADR-related admissions whilst the ADRs in the survey were gathered from 
pharmacists working in various departments and work settings.  
 
3.10.1.2 Spontaneous ADR reporting 
Findings from the survey show that majority of the hospital or clinic pharmacists are actively involved 
in reporting ADRs. This is evident in the MADRAC bulletin where majority of reports received by 
MADRAC in 2010 were from hospital pharmacists working in the public sectors [20]. Only a small 
percentage of community pharmacists in this survey claimed to have ever reported ADRs even 
though many were aware of the existence of report forms and where to obtain them. Similar findings 
were also found in other studies [215, 220, 222, 229].  However, more than 40% of community 
pharmacists reported difficulty in obtaining the forms and its complexity. They have also reported 
that they lack knowledge regarding the regulations and procedure for reporting. These setbacks they 
expressed were also reported in a qualitative Malaysian study of barriers and facilitators to reporting 
of ADRs among community pharmacists [226]. Compared with community pharmacists, the ones in 
the hospitals or clinics in Malaysia have the advantage of receiving up-to-date information on ADR- 
reporting and obtaining report forms from the drug information centre located in almost all the 
public hospitals.  
Pharmacists reported that they were more likely report a reaction if such was severe, not widely 
known, unusual, involved a newly marketed drug, or that there was an obvious causal relationship 
with the drug. Lack of information from affected patients was the major barrier to reporting ADRs. 
Widely known reactions and uncertainty about a causal relationship or the types of ADRs to be 
ƌĞƉŽƌƚĞĚŚĂǀĞĚŝƐĐŽƵƌĂŐĞĚƉŚĂƌŵĂĐŝƐƚƐĨƌŽŵƌĞƉŽƌƚŝŶŐZƐ ?dŚĞĨŝŶĚŝŶŐƐ ‘ƌĞĂĐƚŝŽŶŝƐǁĞůůŬŶŽǁŶ ?
ĂŶĚ ‘ƵŶĐĞƌƚĂŝŶŽĨƚŚĞĂƐƐŽĐŝĂƚŝŽŶďĞƚǁĞĞŶƚŚĞƌĞĂĐƚŝŽŶĂŶĚƚŚĞĚƌƵŐ ?ĂƐďĂƌƌŝĞƌƐƚŽƌĞƉŽƌƚŝŶŐZƐ
were similar with other studies [215, 220, 221, 223, 225, 228]. This shows that pharmacists are still 
not confident and sure of what need to be reported, indicating the need for education on these 
aspects. 
It is a matter of concern that more than 90% of the pharmacists believe that the purpose of 
monitoring ADR reports is to measure incidence of ADRs. The ADR reporting system is unsuitable for 
measuring the incidence due to incomplete numerators (number of ADR reports) and denominators 
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(number of patients exposed to a drug). A few studies have reported this misunderstanding by health 
care professionals [215, 216]. However, the main purposes of monitoring ADRs are also correctly 
reported by more than 80% of the pharmacists: to identifǇ ‘ƵŶĐŽŵŵŽŶZƐ ?ĂŶĚƉƌĞǀŝŽƵƐůǇ
ƵŶŬŶŽǁŶŽŶĞƐĂŶĚ ‘ŵĂŝŶƚĂŝŶĂĚĂƚĂďĂƐĞŽĨZƐ ?DŽƌĞƚŚĂŶ ? ?A?ŽĨƚŚĞƉŚĂƌŵĂĐŝƐƚƐďĞůŝĞǀĞƚŚĂƚ
ADR reports are able to identify the indication for which the drugs are prescribed. This shows that 
either these pharmacists lack knowledge on the process of pharmacovigilance or they have 
misinterpreted the statement. However, this highlights the need for more education in ADR 
reporting systems and pharmacovigilance for pharmacists.  
 
3.10.1.3 Therapeutic failure 
More than 70% of the pharmacists who reported to have observed TFs in the last six months, 
revealed monthly encounters with one or more of its patients. This shows that the occurrence of TF 
was high. Its prevalence was also found to be high in the chart review study (Chapter 2  W Section 
2.3.4). Other studies have also quoted that cases of TF was very common [63, 146]. 
The finding from this specific survey revealed that TF was common in patients with diabetes mellitus 
and hypertension. Studies in Malaysia have also highlighted that prevalence of hypertension and 
diabetes are on the rise, and 80% of the patients have poor control of their medical conditions [33, 
34]. Adding to this, the National Health and Morbidity Survey III cited that hypertension and diabetes 
mellitus were two of the top four chronic medical conditions in Malaysia [260]. 
The actions reported taken by almost all pharmacists (counselling the patients as to the use of their 
drugs and the importance of medication adherence) indicated that most of these TFs are caused by 
ƉĂƚŝĞŶƚƐ ?ƉŽŽƌĂĚŚĞƌĞŶĐĞƚŽĚƌƵŐƐĂŶĚůĂĐŬŽĨŬŶŽǁůĞĚŐĞŽĨƚŚĞŵ ?Similar causes were also reported 
by other studies [143, 146, 152, 153, 289]. This finding also showed that the pharmacists were 
actively involved in patient counselling and in connection, a study by Westerlund et al. [115] showed 
that interventions by community pharmacists were able to reduce or prevent the occurrence of 
adverse drug events [6, 290]. 
Almost 90% of the community pharmacists reported suggesting to patients with suspected TF to 
inform their physician. Where the pharmacists think the patient needs their treatment reviewed to 
Chapter 3 
 
 
201 
 
address the TF, this would be an appropriate course of action for the patient (where there is not an 
immediate need for medical intervention).  
 
3.10.1.4 Medication error 
About 80% of the hospital or clinic pharmacists reported having observed MEs in last six months and 
of these, 75% claimed encountering one or more MEs in a month. In contrast, only less than half of 
the community pharmacists reported having observed one. A high percentage of both groups of 
pharmacists reported of having observed prescribing errors most recently. In response to these 
observed errors, 83% of the hospital or clinic pharmacists claimed to have informed the physicians- 
in-charge, whilst 82% of the community pharmacists explained the errors to the patients. While 22% 
of community pharmacists contacted their physicians, more than 70% on the other hand, resorted to 
suggesting that patients inform their doctors.  Furthermore, less than half of the hospital or clinic 
pharmacists and less than 10% of the community pharmacists claimed to have reported or recorded 
the incidences. 
The specific finding of community pharmacists having observed MEs less commonly was similar with 
a UK-based  investigation of prescribing errors and other problems reported by pharmacists [291]. 
Howver, studies conducted in Germany and Sweden [115, 194] revealed otherwise.  
In common with other studies [147, 292, 293], prescribing error was the cited as the most common 
error. The error could be due to incorrect drug product selection, dose, dosage form, quantity, route 
of administration, concentration, rate of administration, or instructions for use of a drug [49].  
Similar with other studies, the intervention hospital or clinic pharmacists mostly took in response to a 
medication error was contacting physicians [113].  In contrast, a few studies found that community 
pharmacists corrected most of the errors without contacting doing so [115, 195, 291]. However in 
studies by Hammerlein et al. [194] and Doucette et al. [191] physicians were contacted by 
community pharmacists in more than 60% of ME cases. In the present study, on the other hand, 
community pharmacists discussed with patients about the error and corrected them. 
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3.10.1.5 Drug overdose 
The percentage of pharmacists observing patients with DOs was low (32%) and of these, about 60% 
have observed lesser cases of overdose in each month. Overdose related to analgesics (69%), and 
cough and cold medicines (56%) were reported more often by community pharmacists. In response 
to an overdose, more than 80% of the hospital or clinic pharmacists informed the physicians- in-
charge, whilst about 40% of community pharmacists referred patients to hospitals. Only a small 
number of pharmacists reported counselling patients the correct dosage or proper use of drugs (9%). 
The low percentage of pharmacists who have observed DOs may be attributed to low prevalence of 
the occurrence. Other studies in Malaysia have reported the prevalence of overdose to be 0.2% to 
0.4% [164, 165], and overdoses were found in 1.9% of admissions in the in chart review study 
(Chapter 2  W Section 2.3.6). Analgesics were the drug group most often reported responsible for 
overdose cases. This was similar to the findings from other studies in Malaysia [165, 172] and in 
other countries [9, 11, 122, 171]. 
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3.10.2 Methodological considerations 
3.10.2.1 Selection of respondents 
The survey aimed to determine the experiences of health care professionals relating to ADEs. This 
survey was to complement the chart review study by determining the extent of burden of ADEs in 
Malaysia. The initial plan was to survey all health care professionals where the chart review study 
was conducted but due to poor cooperation from the head of medical department, the plan was 
abandoned (see Section 3.2.9.1), and the survey was carried out with pharmacists who are members 
of MPS in Malaysia. 
There are more than 6000 pharmacists registered in Malaysia. However, their complete details 
(names and addresses) were not available due to confidentiality restrictions of the Malaysian Board 
of Pharmacists. The only option was to obtain the information from Malaysian Pharmaceutical 
Society (MPS) where the names, addresses and/or work setting of its members are recorded. These 
details were not provided to the researcher. Staff from MPS agreed to post the questionnaires. 
Furthermore, MPS has experience of regularly sending conference invitations and pamphlets to its 
members. At the time of the study, there were 2000 members registered in MPS. Of these, 750 were 
hospital and health clinic pharmacists, 727 were community pharmacists, and 523 were working in 
other sectors such as industrial and education institutions. In view of poor response rates in other 
surveys conducted among health care professionals in Malaysia which is typically less than 30% [294, 
295], it was decided that all 1477 pharmacists directly providing patient services (750 hospital or 
clinic pharmacists and 727 community pharmacists) should be included in the study. For this reason, 
a sample size calculation was not conducted. 
Of the 472 respondents, 29 (6%) were working in other sectors. This shows that the information 
recorded in the MPS database was not up-to-date. The MPS database relies on pharmacists to 
update any changes in details and this is one of the limitations of this study. Some pharmacists may 
not have responded because their work setting does not involve direct interaction with patients. 
However, the questionnaire did include questions about work setting and whether or not the 
respondents have direct contact with patients. Pharmacists who worked in other sectors were 
requested to skip all the questions and proceed to the last section of the questionnaire which asked 
for demographic data. Perhaps, not being able to answer any of the questions discouraged these 
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respondents from returning the questionnaire. Another limitation may be that, those who have 
observed ADEs and have interaction with patients were more likely to be interested in the subject of 
the survey and therefore, have returned the questionnaires. 
 
3.10.2.2 Questionnaire design and piloting 
The pilot questionnaire was designed based on previously published questionnaire and discussion 
with research supervisors. Upon completion of the pilot study, many changes were made to the 
questionnaire  W addition and/or deletion of questions. Due to time constraints, another pilot study 
was not conducted to test the reliability and validity of the new questionnaire and this is another 
limitation of this study. However the majority of questions remained the same and those that were 
changed or added were due to feedback in the pilot study requesting clarification or indicating 
confusion in the answers. 
Correlation between variables could not be conducted.  For example, a suspected ADR could not be 
correlated with a drug because both questions allowed more than one answers. Similarly, the actions 
taken in response to an ADE could not be correlated with an ADE or the drug(s) involved. However, 
the data from the survey was able to identify the types of ADEs pharmacists observed, the types of 
drugs, and the actions taken by pharmacists, giving an overview of practice in Malaysia and areas for 
possible interventions. 
 The respondents were asked to recall the types of ADEs, causative drugs, and actions taken in 
response to the ADEs observed in the last six months. There are possibilities that pharmacists had 
difficulty recalling the ADEs and tried to please the researcher in their answers.  This meant that 
details may be recalled incorrectly or the events may not have actually taken place within the six-
month-timeframe. Furthermore, pharmacists in the hospitals or specific wards (such as medical 
wards or ICU) may have observed a higher number of ADEs compared with others and it was not 
possible to identify this from the survey. 
Although this survey was done to complement the chart review study (Chapter 2), the type of MEs 
identified through this survey is comprehensive compared with those identified through chart 
review. The list of MEs in the survey question covers all types of MEs (those which have caused harm 
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and those identified and prevented before causing harm), unlike the chart review study where only 
MEs that caused harm and led to hospital admissions were identified. This is due to the survey being 
aimed at both hospital and community pharmacists, and the types of MEs identified by both groups 
may have differed. Thus, the findings gathered on MEs from the chart review study may not be 
directly comparable with that of the survey. 
 
3.10.2.3 Distribution of questionnaires and the response rate 
Based on the results from the pilot study, almost 60% of the respondents preferred email to postal 
survey. The initial plan was to obtain the email addresses of all MPS-registered pharmacists from 
MPS and use an electronic survey program such as Survey Monkey®, in sending the questionnaires to 
the pharmacists. This may have increased the survey response rate.  However, due to confidentiality 
constraints, MPS was not able to provide the email addresses and upon further discussion, it was 
decided to conduct a postal survey. 
 The low response rate (32%) to this survey means the results may not be generalisable to the 
pharmacist members of MPS. Nevertheless, this is typical of surveys in Malaysia that involve health 
care professionals whose response rates to questionnaires since 2000 vary between 30 to 88% [294] 
Moreover, a survey response rate of 37% [295] was reported in a 2010 publication involving 
community pharmacists.  A number of reasons could have affected the low response from 
pharmacists in this survey. The distribution of first mailing was close to the Chinese New Year and 
thus, pharmacists may have been very busy preparing for the long break or on holiday. Other 
possible reasons for the low response include outdated address details found on the MPS database, 
absence of interest in the survey, or low knowledge about the subject by pharmacists. 
 
3.10.2.4 Generalisability of data 
A strength of this survey is that it collected information from pharmacists who were members of 
MPS. They receive constant updates from the society, thus, keeping them updated of the latest 
events or news.  The pharmacist population in this survey may not be representative of all 
pharmacists in Malaysia because the experiences of non-MPS members were not explored. Members 
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of MPS may differ from other Malaysian pharmacists in that they chose to join the professional body, 
and thus, may be more up-to-date with clinical or legal issues affecting the profession. However, the 
ĞǆƚĞŶƚƚŽǁŚŝĐŚďĞŝŶŐŵĞŵďĞƌƐŽĨƚŚĞDW^ǁŽƵůĚŚĂǀĞĂĨĨĞĐƚĞĚƉŚĂƌŵĂĐŝƐƚƐ ?responses is unknown. 
 
3.10.2.5 Ways in which this survey study could have been strengthened 
The study would have been strengthened if all health care professionals were surveyed using the 
questionnaire. This would have given a better overview of the situation in Malaysia. However as 
detailed in Section 3.2.9.1, an attempt to do this was not successful. Perhaps, using professional 
bodies to survey other health care professionals rather than attempting one in a hospital setting 
might have been more successful. 
The study could have also been strengthened if all Malaysian pharmacists were surveyed instead of 
only the MPS members. Unfortunately, this was not possible and the survey was conducted with the 
next most comprehensive group of pharmacists. 
The questions in the questionnaire did not allow for further analysis of correlation between the types 
of ADEs and the causative drugs, or the actions taken in response to ADEs.  This information would 
have given a better overview of the situation and practice in Malaysia. This limitation could 
potentially have been identified and rectified if a second pilot study was conducted, following the 
changes to the questionnaire after the pilot study. Although this would have strengthened this 
research, the information collected from the main study was still able to provide reliable information 
of the types of ADEs the pharmacists observed and their actions in response to them. 
 
 
 
 
 
Chapter 3 
 
 
207 
 
3.10.3 Implications 
 
Health care system and health care professionals  
The most common ADRs observed by the pharmacists were related to the dermatological, 
gastrointestinal, and central nervous systems. Pharmacists should be aware of this and suspect it in 
patients complaining of complications such as rash, itchiness, gastritis, diarrhoea, nausea, and 
dizziness, and thereafter, initiate further investigations. Furthermore, the drug most often reported 
observed by all the responding pharmacists was perindopril. This may be attributable to the 
increased usage of perindopril (almost 70% of increase between year 2006 and 2009) in Malaysia 
[260]. Knowing that ADRs associated with an ACEI are common, pharmacists can play an important 
role in regularly monitoring patients prescribed an ACEI. They have the opportunity to reduce the 
frequency and impact of ADRs through offering more advice on the possible causes of ADRs and 
appropriate therapies. dŚŝƐŚĂƐďĞĞŶƐŚŽǁŶŝŶĂƐƚƵĚǇŽĨƉŚĂƌŵĂĐŝƐƚƐ ?ŝŶƚĞƌǀĞŶƚŝŽŶƐƚŚƌŽƵŐŚƉĂƚŝĞŶƚ
education and follow-up [6]. 
Whilst ADRs were reported as being observed by a high number of the sample pharmacists, there 
were differences in the management of the reactions between the two different groups. The hospital 
or clinic pharmacists have the habit of reporting ADRs while the community pharmacists referred the 
patients to their physicians and discussed the reactions with the patients. One reason for these 
differences could be the types of ADRs observed by both groups of pharmacists. Minor reactions 
such as gastritis, diarrhoea, nausea, and heartburn were more often reported by community 
pharmacists and therefore, may not be reported to MADRAC. These pharmacists solve the problems 
themselves by discussing them with the patients. Another reason could be that the hospital or clinic 
pharmacists are well informed about the procedure and process of reporting ADRs compared with 
community pharmacists. Thus, the latter group is prompted to refer the patients to their physicians 
instead, anticipating that the physicians themselves will be able to solve and report about the ADRs.  
 Although the current practice of reporting ADRs by hospital pharmacists is reassuring, they should 
be regularly updated and reminded of the importance of reporting ADRs to ensure that this practice 
is continued throughout their professional life. Community pharmacists on the other hand, should be 
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educated about the ADR report system and understand that reporting ADRs is the responsibility of all 
health care professionals. 
It was previously known that knowledge and attitudes exerted strong influence on ADR reporting 
[229]. Thus, the low rate of reporting among community pharmacists in this study may be secondary 
to poor knowledge of it and its procedures. Training by MADRAC are mainly conducted in hospitals 
[241, 287] and are usually held within office hours. Such arrangements may have deterred 
community pharmacists from participating. This places the hospital or clinic pharmacists in a better 
position for good information on ADR report system. Furthermore, the existence of a drug 
information centre within each government hospital has made ADR reporting effortless for the said 
group of pharmacists. A study by Granas et al. [232] have shown that an educational program can 
change reporting attitudes of pharmacists in a positive manner. Attitudes are potentially modifiable, 
thus, MADRAC needs to improve and expand the promotion of ADR reporting to community 
pharmacists. MADRAC should understand the nature of work of the said pharmacists and tailor their 
training accordingly.  
MADRAC has urged health care professionals to report all suspected reactions and this approach is 
taken to encourage the reporting culture among them. However, pharmacists in this study believe 
only certain types of ADRs (serious, unusual, or involving a new drug) should be reported. Perhaps, 
better and regular communication between MADRAC and pharmacists would change this 
misconception. Training and workshops should emphasize the expectation from MADRAC and the 
types of ADRs that need to be reported. 
The high number of pharmacists observing patients with therapeutic failure places them in best 
position to provide patient counselling services. The ƉŚĂƌŵĂĐŝƐƚƐ ?ŝŶǀŽůǀĞŵĞŶƚŝŶƉĂƚŝĞŶƚĐŽƵŶƐĞůůŝŶŐ
in this study showed that they understand its importance in improving patient healthcare. The 
introduction of MTAC in Malaysia has provided a platform for pharmacists to educate patients on 
their drugs and monitor its outcomes. MTAC has been running since 2004 in various public hospitals 
and is provided for medical conditions such as diabetes, hypertension, and renal failure. This service 
ǁĂƐĨŽƵŶĚƚŽŚĂǀĞŝŶĐƌĞĂƐĞĚƉĂƚŝĞŶƚƐ ?ĂĚŚĞƌĞŶĐĞƚŽŵedicines [211]. Similar approaches, if 
introduced in community pharmacies, would benefit the public. Additionally, pharmacists should be 
well-trained in educating patients and identifying ADEs.  
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Hospital pharmacists have the advantage of working in a multi-disciplined institution which allows 
them to have direct communication with other health care professionals.  However, community 
pharmacists do not have the opportunity to directly interact with any general practitioners or 
physicians.  A two-way communication will be useful in exchanging information and although the 
current health care system does not allow this between community pharmacists and GPs, the former 
should take the initiatives to contact GPs via telephone using the information provided by patients. It 
is not known whether or not patients who were asked to contact their physicians have actually 
contacted them. Thus, to ensure that patients receive adequate care and avoid further risk of ADEs, 
community pharmacists should be encouraged to communicate with GPs. Furthermore, effective 
communication between health care professionals and patients is important. This is essential so 
patients learn to build trust, be constantly motivated to adhere to medicine and understand 
problems that might influence their medication-taking behaviour.  
The first step in preventing medication error is to design a system that accurately identifies errors 
and their causes. For example  W pharmacist-led interventions or participation in the rounds was 
proven to reduce the occurrence of an error [78] and the use of CPOE [201] was found to detect and 
intercept an error before it reaches a patient. However, no single approach can be identified as the 
best method and each institute should evaluate which combination strategies will work best. For 
example; a medication error reporting system (MERS) in Malaysia was established in 2009 [21]. A 
total of 2,572 medication error reports were received since the system was started [242]. Probably 
due to its being a new system, most of the pharmacists do not have the habit of reporting MEs, or 
may not be aware of, or familiar with the system. Hence, there should be continuous evaluation of 
the system for improvement. Information and reminders should be disseminated regularly so that 
health care professionals are aware of the availability of an active system. If any such system is to 
make a substantial impact on patient care, a no-blame report system and allowance of anonymous 
reporting are needed to encourage self-reporting of errors. Additionally, regular training or 
workshops should be conducted to guide health care professionals as to how to report an incident 
and community pharmacists should be included. Once a system is in place, interventions can be 
targeted at places where high numbers of medication errors occur to improve the medication use 
process and the health care system. 
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Community pharmacists in Malaysia were found to be filling an average of 1.8 prescriptions per day 
[288]. A qualitative study in Malaysia also revealed that 10 out of 16 community pharmacists fill less 
than ten prescriptions per day [226]. DĂůĂǇƐŝĂƐƚŝůůƉƌĂĐƚŝĐĞƐƚŚĞƚƌĂĚŝƚŝŽŶĂů “ĚŝƐƉĞŶƐŝŶŐƉƌĞƐĐƌŝďĞƌƐ ? ?
Thus, community pharmacists have little involvement with dispensing of prescription medicines. 
Owing to this, the occurrence of medication errors related to prescribed drugs observed in 
community pharmacies may be lower compared to other countries. Furthermore, a low proportion 
of pharmacists reported documenting or reporting an error. Documentation of errors and the 
interventions taken to solve the errors should be encouraged. This practice could serve as a 
surveillance of the current health care system and an opportunity to evaluate and improve the 
system. 
The most common errors observed by pharmacists were prescribing errors. The physician-pharmacist 
collaboration has been reported to have the potential to improve a ƉĂƚŝĞŶƚ ?ƐŚĞĂůƚŚ[296].  This 
indicates that there is an opportunity for pharmacists to collaborate with physicians to make 
decisions about the appropriate drug therapy for a patient. Pharmacists can provide information on a 
suitable drug choice and dosage to physicians. The health care system in Malaysia is such that 
community pharmacists are not linked to any general practitioners or patient records. Hence, the 
decisions they make are based on the knowledge and information provided by patients. It is 
important to optimise communication among health care professionals to improve patient safety. 
Thus, community pharmacists should be encouraged to communicate and build good professional 
relationships with physicians whose patients regularly visit their pharmacy.  
A retrospective study in Malaysia revealed that 24% of poisoning patients have already received 
treatment before admission to hospital [172] and most of them received treatment at private 
hospitals or private clinics. Thus, pharmacists may not be the first-line professionals who patients 
seek medical attention from. Nevertheless, despite the low prevalence, pharmacists do observe 
overdose cases during their daily work activity and thus, it is important for them to know what 
actions should be taken. Pharmacists should be educated about assessing overdose patients as 
prompt actions can save lives. A guideline for the pharmacists about overdose-patient management 
could be the first step. Such guideline is currently available for clinicians in the UK [297, 298]. This 
guideline assists them on the steps that need to be taken once a patient reports of taking an 
overdose of a drug. 
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In cases of DO, the current practice by the hospital or clinic pharmacists of informing the physicians- 
in-charge should be enhanced with their involvement in the team for better management. The 
ƉŚĂƌŵĂĐŝƐƚƐ ?ƌŽůĞĂƐƉƌŽǀŝĚĞƌŽĨĚƌƵŐŝŶĨŽƌŵĂƚŝŽŶto other health care professionals has been 
reported in a few studies  [114, 192]. Hence, there are opportunities for them to provide information 
about antidotes that can be used and their availability in the hospitals.  
The types of drugs associated with the cases of overdose observed by community pharmacists 
(analgesics, and cold and cough drugs) are easily available OTC. Community pharmacists have the 
opportunity to reduce the frequency and the impact of drug overdoses through offering more advice 
about its possibilities and on appropriate actions in cases of overdose. Pharmacists should provide 
advice on the proper use of medicines while emphasising safety to the patient. Furthermore, warning 
labels should be affixed on products or product information materials can be given out to the 
patients. As OTC drugs which are usually sold as blister strips do not have warning labels, pharmacists 
should supply them in boxes rather than individual strips. 
 
Patients and society 
Providing better advice to patients about their drugs and the expected ADRs has the potential to 
reduce the impact of ADRs for individuals and society. Patients should be given good counselling 
when medicines are dispensed, so they know what an ADR is and the actions that should be taken in 
response to such, for example, seeing a pharmacist or a doctor. Furthermore, practitioners should 
reassure patients of keeping their personal details confidential. Patients should also be educated on 
the importance of knowing their drugs and disclosing the drugs they have been consuming 
(prescribed, OTC, or herbal remedies) to their health care professionals.  
The high percentage of therapeutic failure observed by the pharmacists is a matter of concern. The 
fact that many patients may lack knowledge on the proper use of their medicines and may have poor 
adherence problems shows that there is potential for an intervention strategy. A patient-centred 
strategy aimed at patients at risk should focus on improving their insights of their medical conditions, 
adherence to medicine, and also encouraging patients to lead a healthy lifestyle. The practice of 
 ‘ĚŽĐƚŽƌŽƌƉŚĂƌŵĂĐŝƐƚ-ŚŽƉƉŝŶŐ ?ďǇDĂůĂǇƐŝĂŶƐŵĂŬĞƐŵŽŶŝƚŽƌŝŶŐŽĨĚŝƐĞĂƐĞŽƵƚĐŽŵĞƐĚŝĨĨŝĐƵůƚ ?
Perhaps, patients or their families should carry a list of all prescription drugs, OTC drugs, herbal 
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remedies and supplements, the indications for each drug, and any known drug allergies with them all 
the time. Every health care professional involved in patient care should have access to this list. 
Although this study did not identify who was responsible for the occurrences of errors, patients can 
do a great deal to decrease their chances of experiencing a ME. Patients should know what questions 
to ask their health care professionals, how to insist on answers, and how to recognise situations that 
could result in MEs. Furthermore, patients should be involved in the process of decision making with 
regard to management of their medical conditions. Their participation could ensure that they 
understand why certain medicines are prescribed to them.  
As discussed in Chapter 2  W Section 2.4.5, patients should be advised about the consequences of DO 
and to reach out for help in case of emotional distress. Patients should be advised on purchasing OTC 
drugs  W only the amount required should be bought. Any unused drug should be appropriately 
disposed of, returning them to pharmacists or to physicians. In addition, it is important to educate 
patients about what actions to take in response to overdoses. Prompt actions may help in minimising 
the impacts of the events. 
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Research 
x This study found that ADRs associated with perindopril was observed by most of the 
pharmacists.  This may be the result of its increased usage.  However, further investigation is 
needed especially on the types of reactions associated with the drug, so that appropriate 
measurement can be taken to reduce the frequency of these reactions.  
x The findings from this study could provide a good source in designing an educational 
program aimed at promoting the reporting culture among community pharmacists. Further 
studies could be conducted in the future to evaluate the impacts of interventional strategies.  
x The factors that encourage and discourage ADR reporting identified in this study were 
correlated with the questions asked in the questionnaire. Other factors which might have 
ŝŶĨůƵĞŶĐĞĚƚŚĞƉŚĂƌŵĂĐŝƐƚƐ ?ĚĞĐŝƐŝŽŶƚŽƌĞƉŽƌƚZƐŵĂǇďĞŝĚĞŶƚŝĨŝĞĚƵƐŝŶŐƋƵĂůŝƚĂƚŝǀĞ
studies. 
x Further research to determine the causes of TFs could determine the areas for prevention 
strategies. The study should investigate medication-taking behaviour of patients and their 
beliefs about their medical conditions and medication.  
x The high percentage of pharmacists who have observed TFs means that there is opportunity 
for an intervention study to advice patients on the best use of medicines.  Despite the 
implementation of MTAC for diabetic and hypertension patients, a high percentage of 
pharmacists still have observed TFs in patients with diabetes mellitus and hypertension. 
Therefore, effectiveness of these services should be evaluated to ensure they deliver what 
they are expected to deliver and that further investigation could provide insights on 
improving the services. 
x This survey was able to identify the most common MEs observed by the pharmacists.  
However, further investigation on the types of MEs and their causes is needed to identify the 
areas in need of attention.   
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x A study of the awareness of health care professionals of the existence of the current ME-
report system and the barriers to report the events could provide information on improving 
the system.  
x Further research is needed to provide more insights into the types of drugs involved in 
overdoses. The common modes and types of overdoses (accidental or intentional), and the 
group of consumers involved in such events should also be identified and explored before 
any intervention or prevention strategies are initiated.  
x Analgesics have been found to be the common drug group used in overdoses, thus, further 
investigation on where these drugs are obtained and the actions that should be taken to 
overcome this problem should be made to provide a better view of the actual problem. 
 
3.11 Summary 
This study shows that pharmacists in Malaysia encounter patients with adverse drug events in their 
daily work activities. There were differences in the management of ADE patients by hospital or clinic 
pharmacists and community pharmacists. The role of pharmacists in identifying, resolving and 
preventing adverse drug events can be further enhanced through education and training, and better 
communication with physicians. Pharmacists also play an important role in educating patient about 
their drug therapy. 
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4 CHAPTER 4: SUMMARY DISCUSSION 
CHAPTER 4 
 
SUMMARY DISCUSSION 
 
This chapter collates the main findings from the chart review study and survey study. It provides a 
discussion of the important issues which have emerged from both studies and presents the 
implications of the findings for policy, practice, and future research.  
The first aim of this thesis was to measure the prevalence of ADE-related admissions so that the 
extent of this problem and the drugs which are largest target for potential interventions can be 
identified.  The second aim was to obtain the opinions of health care professionals in Malaysia and 
understand the current practices in their professions, so appropriate actions or interventions could 
be suggested to resolve any problems. The following key issues emerged from the two studies: 
1) The occurrence of ADEs in a Malaysian hospital was high. 
2) The most common drug classes associated with ADEs were cardiovascular drugs, anti-
diabetics, anti-asthmatic drugs and analgesics. 
3) Community pharmacists were not actively involved in ADR reporting. 
4) Given the high levels of ADEs, the use of analgesics should be monitored carefully. 
5) Prescribing errors were major contributor to medication error 
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The occurrence of ADEs in a Malaysian hospital  
The findings of chart review and survey studies suggest that ADEs continue to be an important health 
care problem. The chart review study identified that 39% of admissions to two medical wards were 
related to ADEs, which is high compared with studies in other countries. Additionally, at least half of 
the respondents to the survey reported having observed ADRs, MEs, and/or TFs in the last six 
months. These suggest that ADEs may result in a large burden to the Malaysian health care system 
and that the extent of this may not be widely known. Thus, these studies (chart review and survey) 
may be the starting point in determining the actual situation in Malaysia. 
It is important that the current emphasis on patient safety in Malaysia  W the establishment of patient 
safety council, continuous efforts from MADRAC to promote the ADR reporting culture, and 
introduction of MERS  W continues to receive support to ensure that the high proportion of ADEs is 
addressed. 
Patient safety can be maximised and the optimal effects of drug treatment can be achieved by 
identifying, preventing, and solving potential complications  W the core processes of pharmaceutical 
care [42]. Considering more than half of the pharmacists who responded to the questionnaire were 
able to identify ADEs in their daily work activities, it would be useful to include them in any 
prevention programs.  As reported in the survey study, pharmacists perform a valuable role in 
supporting the patients in safely managing their medicines: communicating with them about ADEs, 
counselling them on the right way to consume medicines, and emphasising the importance of 
adherence. Although these roles are laudable, it is important that they are clearly defined and 
recognised within the health care system.  
Pharmacists were able to identify ADEs during their daily work activities, so documenting them and 
the actions taken to resolve them should become part of routine practice for pharmacists. These 
data will be useful in monitoring the occurrence of ADEs, and sharing the documented information 
with MADRAC and other health care providers could improve awareness and therefore, improve ADE 
prevention. 
The findings from both studies although useful, are limited in that they do not give a full picture of 
the prevalence of ADEs and the practices of all health care professionals in preventing ADEs in 
Malaysia. In order to fully understand the frequency of ADEs, a larger and multi-centred chart review 
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study involving public and private hospitals in Malaysia should be conducted. Although time-
consuming and resource intensive, it would be able to provide a better picture. Furthermore, the 
practices of other health care professionals should be identified and evaluated in order to suggest 
educational interventions for efficient prevention strategies.  
 
Drug classes associated with ADEs  
The chart review and survey studies both identified some group of drugs which were responsible for 
the majority of ADEs. Both studies identified the following drug groups as major contributors: 
cardiovascular drugs, antidiabetics, anti-asthmatic drugs and analgesics.  The four main medical 
conditions (hypertension, diabetes mellitus, asthma, and heart disease) that are prevalent in the 
Malaysian population [260], were  implicated in the ADEs found in the chart review study and 
reported by pharmacists in the survey.  The widespread use of these drugs may reflect the medical 
conditions that are highly prevalent in Malaysia, and probably explains the high ADE rate.  
Targeting interventions at the prescription, administration and monitoring of these drugs could 
substantially reduce the prevalence of ADEs. This would result in better quality of life for patients 
and cost savings for Malaysian health care system. Some useful strategies for prevention could 
include targeted education about the main causes of ADEs (updates on the most common drugs 
causing ADEs and strategies to identify ADEs), targeted patient monitoring (patients prescribed drugs 
most likely to result in ADEs should be carefully monitored) and targeted computer alerts (using 
computerised databases for records and prescribing could help reduce ADEs both in preventing and 
identifying problems).  
Due to the increasing number of drugs available, regimen complexity, changing drug interactions and 
adverse events, health care professionals need to be kept up to date. Thus, education on main 
causes of ADEs whether it be as bulletin posts, online alerts, seminars, or workshops should be 
available to health care professionals to both help prevent ADEs and identify them where they do 
occur. 
Cardiovascular drugs, antidiabetics, anti-asthmatic drugs and analgesics were the major causes of 
ADEs in the present studies and patients prescribed these drugs are likely to be at higher risk of 
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experiencing an ADE. Thus, these patients should be monitored for ADEs by all the health care 
professionals involved in their care. Health care professionals also have a responsibility to ensure 
that patients are aware of the risks with the medicines they are taking and what to do if they 
experience any unwanted effects. 
Computerized systems at hospitals perform many different functions. The essential functions in 
relation to ADEs are in their identification, monitoring, and prevention [111, 131, 201]. Computer 
alerts could be targeted at the drugs most likely to cause ADEs. These may aid in both the prevention 
of ADEs and in decreasing the harm resulting from ADEs. Many hospitals in Malaysia are not yet 
equipped with computerised systems, although some do have such systems, computer ADE alerts 
may play an important role in preventing future ADEs in these hospitals. Nevertheless, further 
research is needed to assess the effectiveness of any system in producing alerts and minimising 
ADEs. 
 
Community pharmacists and ADR reporting 
The role of community pharmacists in spontaneous ADR reporting is crucial since it enables 
monitoring of patient treatment in real-life conditions. The majority of community pharmacists who 
responded to the survey had not reported an ADR.  This may be attributable to a lack of awareness of 
the reporting system in Malaysia or that any reactions they see may be mild or moderate, something 
the pharmacists felt they were able to resolve and therefore were not important enough to report. 
 The literature shows that knowledge and attitudes towards ADR reporting exerts a strong influence 
on actual reporting [229].  However, knowledge and attitudes are modifiable and therefore 
educational programmes targeted at community pharmacists could increase reporting. Such 
programmes ŚĂǀĞďĞĞŶƐŚŽǁŶƚŽƐŝŐŶŝĨŝĐĂŶƚůǇŵŽĚŝĨǇƉŚĂƌŵĂĐŝƐƚƐ ?ƌĞƉŽƌƚŝŶŐ-related attitudes, and 
influence the ADR reporting behaviour in a positive way[232]. MADRAC should encourage 
community pharmacists to report ADRs by involving them in their training which should be tailored 
ƚŽƚŚĞŶĂƚƵƌĞŽĨĐŽŵŵƵŶŝƚǇƉŚĂƌŵĂĐŝƐƚƐ ?ǁŽƌŬ ?DZƐŚŽƵůĚĂůƐŽĨĂĐŝůŝƚĂƚĞƚŚĞƉƌŽĐĞƐƐŽĨ
reporting by making reporting forms easily available and easy to complete. It is also important to 
improve communication between MADRAC and community pharmacists if reporting rates are to 
increase ?dŚĞƉƌŽƉŽƐĞĚƚƌĂŝŶŝŶŐƐŚŽƵůĚďĞĂƐƐĞƐƐĞĚďǇĞǀĂůƵĂƚŝŶŐƚŚĞƉŚĂƌŵĂĐŝƐƚƐ ?ĂƚƚŝƚƵĚĞƐƚŽǁĂƌĚƐ
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ADR reporting before and after such programmes.  This will provide an insight whether these 
educational interventions are successful or need further improvement. 
 
The use of analgesics should be carefully monitored 
Analgesics were found to be the most common drugs associated with overdose in the chart review 
and survey studies. These drugs were also found to be one of the most common drugs implicated in 
ADRs in the survey study. As these drugs are known to be associated with ADEs and are widely used 
[299] careful monitoring of patients using such medicines is essential. 
The most common analgesic associated with overdose in the chart review study was paracetamol.  
Pharmacists reported diclofenac, mefenamic acid and paracetamol were associated with ADRs in the 
survey study. A survey in Malaysia reported that analgesics were the most commonly used 
nonprescription medications with paracetamol as the most common active ingredient [299]. 
Although a high number of pharmacists, especially community pharmacists in the survey, reported 
having observed overdoses associated with analgesics, it was not possible to identify the type of 
analgesics from the questionnaire. It is not known where the drugs were obtained by patients but in 
Malaysia it was reported that many patients purchase these medications from pharmacies, and less 
than 30% obtained them from non-ƉŚĂƌŵĂĐǇŽƵƚůĞƚƐƐƵĐŚĂƐĚŽĐƚŽƌƐ ?ĐůŝŶŝĐƐ ?ŐƌŽĐĞƌǇƐŚŽƉƐ ?ŚŝŶĞƐĞ
medical halls, supermarkets, and convenient stores [299].   
Because of the widespread availability of analgesics, self-medication with these drugs has become 
commonplace. Patients may not realise the potential toxicity and adverse effects associated with the 
long-term or inappropriate use of analgesics. They may use the drugs at higher than recommended 
doses or in combinations that magnify the risk of adverse effects. Pharmacists who responded to the 
survey were able to identify ADRs and overdoses related to analgesics and therefore have a 
significant role in providing good quality information about analgesics, including warning consumers 
of their potential side effects. Furthermore, pharmacists could also play an important role in the 
selection and safe use of these drugs. The maximum doses of paracetamol for adults should not 
exceed 4 grams (usually 8 tablets) per day, and pharmacists must emphasize such precautions to the 
general public to prevent misuse and to minimize the occurrence of side effects.  
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Better monitoring by health care professionals is needed in terms of adverse reactions and overdose 
to analgesics. Increased collaboration among poison centres, pharmacists and other health care 
professionals is needed, together with better databases for recording information to identify 
problems and allow appropriate remedial actions. Where analgesics are supplied, health care 
professionals should be aware of potential adverse effects of these drugs when prescribing. 
Additionally, patients should be properly counselled on the appropriate and safe use of analgesics.  
 
Prescribing errors are major contributor to medication error 
At every stage of the medication-use process there is a risk of error and the stages most frequently 
associated with errors are prescribing and administration [3] and are important targets for 
prevention. In the chart review study there were 15 ME cases - all of them were due to prescribing 
error. Additionally in the survey study, the most common MEs reported by pharmacists were 
prescribing errors. 
Pharmacists play a key role in preventing and resolving prescribing errors. The survey showed that 
pharmacists were able to identify and classify medication errors.  They had also tried to resolve the 
errors by correcting them, contacting or informing the prescribers and discussing with the patient 
about the error. There are several other ways pharmacists can play their part in reducing prescribing 
errors such as: checking for errors as prescriptions are received; contacting prescribers for 
clarification or amendment before filling prescriptions; visiting the wards to review patient charts;  
providing suggestion to the prescribers; conducting medicine reconciliation and medication review 
[300]. These roles should be maintained and developed as a part of a strategy to reduce prescribing 
errors. Pharmacists need to equip themselves with sufficient skills and spend adequate time on 
clinical duties. Interventions made by pharmacists should be documented as analysing those 
interventions is a useful method to investigate prescribing errors and therefore devising ways to 
prevent or reduce them. Although this study was able to give an overview of the type of errors 
observed in the hospital and community settings, it was not able to provide the cause or source of 
the errors nor was it able to determine whether or not the actions taken or suggested by pharmacists 
were accepted by prescribers or resulted in positive outcomes for patients. Further research would 
provide details about strategies that work best to prevent or reduce ME in the Malaysian context. 
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Inappropriate prescribing involves the use of medicines that pose more risk than benefit, misuse of 
medicines (inappropriate dose or duration), the prescription of medicines with clinically significant 
drug-drug and drug-disease interactions and the underuse of potentially beneficial medications 
[185].  Education is the main strategy to ensure that prescribers are equipped to prescribe 
appropriately and safely [208]. This strategy should focus on stopping the errors before they occur. 
For example, prescribers should be educated in how to determine the dose of a drug and its 
frequency of administration, including how the medicine should be monitored and any adjustments 
made. In any attempt to prevent errors, it is important that prescribers are aware the patterns of 
error and the most common medications involved. These patterns may change over time as new 
medicines come to market and changes in disease patterns. Thus, such information should be 
disseminated to the prescribers, accompanied by education on appropriate prescribing. Prescribers 
should actively interact with pharmacists to obtain drug information and work together to minimise 
medication errors. In a health care system where patients can consult more than one physician and 
may use multiple pharmacies, communication between health care professionals is essential in 
providing care that is in the interest of patients. The survey study investigated the types of MEs 
observed and the actions taken by pharmacists but little is known about the experiences and 
practices of other health care professionals. Expanding the survey to other health care professionals 
would provide a wider picture of the situation in Malaysia. 
Recently the Malaysian Ministry of Health (MOH) established a Medication Error Reporting System 
(MERS) to encourage ME reporting and documentation [21]. The system was launched during the 
survey and so the survey was not able to obtain information about the utilisation of the system by 
pharmacists. This move by MOH is commendable and all health care professionals should be trained 
and encouraged to report MEs in order to move towards safer practice. The details of reports 
received by MERS should be made public, whilst maintaining the confidentiality of the reporters. By 
reviewing the errors and sharing them openly, health care professionals can learn safer methods of 
practice which will benefit patients. Future studies should focus on investigating the reports received 
by MERS in terms of the types of errors and reporters. 
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4.1 Summary 
The occurrence of ADEs in a hospital in Malaysia was found to be high with cardiovascular drugs as 
the major contributor. Pharmacists play an important role in preventing ADEs by providing education 
and counselling to patients. Educational interventions on the main causes of adverse drug events, 
patient monitoring and appropriate prescribing should be developed to both prevent ADEs and 
minimise their impact, where they do occur. Adverse drug events and interventions taken in relation 
to them should be documented as this will be useful in monitoring such events.  Dissemination of 
ADE information to both health care professionals and patients has the potential to improve 
awareness and reduce harm.  
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Appendix 1 : Piloted data collection form 
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ADE- Related Hospital Admissions: 
 A PILOT STUDY  
  
 
 
 
 
 
 
 
 
 
 
 
Drugs on admission: 
Drug  Dosage Regimen 
   
   
 
 
Ref. No. 
Ward: 
            8A / 8B 
Race: 
 
Gender: 
M / F 
Year of birth: WĂƚŝĞŶƚ ?Ɛ/ P 
Date of admission: 
Presenting complaints: 
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Past Medical History: 
Diabetes Mellitus 
  
Hypertension 
 
Asthma 
 
Hyperlipidaemia 
 
Heart Disease 
  
Stroke 
  
Liver Disease 
  
Renal Failure 
  
Tuberculosis 
  
Cancer 
  
HIV / AIDS 
  
Alcoholic 
  
Smoker 
  
Drug abuser 
  
Hepatitis B carrier 
 
Others 
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Past Medication History (including OTC/ Herbal products): 
Drug  Dosage Regimen 
   
   
   
   
   
   
   
   
   
  
 
 
 
 
 
Initial diagnosis: 
Confirmed diagnosis: 
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Laboratory data 
Tests 
Normal 
Range         
           
           
           
           
           
           
           
        
         
         
         
         
       
 
 
 
 
 
Other details: 
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Appendix 2: Modified trigger tool 
 
 
 
 
 
 
 
 
 
 
 251 
 
 
 
Trigger tool list  
T1  Antihistamines : Calamine Lotion, Loratidine (Clarityne), Cetirizine (Zyrtec), Chlopheniramine 
Maleate (Piriton), Diphenhydramine (Benadryl), Dexchlopheniramine (Polaramine), Promethazine 
(Phenergan) 
T2 Vitamin K (Konakion) : anti-haemorrhagic  
T3 Flumazenil (Anexate) : for benzodiazepine overdose 
T4 Antiemetics: metoclopromide (maxolon), prochlorperazine (stemetil) 
T5 Anti-diarrheals: Charcoal, Diphenoxylate (Lomotil), oral rehydration salt, Loperamide (Imodium) 
T6: Sodium/Calcium Polysterene Sulphonate (Resonium A): for hyperkalaemia 
T7: Antacids: Magnesium Trisilicate, Cimetidine (Tagamet), Ranitidine (Zantac), Omeprazole (Losec), 
Pantoprazole (Controloc), Lansoprazole (Prevacid), Sucralfate 
T8: Anti-constipation: Liquid Paraffin, Bisacodyl (Dulcolax), Lactulose 
T9: Clostridium difficile positive stool  
T9: Abrupt cessation of medication/ change in doses 
T10: Abnormalities in laboratory data(s) 
T11: Rash/ Steven-Johnson Syndrome 
T12: Over sedation/ lethargy/ low BP / HR/ fall 
T13: Uncontrolled disease/ recurrent/ worsening of a disease 
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Appendix 3 Pt,K ?ƐZĐĂƵƐĂůŝƚǇƐĐĂůĞ 
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Causality Scale Description
C1: Certain
A clinical event, including laboratory test abnormality, 
occurring in a plausible time relationship to drug 
administration, and which cannot be explained by concurrent 
disease or other drugs or chemicals. The response to 
withdrawal of the drug (dechallenge) should be clinically 
plausible. The event must be definitive pharmacologically or 
phenomenologically, using a satisfactory rechallenge procedure 
if necessary.
C2: Probable/ Likely
A clinical event, including laboratory test abnormality, with a 
reasonable time sequence to administration of the drug, 
unlikely to be attributed to concurrent disease or other drugs 
or chemicals, and which follows a clinically reasonable response 
on withdrawal (dechallenge). Rechallenge information is not 
required to fulfil this definition.
C3: Possible
A clinical event, including laboratory test abnormality, with a 
reasonable time sequence to administration of the drug, but 
which could also be explained by concurrent disease or other 
drugs or chemicals. Information on drug withdrawal may be 
lacking or unclear.
C4: Unlikely
A clinical event, including laboratory test abnormality, with a 
temporal relationship to drug administration which makes a 
causal relationship improbable, and in which other drugs, 
chemicals or underlying disease provide plausible explanations.
C5: Conditional/ Unclassified
A clinical event, including laboratory test abnormality, reported 
as an adverse reaction, about which more data is essential for a 
proper assessment or the additional data are under 
examination.
C6: Unassessible/ Unclassifiable
A report suggesting an adverse reaction which cannot be 
judged because information is insufficient or contradictory, and 
which cannot be supplemented or verified.
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Appendix 4: Ethics approval letter to conduct pilot chart review study 
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Translation: Medical Ethics and Research Committee (MREC) has no objection to the project. 
MREC understands that the project does not involve any clinical intervention and only requires 
ĚĂƚĂĐŽůůĞĐƚŝŽŶĨƌŽŵƐƵďũĞĐƚƐ ?ƌĞĐŽƌĚ ?ůůƌĞĐŽƌĚƐĂŶĚĚĂƚĂĂƌĞKE&/Ed/>ĂŶĚŵƵƐƚŽŶůǇďĞ
used for research purpose, and all procedure pertaining to data confidentiality must be 
followed. Permission must be obtained from the Hospital Director before conducting the 
research. Researcher must accept the final decision made by the Hospital Director. 
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Appendix 5: Ethics approval letter to conduct the chart review study 
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Translation: Medical Ethics and Research Committee (MREC) has no objection to the project. 
MREC understands that the project does not involve any clinical intervention and only requires 
ĚĂƚĂĐŽůůĞĐƚŝŽŶĨƌŽŵƐƵďũĞĐƚƐ ?ƌĞĐŽƌĚ ?ll records and data are CONFIDENTIAL and must only be 
used for research purpose, and all procedure pertaining to data confidentiality must be 
followed. Permission must be obtained from the Hospital Director before conducting the 
research. Researcher must accept the final decision made by the Hospital Director. 
 258 
 
 
 
 
 
 
 
Appendix 6: Data collection form for the chart review study 
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ADE- Related Hospital Admissions: 
 PHASE 2 STUDY  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drugs on admission (and any changes in the ward): 
Drug  Dosage Regimen 1st day 2nd day 3rd day 
      
      
      
      
      
 
Race: 
M / I / C / 
Others / 
Foreigners 
 
Gender: 
M / F 
Year of birth: WĂƚŝĞŶƚ ?Ɛ/ P 
Ref. No. 
Date of admission: 
Ward: 
   7A / 8B 
Bed: 
 
Presenting complaints: 
 
 
 
 
 
 
 
 
 
BP: 
 
T (
o
C): RR: 
 
PR: 
 
RBS (DXT): 
 
SPO2: 
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Tick 
Type (eg IHD, ESRF, ARF, 
BA, COAD etc) 
Years 
Diabetes Mellitus     
Hypertension    
Asthma    
Hyperlipidaemia    
Heart Disease     
Stroke     
Liver Disease     
Renal Failure     
Tuberculosis     
HIV / AIDS     
Seizure/epilepsy     
Gastritis    
Hepatitis B, C    
Others:    
     
Social History     
Alcoholic     
Smoker    
Drug abuser    
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Past Medication History (including OTC/ Herbal products): 
Drug  Dosage Regimen Date/Year started 
    
    
    
    
    
    
    
    
    
   
   
   
 
 
 
 
Vital signs in the ward: 
Date       
BP       
Temperature       
RR       
PR       
SPO2       
 
Initial diagnosis: 
Confirmed diagnosis: 
 262 
 
Laboratory data 
Tests/Date 
Normal 
Range         
DXT (RBS) <11.1      
Urine glucose       
Urine ketone       
       
       
Electrolytes:           
Na 136-145          
K 3.5-5.1          
HCO3
- 18-24          
           
       
       
Renal function tests           
Urea 2.5-6.4          
Creatinine 62-106       
         
       
Liver function tests         
T.Protein 60-85        
Albumin 34-50        
T.Bilirubin <17.2      
Direct bilirubin <5.0      
INR       
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PT 11.9-14.5      
aPTT 29.5-42.3      
AST 0-37      
ALP 40-130      
       
       
FBC       
Hgb 
13-17 (m) 
12-16 (f)      
Hct 
40-58 (m) 
37-46 (f)      
RBC 4.5-5.5      
WBC 
4.1-
10.9x103      
Platelet 140-450      
MCH 31-37      
MCV 76-100      
MCHC 32-36%      
       
       
Cardiac enzymes       
CK 38-170      
LDH 100-190      
Troponin I <0.05      
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Therapeutic drug monitoring 
Drug Normal level Results Remarks (toxic etc) 
    
    
    
 
Other findings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other details/ Patient interview: 
 
 
 
 
 
CXR: 
 
CT Scan: 
 
Mantoux test: 
 
OGDS: 
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Appendix 7: Piloted questionnaire 
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 271 
 
 
 272 
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Appendix 8: Information sheet 
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Appendix 9: Questionnaire for the pharmacists 
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Appendix 10: Questionnaire for doctors and nurses 
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Appendix 11:  Approval letter from National Institutes of Health to conduct 
survey of doctors and nurses 
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Appendix 12: Cover letter for main survey 
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Appendix 13: Reminder cover letter 
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